var title_f32_47_33520="Neuroblastoma";
var content_f32_47_33520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal neuroblastoma at 18 weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of fetal abdomen at gestational age of 18 weeks shows an echogenic mass adjacent to the spine. The differential diagnosis for a lesion in this location with this appearance is neuroblastoma or sequestration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33520=[""].join("\n");
var outline_f32_47_33520=null;
var title_f32_47_33521="Tuberous xanthoma";
var content_f32_47_33521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberous xanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellow papules on the elbow in a case of tuberous xanthoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33521=[""].join("\n");
var outline_f32_47_33521=null;
var title_f32_47_33522="Patient information: Flu (The Basics)";
var content_f32_47_33522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/55/18291\">",
"         Patient information: Cough, runny nose, and the common cold (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/57/914\">",
"         Patient information: Sore throat in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/12/12483\">",
"         Patient information: What you should know about antibiotics (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/31/36338\">",
"         Patient information: When to worry about a fever (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/12/39105\">",
"         Patient information: Influenza prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/12/35013\">",
"         Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Flu (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/flu-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H387365389\">",
"      <span class=\"h1\">",
"       What is the flu?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The flu is an infection that can cause fever, cough, body aches, and other symptoms. There are different forms of the flu, including the &ldquo;seasonal&rdquo; flu, the 2009-2010 pandemic H1N1 flu (also called the &ldquo;swine&rdquo; flu), and the bird flu. All forms of the flu are caused by viruses. The medical term for the flu is &ldquo;influenza.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10016716\">",
"      <span class=\"h1\">",
"       What is a flu pandemic?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A flu pandemic is when a new strain of a flu virus spreads to many people in different parts of the world. Pandemic flu strains sometimes cause more severe symptoms than seasonal flu viruses (which infect some people every year). The most recent flu pandemic was in 2009-2010 and was caused by an H1N1 flu or &ldquo;swine&rdquo; flu virus. In the past, flu pandemics have been caused by other flu strains, such as strains of the bird flu. Bird flu (also known as &ldquo;avian flu&rdquo;) is a severe form of the flu that is caused by a strain of a flu virus that first infected birds.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H387365396\">",
"      <span class=\"h1\">",
"       What are the most common flu symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;All forms of the flu can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever (temperature higher than 100&ordm;F or 37.8&ordm;C)",
"       </li>",
"       <li>",
"        Cough",
"       </li>",
"       <li>",
"        Headache or body aches",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Less common symptoms are sore throat and a runny nose.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H387365403\">",
"      <span class=\"h1\">",
"       Is the flu dangerous?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It can be. Most people get over the flu on their own, without any lasting problems. But some people need to go to the hospital because of the flu. And some people even die from it. This is because the flu can cause a serious lung infection called pneumonia. That's why it's important to keep from getting the flu in the first place.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H387365410\">",
"      <span class=\"h1\">",
"       How can I protect myself from the flu?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wash your hands often with soap and water, or use alcohol hand rubs",
"       </li>",
"       <li>",
"        Stay away from people you know are sick",
"       </li>",
"       <li>",
"        Get the flu vaccine every year",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H387365424\">",
"      <span class=\"h1\">",
"       What should I do if I get the flu?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you think you have the flu, stay home, rest, and drink plenty of fluids. You can also take",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sold as Tylenol&reg; and other brands) to relieve fever and aches.",
"     </p>",
"     <p>",
"      Do not give",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      or medicines that contain aspirin to children younger than 18. In children, aspirin can cause a serious problem called Reye syndrome.",
"     </p>",
"     <p>",
"      Most people with the flu get better on their own within 1 to 2 weeks. But you should call your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have trouble breathing or are short of breath",
"       </li>",
"       <li>",
"        Feel pain or pressure in your chest or belly",
"       </li>",
"       <li>",
"        Get suddenly dizzy",
"       </li>",
"       <li>",
"        Feel confused",
"       </li>",
"       <li>",
"        Have severe vomiting",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Take your child to the doctor if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Starts breathing fast or has trouble breathing",
"       </li>",
"       <li>",
"        Starts to turn blue or purple",
"       </li>",
"       <li>",
"        Is not drinking enough fluids",
"       </li>",
"       <li>",
"        Will not wake up or will not interact with you",
"       </li>",
"       <li>",
"        Is so unhappy that he or she does not want to be held",
"       </li>",
"       <li>",
"        Gets better from the flu but then gets sick again with a fever or cough",
"       </li>",
"       <li>",
"        Has a fever with a rash",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you decide to go to a walk-in clinic or a hospital because of the flu, tell someone right away why you are there. The staff might ask you to wear a mask or to wait someplace where you are less likely to spread your infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H387365431\">",
"      <span class=\"h1\">",
"       Can the flu be treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, people with the flu can get medicines called antiviral medicines. These medicines can help people avoid some of the problems caused by the flu. Not every person with influenza needs an antiviral medicine, but some people do. Your doctor or nurse will decide if you need an antiviral medicine. Antibiotics DO NOT WORK on the flu.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H387365438\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The flu can be very dangerous for pregnant women. If you are pregnant, it is very important that you get vaccinated against the flu. You should also avoid taking care of anyone who has the flu.",
"     </p>",
"     <p>",
"      If you are pregnant, call your doctor or nurse right away if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        You may have been near someone with the flu.",
"       </li>",
"       <li>",
"        You think you may be coming down with the flu. In pregnant women, the symptoms of the flu can get worse very quickly. The flu can even cause trouble breathing or lead to death of the woman or her baby. That is why it is so important that you talk to doctor or nurse as soon as you notice any of the flu symptoms listed above. You will need an antiviral medicine if you are pregnant and have the flu.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H387365445\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/55/18291?source=see_link\">",
"       Patient information: Cough, runny nose, and the common cold (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/57/914?source=see_link\">",
"       Patient information: Sore throat in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/12/12483?source=see_link\">",
"       Patient information: What you should know about antibiotics (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/31/36338?source=see_link\">",
"       Patient information: When to worry about a fever (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"       Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=see_link\">",
"       Patient information: Influenza prevention (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/47/33522?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15369 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33522=[""].join("\n");
var outline_f32_47_33522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H387365389\">",
"      What is the flu?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10016716\">",
"      What is a flu pandemic?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H387365396\">",
"      What are the most common flu symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H387365403\">",
"      Is the flu dangerous?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H387365410\">",
"      How can I protect myself from the flu?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H387365424\">",
"      What should I do if I get the flu?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H387365431\">",
"      Can the flu be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H387365438\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H387365445\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/12/39105?source=related_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/57/914?source=related_link\">",
"      Patient information: Sore throat in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/12/12483?source=related_link\">",
"      Patient information: What you should know about antibiotics (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/31/36338?source=related_link\">",
"      Patient information: When to worry about a fever (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_47_33523="Reconstruction with Lat flap PI";
var content_f32_47_33523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Reconstruction with Lat flap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 529px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Women who have reconstruction with a Lat flap have a flap of muscle and skin freed from their back. (The back muscle that is used is called the \"latissimus dorsi\" muscle.) After freeing the flap, surgeons tunnel it under the skin, around the armpit, and over to the chest. Then they attach the flap to the chest so that it becomes the new breast. Usually, they also put an implant under the muscle layer, so that the new breast can match the other one in size. Later, surgeons can also reconstruct a nipple.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jorge de la Pedraja, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33523=[""].join("\n");
var outline_f32_47_33523=null;
var title_f32_47_33524="Flurazepam: Patient drug information";
var content_f32_47_33524=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flurazepam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/3/27703?source=see_link\">",
"     see \"Flurazepam: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/24/12678?source=see_link\">",
"     see \"Flurazepam: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Flurazepam&reg;;",
"     </li>",
"     <li>",
"      Dalmane&reg;;",
"     </li>",
"     <li>",
"      Som Pam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to flurazepam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on soft food or liquid. Do not chew.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12490 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33524=[""].join("\n");
var outline_f32_47_33524=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015841\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015843\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015842\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015847\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015848\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015850\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015845\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015846\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015851\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015852\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/3/27703?source=related_link\">",
"      Flurazepam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/24/12678?source=related_link\">",
"      Flurazepam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_47_33525="Activated charcoal: Pediatric drug information";
var content_f32_47_33525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Activated charcoal: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"    see \"Activated charcoal: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/33/21012?source=see_link\">",
"    see \"Activated charcoal: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actidose&reg; with Sorbitol [OTC];",
"     </li>",
"     <li>",
"      Actidose&reg;-Aqua [OTC];",
"     </li>",
"     <li>",
"      Charcoal Plus&reg; DS [OTC];",
"     </li>",
"     <li>",
"      CharcoCaps&reg; [OTC];",
"     </li>",
"     <li>",
"      EZ-Char&reg; [OTC];",
"     </li>",
"     <li>",
"      Kerr Insta-Char&reg; in Aqueous Base [OTC];",
"     </li>",
"     <li>",
"      Kerr Insta-Char&reg; in Sorbitol Base [OTC];",
"     </li>",
"     <li>",
"      Requa&reg; Activated Charcoal [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Charac-25 [OTC];",
"     </li>",
"     <li>",
"      Charac-50 [OTC];",
"     </li>",
"     <li>",
"      Charactol-25 [OTC];",
"     </li>",
"     <li>",
"      Charactol-50 [OTC];",
"     </li>",
"     <li>",
"      Charcodote Susp [OTC];",
"     </li>",
"     <li>",
"      Charcodote TFS [OTC];",
"     </li>",
"     <li>",
"      Charcodote-Aqueous Sus;",
"     </li>",
"     <li>",
"      Premium Activated Charcoal [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiarrheal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Adsorbent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiflatulent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=see_link\">",
"      see \"Activated charcoal: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute poisoning:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Single dose: Charcoal with sorbitol (",
"     <b>",
"      Note:",
"     </b>",
"     The use of repeated oral charcoal with sorbitol doses is not recommended):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;1 year: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1-12 years: 1-2 g/kg or 25-50 g or approximately 5-10 times the weight of the ingested poison on a gram-to-gram basis; 1 g adsorbs 100-1000 mg of poison; in young children sorbitol should be repeated",
"     <b>",
"      no more",
"     </b>",
"     than 1-2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents and Adults: 30-100 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Single dose: Charcoal in water (a cathartic such as sorbitol should be added in appropriate doses):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;1 year: 1 g/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1-12 years: 1-2 g/kg or 25-50 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents and Adults: 30-100 g or 1-2 g/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multiple dose: Charcoal in water (doses are repeated until clinical observations of toxicity subside and serum drug concentrations have returned to a subtherapeutic range or until the development of absent bowel sounds or ileus; use only one dose of cathartic daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;1 year: 1 g/kg every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1-12 years: 1-2 g/kg or 15-30 g every 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents and Adults: 25-60 g or 1-2 g/kg every 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastric dialysis: Adults: 20-50 g every 6 hours for 1-2 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CharcoCaps&reg;: 260 mg [dietary supplement]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pellets for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EZ-Char&reg;: 25 g/bottle (1s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: USP: 100% (30 g, 240 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Actidose&reg;-Aqua: 15 g (72 mL); 25 g (120 mL); 50 g (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerr Insta-Char&reg; in Aqueous Base: 25 g (120 mL); 50 g (240 mL) [contains propylene glycol (in flavoring packet), sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerr Insta-Char&reg; in Aqueous Base: 50 g (240 mL) [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [with sorbitol]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Actidose&reg; with Sorbitol: 25 g (120 mL); 50 g (240 mL) [contains sorbitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerr Insta-Char&reg; in Sorbitol Base: 25 g (120 mL); 50 g (240 mL) [contains propylene glycol (in flavoring packet), sodium benzoate, sorbitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Requa&reg; Activated Charcoal: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Charcoal Plus&reg; DS: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Powder",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer as soon as possible after ingestion, preferably within 1 hour for greatest effect. Shake well before use; do not mix with milk, ice cream, sherbet, or marmalade; may be mixed with chocolate or fruit syrup to increase palatability. Instruct patient to drink slowly, rapid administration may increase frequency of vomiting; if patient has persistent vomiting, multiple doses may be administered as a continuous enteral infusion",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adsorbs gases from air; store in closed container",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Emergency treatment in poisoning by drugs and chemicals (FDA approved in all ages); repetitive doses for GI dialysis in drug overdose to enhance the elimination of certain drugs (eg, theophylline, phenobarbital, carbamazepine, dapsone, quinine) (FDA approved in all ages); has also been used in uremia to adsorb various waste products; dietary supplement (digestive aid)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Actidose&reg; may be confused with Actos&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F149219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appendicitis, bowel obstruction, constipation, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Corneal abrasion (with direct contact)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Aspiration, respiratory failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Fecal discoloration (black)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with an unprotected airway (eg, depressed CNS state without endotracheal intubation); patients at increased risk and severity of aspiration (eg, ingestion of hydrocarbon with a high potential for aspiration); patients at risk of GI perforation or hemorrhage due to medical conditions, recent surgery, or other pathology;",
"     <b>",
"      Note",
"     </b>",
"     : Ingestion of a corrosive (caustic) substance is",
"     <b>",
"      not",
"     </b>",
"     a contraindication if charcoal is used for coingested systemic toxin. Charcoal is not effective for cyanide, mineral acids, caustic alkalis, organic solvents, iron, ethanol, methanol, or lithium poisonings; do not use charcoal with sorbitol in patients with fructose intolerance; charcoal with sorbitol is not recommended in children &lt;1 year of age",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When using ipecac with charcoal, induce vomiting with ipecac before administering activated charcoal since charcoal adsorbs ipecac syrup. Charcoal may cause vomiting; rate is higher with sorbitol; vomiting is hazardous in petroleum distillate and caustic ingestions. Charcoal (especially in multiple doses) may adsorb maintenance medications and place the patient at risk for exacerbation of concomitant disorders.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If charcoal in sorbitol is administered, doses should be limited to prevent excessive fluid and electrolyte losses. Excessive amounts of activated charcoal with sorbitol may cause hypernatremic dehydration in pediatric patients. Aspiration may cause tracheal obstruction in infants but usually not a major problem in adults; aspiration pneumonitis, bronchiolitis obliterans, and ARDS have been reported following aspiration of charcoal; however, these problems may be due to the aspiration of gastric contents and not charcoal per se.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some suspensions (eg, Kerr Insta-Char&reg;) contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; use activated charcoal products containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Charcoal, Activated may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to charcoal when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: Charcoal, Activated may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to charcoal when possible. Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1051626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Certain flavoring agents (eg, milk, ice cream, sherbet, marmalade) reduce the adsorptive capacity of activated charcoal and should be avoided (use of activated charcoal-water slurries is preferred).",
"     <b>",
"      Note:",
"     </b>",
"     These flavoring agents do not completely compromise the effectiveness of activated charcoal and may be required in select cases to enhance compliance; some experts recommend increasing the dose of activated charcoal if using with ice cream or sherbet (Cooney, 1995; Dagnone, 2002). Chocolate or fruit syrup do not appear to reduce efficacy.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13657798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Activated charcoal is not absorbed systemically following oral administration. Systemic absorption would be required in order for activated charcoal to cross the placenta and reach the fetus. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluid status, sorbitol intake, number of stools, electrolytes if increase in stools or diarrhea occurs; continually assess for active bowel sounds in patients receiving multiple dose activated charcoal",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adsorbs toxic substances or irritants, thus inhibiting GI absorption; for select drugs, increases drug clearance by interfering with enterohepatic recycling or causing dialysis across intestinal membrane; adsorbs intestinal gas; the addition of sorbitol results in hyperosmotic laxative action causing catharsis",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In studies using adult human volunteers: Mean",
"     <b>",
"      reduction",
"     </b>",
"     in drug absorption following a single dose of activated charcoal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     All size doses of activated charcoal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Given within 30 minutes after ingestion: 69.1% reduction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Given at 60 minutes after ingestion: 34.4% reduction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     50 g activated charcoal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Given within 30 minutes after ingestion: 88.6% reduction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Given at 60 minutes after ingestion: 37.3% reduction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Not absorbed from the GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted as charcoal in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/33/21012?source=see_link\">",
"      see \"Activated charcoal: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Charcoal causes the stools to turn black",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     5-6 tablespoonfuls of activated charcoal powder is approximately equal to 30 g; minimum dilution of 240 mL water per 20-30 g activated charcoal should be mixed as an aqueous slurry; multiple dose activated charcoal has been shown to be effective in increasing the elimination of certain drugs (carbamazepine, theophylline, phenobarbital) even after these drugs have been absorbed",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The Position Paper on single dose activated charcoal by The American Academy of Clinical Toxicology and The European Association of Poisons Centres and Clinical Toxicologists (Chyka, 2005) does not advocate",
"     <b>",
"      routine",
"     </b>",
"     use of single dose activated charcoal in the treatment of poisoned patients. Scientific literature supports the use of activated charcoal within 1 hour of toxin ingestion, when it will be more likely to produce benefit. Studies in volunteers demonstrate that the effectiveness of activated charcoal decreases as the time of administration after toxin ingestion increases. Therefore, this publication states that activated charcoal may be considered up to 1 hour following ingestion of a potentially toxic amount of poison. In addition, the use of activated charcoal may be considered greater than 1 hour following ingestion, since the potential benefit cannot be excluded. Furthermore, based on current literature, the routine administration of a cathartic with activated charcoal is not recommended; when cathartics are used, only a single dose should be administered so as to decrease adverse effects (Position Paper: Cathartics, 2004).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     A policy statement by the American Academy of Pediatrics states that it is currently premature to recommend the",
"     <b>",
"      routine",
"     </b>",
"     administration of activated charcoal as a home treatment strategy for poisonings (AAP, 2003).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention, &ldquo;Poison Treatment in the Home,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(5):1182-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33525/abstract-text/ 14595067 /pubmed\" id=\" 14595067 \" target=\"_blank\">",
"        14595067",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burns MM, &ldquo;Activated Charcoal as the Sole Intervention for Treatment After Childhood Poisoning,&rdquo;",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 2000, 12(2):166-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33525/abstract-text/10763768/pubmed\" id=\"10763768\" target=\"_blank\">",
"        10763768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chyka PA, Seger D, Krenzelok EP, et al, \"Position Paper: Single-Dose Activated Charcoal,\"",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2005, 43(2):61-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33525/abstract-text/15822758/pubmed\" id=\"15822758\" target=\"_blank\">",
"        15822758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooney DO,",
"      <i>",
"       Development of Palatable Formulations, Activated Charcoal in Medical Applications",
"      </i>",
"      , Cooney DO, ed, New York, NY: Marcel Dekker, Inc, 1995, 397-417.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dagnone D, Matsui D, and Rieder MJ, \"Assessment of the Palatability of Vehicles for Activated Charcoal in Pediatric Volunteers,\"",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2002, 18(1):19-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33525/abstract-text/11862132/pubmed\" id=\"11862132\" target=\"_blank\">",
"        11862132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farley TA, &ldquo;Severe Hypernatremic Dehydration After Use of an Activated Charcoal-Sorbitol Suspension,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1986, 109(4):719-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33525/abstract-text/3761093 /pubmed\" id=\"3761093 \" target=\"_blank\">",
"        3761093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Position Statement and Practice Guidelines on the Use of Multi-dose Activated Charcoal in the Treatment of Acute Poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1999, 37(6):731-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33525/abstract-text/10584586 /pubmed\" id=\"10584586 \" target=\"_blank\">",
"        10584586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Position Paper: Cathartics,\"",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2004, 42(3):243-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33525/abstract-text/9482428/pubmed\" id=\"9482428\" target=\"_blank\">",
"        9482428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shannon M, &ldquo;Ingestion of Toxic Substances by Children,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):186-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33525/abstract-text/10639545/pubmed\" id=\"10639545\" target=\"_blank\">",
"        10639545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13142 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-41.78.124.10-CD13024F2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33525=[""].join("\n");
var outline_f32_47_33525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149199\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149200\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051616\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051609\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149185\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149172\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051619\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051611\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051618\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149220\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149219\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051623\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051608\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051607\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299010\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149180\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051626\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657798\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051615\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051606\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051621\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051622\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051613\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051624\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13142\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13142|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/52/39750?source=related_link\">",
"      Activated charcoal: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/33/21012?source=related_link\">",
"      Activated charcoal: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_47_33526="Tolcapone: Drug information";
var content_f32_47_33526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolcapone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/60/34756?source=see_link\">",
"    see \"Tolcapone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tasmar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F229018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, COMT Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F229002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     If clinical improvement is not observed after 3 weeks of therapy (regardless of dose), tolcapone treatment should be discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Parkinson's Disease:",
"     </b>",
"     Oral: Initial: 100 mg 3 times/day; may increase as tolerated to 200 mg 3 times/day.",
"     <b>",
"      Note:",
"     </b>",
"     Levodopa dose may need to be decreased upon initiation of tolcapone (average reduction in clinical trials was 30%). As many as 70% of patients receiving levodopa doses &gt;600 mg daily required levodopa dosage reduction in clinical trials. Patients with moderate-to-severe dyskinesia prior to initiation are also more likely to require dosage reduction.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F229003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2838266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment necessary for mild-moderate impairment. Use caution with severe impairment; no safety information available in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2838267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use. Discontinue immediately if signs/symptoms of hepatic impairment develop.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F228980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tasmar&reg;: 100 mg, 200 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F228967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11236687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A patient signed consent form acknowledging the risks of hepatic injury should be obtained by the treating physician.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1630562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. In clinical studies, the first dose of the day was administered with carbidopa/levodopa, and the subsequent doses were administered 6 hours and 12 hours later.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F228981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to levodopa and carbidopa for the treatment of signs and symptoms of idiopathic Parkinson's disease in patients with motor fluctuations not responsive to other therapies",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F229016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (14% to 32%), sleep disorder (24% to 25%), hallucinations (8% to 24%), excessive dreaming (16% to 21%), dizziness (6% to 13%), headache (10% to 11%), confusion (10% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (28% to 50%), diarrhea (16% to 34%; approximately 3% to 4% severe), anorexia (19% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dyskinesia (42% to 51%), dystonia (19% to 22%), muscle cramps (17% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Syncope (4% to 5%), chest pain (1% to 3%), hypotension (2%), palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (3% to 7%), loss of balance (2% to 3%), agitation (1%), euphoria (1%), hyperactivity (1%), malaise (1%), panic reaction (1%),  irritability (1%), mental deficiency (1%), fever (1%), depression, hypoesthesia, tremor, speech disorder, vertigo, emotional lability, hyperkinesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (1%), bleeding (1%), tumor (1%), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (8% to 10%), constipation (6% to 8%), xerostomia (5% to 6%), abdominal pain (5% to 6%), dyspepsia (3% to 4%), flatulence (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: UTI (5%), hematuria (4% to 5%), urine discoloration (2% to 3%), urination disorder (1% to 2%), uterine tumor (1%), incontinence, impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (1% to 3%; 3 times ULN, usually with first 6 months of therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (1% to 3%), hyper-/hypokinesia (1% to 3%), arthritis (1% to 2%), neck pain (2%), stiffness (2%), myalgia, rhabdomyolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Cataract (1%), eye inflammation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (5% to 7%), dyspnea (3%), sinus congestion (1% to 2%), bronchitis, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (4% to 7%), influenza (3% to 4%), burning (1% to 2%), flank pain, injury, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal stools, abscess, allergic reaction, amnesia, anemia, antisocial reaction, apathy, apnea, arteriosclerosis, arthrosis, asthma, bladder calculus, breast neoplasm, carcinoma, cardiovascular disorder, cellulitis, cerebral ischemia, cerebrovascular accident, chills, cholecystitis, cholelithiasis, choreoathetosis, colitis, cough increased, death, dehydration, delirium, delusions, diabetes mellitus, diplopia, duodenal ulcer, dysphagia, dysuria, ear pain, eczema, edema, encephalopathy, epistaxis, erythema multiforme, esophagitis, extrapyramidal syndrome, eye hemorrhage, eye pain, facial edema, furunculosis, gastroenteritis, gastrointestinal carcinoma, gastrointestinal hemorrhage, glaucoma, hemiplegia, hernia, herpes simplex, herpes zoster, hiccup, hostility, hypercholesteremia, hyperventilation, hypoxia, infection (bacterial), infection (fungal), joint disorder, kidney calculus, lacrimation disorder, laryngitis, leukemia, libido changes, lung edema, manic reaction, meningitis, mouth ulceration, myoclonus, neoplasm, nervousness, neuralgia, neuropathy, nocturia, oliguria, otitis media, ovarian carcinoma, pain, paranoid reaction, parosmia, pericardial effusion, polyuria, prostatic carcinoma, prostatic disorder, pruritus, psychosis, rectal disorder, rhinitis, salivation increased, seborrhea, skin discoloration, skin disorder, stomach atony, surgical procedure, tenosynovitis, thinking abnormal, thirst, thrombocytopenia, thrombosis, tongue disorder, twitching, urinary retention, urinary tract disorder, urticaria, uterine atony, uterine disorder, uterine hemorrhage, vaginitis, viral infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F228985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tolcapone or any component of the formulation; history of liver disease or tolcapone-induced hepatocellular injury; nontraumatic rhabdomyolysis or hyperpyrexia and confusion",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F228971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: Has been associated with delayed development of diarrhea (onset after 2-12 weeks); use with caution in patients with lower gastrointestinal disease or an increased risk of dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hallucinations: May cause hallucinations, which may improve with reduction in levodopa therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopaminergic agents used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Due to reports of fatal liver injury associated with use of this drug, the manufacturer is advising that tolcapone be reserved for patients who are experiencing inadequate symptom control or who are not appropriate candidates for other available treatments.",
"     </b>",
"     Patients must provide written consent acknowledging the risks of hepatic injury. Liver disease should be excluded prior to initiation; laboratory monitoring is recommended. Discontinue if signs and/or symptoms of hepatic injury are noted (eg, transaminases &gt;2 times upper limit of normal) or if clinical improvement is not evident after 3 weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome: Tolcapone, in conjunction with other drug therapy that alters brain biogenic amine concentrations (eg, MAO inhibitors, SSRIs), has been associated with a syndrome resembling neuroleptic malignant syndrome (hyperpyrexia and confusion - some fatal) on abrupt withdrawal or dosage reduction. Concomitant use of tolcapone and nonselective MAO inhibitors should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension and syncope; Parkinson's disease patients appear to have an impaired capacity to respond to a postural challenge; use with caution in patients at risk of hypotension (such as those receiving antihypertensive drugs) or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Parkinson's patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Dopaminergic agents from the ergot class have been associated with fibrotic complications, such as retroperitoneal fibrosis, pulmonary infiltrates or effusion and pleural thickening. It is unknown whether non-ergot, pro-dopaminergic agents like tolcapone confer this risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rhabdomyolysis: Severe rhabdomyolysis has been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyskinesia: Use with caution in patients with pre-existing dyskinesias; exacerbation of pre-existing dyskinesia has been reported. Levodopa dosage reduction may be required, particularly in patients with levodopa dosages &gt;600 mg daily or with moderate-to-severe dyskinesia prior to initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Concomitant use of tolcapone and nonselective MAO inhibitors should be avoided. Selegiline is a selective MAO type B inhibitor (when given orally at  &le;10 mg/day) and can be taken with tolcapone.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F229013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     COMT, CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F228975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Substrates: COMT Inhibitors may decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: COMT Inhibitors may enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F228996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Tolcapone, taken with food within 1 hour before or 2 hours after the dose, decreases bioavailability by 10% to 20%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F228976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2838239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolcapone may be teratogenic based on animal studies. There are no adequate and well-controlled studies in pregnant women. Use only if benefit outweighs risk.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F229005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F1630561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F228987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tasmar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (90): $1444.66",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F228978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, symptoms of Parkinson's disease, liver enzymes at baseline and then every 2-4 weeks for the first 6 months of therapy; thereafter, periodic monitoring should be conducted as deemed clinically relevant. If the dose is increased to 200 mg 3 times/day, reinitiate LFT monitoring every 2-4 weeks for 6 months, and then resume periodic monitoring. Discontinue therapy if the ALT or AST exceeds 2 times  ULN  or if the clinical signs and symptoms suggest the onset of liver failure.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4324166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tasmar (AR, AT, BB, BE, BG, BM, BR, BS, BZ, CH, CN, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, GY, HN, IE, IT, JM, MT, MX, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SK, SR, SV, TR, TT, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F228970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolcapone is a selective and reversible inhibitor of catechol-o-methyltransferase (COMT). In the presence of a decarboxylase inhibitor (eg, carbidopa), COMT is the major degradation pathway for levodopa. Inhibition of COMT leads to more sustained plasma levels of levodopa and enhanced central dopaminergic activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F228984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 9 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99.0%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via glucuronidation, to inactive metabolite (&gt;99%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% as metabolites, 0.5% as unchanged drug);  feces (40%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kurth MC, Adler CH, Hilaire MS, et al, &ldquo;Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients With Parkinson's Disease Experiencing Motor Fluctuations: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 48(1):81-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33526/abstract-text/9008498/pubmed\" id=\"9008498\" target=\"_blank\">",
"        9008498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olanow CW, Watts RL, and Koller WC, &ldquo;An Algorithm (Decision Tree) for the Management of Parkinson's Disease (2001): Treatment Guidelines,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2001, 56(11 Suppl 5):1-88.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pahwa R, Factor SA, Lyons KE, et al, &ldquo;Practice Parameter: Treatment of Parkinson Disease With Motor Fluctuations and Dyskinesia (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2006, 66(7):983-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33526/abstract-text/16606909/pubmed\" id=\"16606909\" target=\"_blank\">",
"        16606909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sedek G, Jorga K, Schmitt M, et al, &ldquo;Effect of Tolcapone on Plasma Levodopa Concentrations After Coadministration With Levodopa/Carbidopa to Healthy Volunteers,&rdquo;",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 1997, 20(6):531-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/47/33526/abstract-text/9403227/pubmed\" id=\"9403227\" target=\"_blank\">",
"        9403227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10290 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33526=[""].join("\n");
var outline_f32_47_33526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708909\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228999\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229018\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229002\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229003\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2838266\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2838267\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228980\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228967\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11236687\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1630562\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228981\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229016\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228985\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228971\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229013\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228975\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228996\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228976\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2838239\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229005\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1630561\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228987\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228978\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4324166\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228970\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228984\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10290\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10290|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/60/34756?source=related_link\">",
"      Tolcapone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_47_33527="Hashimoto's encephalopathy";
var content_f32_47_33527=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hashimoto's encephalopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/47/33527/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33527/contributors\">",
"     Devon I Rubin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/47/33527/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33527/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33527/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/47/33527/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33527/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/47/33527/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hashimoto's encephalopathy (HE) is an uncommon syndrome associated with Hashimoto's thyroiditis. Originally described in 1966, it remains a somewhat controversial disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/1\">",
"     1",
"    </a>",
"    ]. HE is most often characterized by a subacute onset of confusion with altered level of consciousness, seizures, and myoclonus. In contrast to the cognitive dysfunction associated with hypothyroidism or hyperthyroidism, HE is believed to be an immune-mediated disorder rather than representing the direct effect of an altered thyroid state on the central nervous system.",
"   </p>",
"   <p>",
"    Although there is some debate regarding the appropriateness of the term Hashimoto's encephalopathy, it remains the most widely used term to describe this syndrome. Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT) and a more general term, nonvasculitic autoimmune meningoencephalitis, are also used to describe this condition.",
"   </p>",
"   <p>",
"    Hashimoto's encephalopathy will be reviewed here. Hashimoto's thyroiditis and other neurologic complications of thyroid disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27833?source=see_link\">",
"     \"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8566?source=see_link\">",
"     \"Myxedema coma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36585?source=see_link\">",
"     \"Neurologic manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30057?source=see_link\">",
"     \"Neurologic manifestations of hyperthyroidism and Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of Hashimoto's encephalopathy (HE) is unknown. It does not appear to be directly related to hypothyroidism or hyperthyroidism, as the majority of reported patients are euthyroid at the time of presentation. A toxic effect of increased thyrotropin-releasing hormone on the central nervous system has been proposed, as some patients appear to improve with thyroid supplementation despite being euthyroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, these cases appear to be the exception rather than the rule.",
"   </p>",
"   <p>",
"    The bulk of evidence points to an autoimmune vasculitis or other inflammatory process, perhaps associated with immune complex deposition, and possibly disrupting the cerebral microvasculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pathologic examination at autopsy or brain biopsy in a few patients has identified lymphocytic infiltration around small arterioles and venules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3,6\">",
"       3,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most patients with HE appear to respond to corticosteroid therapy or other immunosuppressive therapies.",
"     </li>",
"     <li>",
"      The disorder is more common in women, as is true of most autoimmune disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated antithyroid antibodies, an essential feature of this disorder, are consistent with an active autoimmune process.",
"     </li>",
"     <li>",
"      In one series, seven of eight patients had HLA B8 DRw3 haplotypes compared with 30 percent of a control population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/7\">",
"       7",
"      </a>",
"      ]. This profile is common to other patients with autoimmune diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nature of the relationship between Hashimoto's thyroiditis (HT) and HE is unclear. Some argue that the association is entirely spurious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/8\">",
"     8",
"    </a>",
"    ]. Elevated antithyroid antibodies in the serum correlate well with pathologic thyroiditis. However, elevated titers are prevalent in the general healthy population, occurring in 2 to 10 percent of young adults and 5 to 20 percent of older adults. It is possible, therefore, that elevated titers are a coincidental finding.",
"   </p>",
"   <p>",
"    Others argue that the relationship between HT and HE is just that seen among autoimmune disorders in general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3\">",
"     3",
"    </a>",
"    ]. HT itself is associated with neurologic and systemic autoimmune diseases including myasthenia gravis, systemic lupus erythematosus, and type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/7\">",
"     7",
"    </a>",
"    ]. Support for this argument includes the observation that the symptoms of HE are not paralleled by symptoms of thyroiditis. In addition, changes in antithyroid autoantibody levels do not consistently correspond with neurologic symptoms or improvement with treatment. These findings lead some to propose that steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT) is a more appropriate designation for this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nature of the putative autoimmune response in HE is speculative. A number of observations and investigations in small numbers of patients have elicited different theories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HE may result from a direct antibody-mediated neuronal injury. Immunohistochemical analysis in one patient with HE detected an anti-neuronal antibody that reacted with human cerebral cortex [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HE may represent a vasculitis that results from either endothelial inflammation or immune complex deposition. Findings of perfusion deficits on single photon emission computed tomography (SPECT) suggest vascular involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3,7,13\">",
"       3,7,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A potentially specific marker for HE has been identified in an autoantibody expressed against the amino terminal end of the enzyme alpha enolase. In one study, reactivity was found in five of six HE patients compared with 2 of 17 patients with HT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/14\">",
"       14",
"      </a>",
"      ]. No reactivity was found either in 25 healthy controls or in 25 patients with other autoimmune or encephalopathic neurologic disorders. A pathogenic role for this antibody is not understood; however, as alpha enolase is expressed on endothelial cells it may mediate a vasculitis.",
"     </li>",
"     <li>",
"      HE may be a primary demyelinating process akin to acute disseminated encephalomyelitis (ADEM). This is corroborated by pathologic and magnetic resonance imaging (MRI) findings in a few patients with HE, which appear similar to those seen in ADEM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3,15\">",
"       3,15",
"      </a>",
"      ]. However, MRI findings of white matter disease are not typical of most reported patients with HE. These ADEM-like cases may represent anomalous cases of acute demyelinating disease in patients with incidentally elevated antithyroid antibody levels.",
"     </li>",
"     <li>",
"      HE may represent an immune complex disease, since immune complexes were found in the cerebrospinal fluid (CSF) in a series of six patients with HE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/16\">",
"       16",
"      </a>",
"      ]. However, CSF IgG indices are inconsistently elevated in HE. Also, the degree of inflammation on CSF analysis and neuroimaging appears mild in HE and therefore at odds with this pathogenesis.",
"     </li>",
"     <li>",
"      It seems unlikely that the antithyroid antibodies play a pathogenic role in HE. There is no evidence of a central nervous system antigen recognized by these antibodies. On the other hand, antithyroid antibodies were identified in the CSF of all six of the patients with HE in one report and in none of the controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/16\">",
"       16",
"      </a>",
"      ]. This, in the absence of blood brain barrier disruption, suggests possible intrathecal synthesis of these antibodies. However, others have not found these antibodies to be reliably present in the CSF in patients with HE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELATED DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonvasculitic autoimmune inflammatory meningoencephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less frequently reported than Hashimoto's encephalopathy (HE) are similar syndromes in other autoimmune disorders (eg, Sjogren's syndrome) that have been labeled nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. HE and NAIM are clinically similar and have similar diagnostic findings, suggesting that HE may be a subset of NAIM. A lymphocytic pleocytosis in the cerebrospinal fluid (CSF) is not, as one might expect from its name, a cardinal feature of NAIM and is also relatively uncommon among reported cases of HE. A steroid-responsive encephalopathy has been reported in one patient with Graves' disease, an autoimmune disorder that causes hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acute disseminated encephalomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute disseminated encephalomyelitis (ADEM) is an inflammatory, presumably autoimmune, demyelinating disease of the central nervous system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/52/25416?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some propose that HE is a form of ADEM. One series identified a high rate of possible provoking factors for HE, such as infection and surgery, which are also noted in ADEM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/7\">",
"     7",
"    </a>",
"    ]. Although a few reported cases of HE have similar magnetic resonance imaging (MRI) and pathologic findings to ADEM, most do not. It seems possible that these exceptional cases are in fact cases of ADEM with incidental elevations of antithyroid antibodies. Unlike HE, ADEM is a monophasic disorder and is not generally associated with other autoimmune diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review published in 2006 identified only 121 published cases of Hashimoto's encephalopathy (HE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the syndrome may be underrecognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2\">",
"     2",
"    </a>",
"    ]. A hospital-based epidemiologic study aggressively screened for HE in patients with unexplained neurologic symptoms consistent with HE and estimated the prevalence of HE to be 2.1 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among reported cases, the mean age of onset of initial symptoms is 41 to 44 years (range 9 to 78) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2-4,21\">",
"     2-4,21",
"    </a>",
"    ]. Women are more commonly affected than men, at a ratio of approximately four to one.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of Hashimoto's encephalopathy (HE) most often include an acute to subacute onset of confusion with alteration of consciousness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Two patterns of presentation have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A stroke-like pattern of multiple, recurrent, acute to subacute episodes of focal neurologic deficits with a variable degree of cognitive dysfunction and alteration of consciousness. Approximately 25 percent of patients follow this course [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A diffuse, progressive pattern, characterized by slowly progressive cognitive impairment with dementia, confusion, hallucinations, or somnolence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2,23\">",
"       2,23",
"      </a>",
"      ]. Some cases have a more fulminant presentation in which rapid deterioration to coma occurs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2,7\">",
"       2,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These clinical patterns can overlap. In addition to confusion and mental status changes, other neurologic signs are common in both groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately two-thirds of patients experience focal or generalized tonic-clonic seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3,21,24,25\">",
"       3,21,24,25",
"      </a>",
"      ]. Status epilepticus has been reported in 12 percent.",
"     </li>",
"     <li>",
"      Myoclonus or tremor is seen in up to 38 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3,21\">",
"       3,21",
"      </a>",
"      ]. Myoclonus may be focal or multifocal.",
"     </li>",
"     <li>",
"      Diffuse hyperreflexia and other pyramidal tract signs are present in 85 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Psychosis, particularly visual hallucinations, but also paranoid delusions, have been reported in 25 to 36 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3,21\">",
"       3,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The long-term course of illness may be self-limited, relapsing-remitting, or progressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare syndromes associated with HE include a cerebellopathy with or without encephalopathy, isolated myelopathy, and chorea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. Peripheral nervous system involvement with electrophysiological evidence of a sensory ganglionopathy, demyelinating polyneuropathy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amyotrophy has been described in individual cases of HE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no systemic symptoms, including fever, with rare exceptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/7\">",
"     7",
"    </a>",
"    ]. Neurologic symptoms can occur in patients with a known diagnosis of Hashimoto's thyroiditis (HT) or in patients without a previous diagnosis. The development of clinical HT may occur up to three years after presentation with HE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antithyroid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated serum level of anti-thyroid peroxidase antibody (TPOAb)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antithyroglobulin antibody (TgAb) is an essential laboratory feature of Hashimoto's encephalopathy (HE). However, there is no clear relationship between the severity of neurologic symptoms and the type or serum concentration of antibodies; in addition, antibody levels may or may not decrease following treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3,7,11,21,22\">",
"     3,7,11,21,22",
"    </a>",
"    ]. Given the prevalence of these antibodies in the general healthy population of 2 to 20 percent, this cannot be considered to be a specific finding for HE.",
"   </p>",
"   <p>",
"    Antithyroid antibodies are infrequently measured in the cerebrospinal fluid (CSF). One case series found that 9 of 12 patients with encephalopathy and elevated serum antithyroid antibodies had elevated CSF autoantibody titres [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/22\">",
"     22",
"    </a>",
"    ]. The authors suggested that serum antibody titers were overly sensitive. However, other investigators did not find antithyroid antibodies in the CSF of patients with HE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/5\">",
"     5",
"    </a>",
"    ]. The specificity and sensitivity of anti-thyroid antibodies in the CSF are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Thyroid hormone levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid status varies among patients with reported HE, ranging from overt hypothyroidism to overt hyperthyroidism. In systematic reviews, 23 to 35 percent of patients with HE have subclinical hypothyroidism and 17 to 20 percent have overt hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3,21\">",
"     3,21",
"    </a>",
"    ]. About 7 percent are hyperthyroid; the remainder are euthyroid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrospinal fluid analysis is abnormal in approximately 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2\">",
"     2",
"    </a>",
"    ]. The following findings have been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common abnormality is an elevated protein concentration (reported range 48 to 298",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      which occurs in approximately 75 percent of patients. Levels greater than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      are uncommon, occurring in about 20 percent.",
"     </li>",
"     <li>",
"      A lymphocytic pleocytosis (8 to 169 cells) is present in 10 to 25 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2,21\">",
"       2,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The glucose concentration is normal.",
"     </li>",
"     <li>",
"      Both the presence and absence of oligoclonal bands are reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated 14-3-3 protein, a finding associated with Creutzfeldt-Jakob disease, has been reported in HE but is not a universal finding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/21,27,36\">",
"       21,27,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific electroencephalographic (EEG) abnormalities are seen in 90 to 98 percent of patients, usually demonstrating nonspecific slowing of background activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2,7,9,37\">",
"     2,7,9,37",
"    </a>",
"    ]. Focal spikes or sharp waves and transient epileptic activity are less common. Triphasic waves and frontal intermittent rhythmic delta activity (FIRDA) have also been described.",
"   </p>",
"   <p>",
"    Some report that EEG abnormalities recover rapidly with steroid administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/9\">",
"     9",
"    </a>",
"    ], whereas others note that EEG improvement lags behind clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/7,38\">",
"     7,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) in patients with HE is usually normal, but may demonstrate cerebral atrophy or nonspecific T2 signal abnormalities in the subcortical white matter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3\">",
"     3",
"    </a>",
"    ]. The latter have been described in about one-half of patients and are not associated with gadolinium enhancement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2,3,7\">",
"     2,3,7",
"    </a>",
"    ]. This may be an incidental finding, although a few reports have described regression or resolution of these findings with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In exceptional cases of HE, MRI findings of diffuse or focal white matter changes suggesting primary demyelination have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3,15,39,40\">",
"     3,15,39,40",
"    </a>",
"    ]. Other findings noted in individual case reports include meningeal enhancement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/40\">",
"     40",
"    </a>",
"    ] and T2 signal abnormalities in both hippocampi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up imaging is not often described. In some cases, the findings appear to regress or resolve with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other tests also reveal nonspecific findings. Cerebral angiography, when performed, is normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2\">",
"     2",
"    </a>",
"    ]. Single photon emission computed tomography (SPECT) may show focal, multifocal, or global hypoperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3,7,13\">",
"     3,7,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;C-reactive protein and the erythrocyte sedimentation rate are elevated in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/40\">",
"     40",
"    </a>",
"    ]. In one series, mild elevations of liver enzymes were found in 12 of 20 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any disease associated with a syndrome of delirium or rapidly progressive dementia may be confused with Hashimoto's encephalopathy (HE). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Creutzfeldt-Jakob disease",
"     </li>",
"     <li>",
"      Acute disseminated encephalomyelitis",
"     </li>",
"     <li>",
"      Toxic metabolic encephalopathies (",
"      <a class=\"graphic graphic_table graphicRef59893 \" href=\"mobipreview.htm?3/43/3773\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Meningoencephalitis",
"     </li>",
"     <li>",
"      Psychiatric disease (depression, anxiety, psychosis)",
"     </li>",
"     <li>",
"      Carcinomatous meningitis",
"     </li>",
"     <li>",
"      Paraneoplastic encephalitis",
"     </li>",
"     <li>",
"      Degenerative dementia (Alzheimer disease, dementia with Lewy bodies, frontotemporal dementia)",
"     </li>",
"     <li>",
"      Stroke or transient ischemic attack",
"     </li>",
"     <li>",
"      Basilar or hemiplegic migraine",
"     </li>",
"     <li>",
"      Cerebral vasculitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study examined the clinical features of 32 patients presenting with progressive encephalopathy associated with elevated antithyroid antibody titers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/40\">",
"     40",
"    </a>",
"    ]. Of the 12 patients who did not respond to steroids, four with autopsy data were later proven to have alternative diagnoses: Creutzfeldt Jacob disease, frontotemporal dementia, and dementia with Lewy bodies. Notably, these are all untreatable conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of elevated anti-thyroid peroxidase antibody (TPOAb) or antithyroglobulin antibody (TgAb) in patients with a compatible clinical presentation is required for the diagnosis of Hashimoto's encephalopathy (HE). These findings and a response to corticosteroids generally defines this syndrome. Thyroid hormone levels should be measured but, as noted above, thyroid status is variable in HE. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Thyroid hormone levels'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Essential testing to exclude other diagnoses includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lumbar puncture to include cultures for bacteria, viruses, fungi, and mycobacterium",
"     </li>",
"     <li>",
"      Electroencephalography",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) with gadolinium administration",
"     </li>",
"     <li>",
"      Laboratory testing for usual causes of delirium (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link&amp;anchor=H31#H31\">",
"       \"Diagnosis of delirium and confusional states\", section on 'Diagnostic tests'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the treatment of HE consists of immunosuppressive therapy, it is especially important to thoroughly exclude infection. Other, less routine diagnostic test considerations should include cerebrospinal fluid (CSF) analysis for 14-3-3 protein (for possible Creutzfeldt-Jacob disease), CSF cytology, antibody testing for possible paraneoplastic encephalopathy, and screening for underlying neoplasm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=see_link\">",
"     \"Paraneoplastic and autoimmune encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hashimoto's encephalopathy (HE) is usually treated with corticosteroids and treatment of a dysthyroid state, if present. Given the rarity of the disorder, an optimal steroid dose has not been defined. Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses ranging from 50 mg to 150 mg daily have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2\">",
"     2",
"    </a>",
"    ]. High-dose intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    has been administered in a few patients, but a benefit compared with oral corticosteroids is unknown.",
"   </p>",
"   <p>",
"    Most patients (90 to 98 percent) respond to steroid therapy. Symptoms typically improve or resolve over a few months. The duration of treatment and the rate of taper is generally titrated to the clinical response. In some patients, this is as long as two years.",
"   </p>",
"   <p>",
"    Several patients have been treated with other immunosuppressive medications, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/5,7,41\">",
"     5,7,41",
"    </a>",
"    ]. These are generally reserved for patients who cannot tolerate corticosteroids, or who do not respond to or relapse after or during tapering of corticosteroid therapy. Clinical improvement with intravenous immunoglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/42\">",
"     42",
"    </a>",
"    ], and plasmapheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/43-45\">",
"     43-45",
"    </a>",
"    ] has been reported in individual cases.",
"   </p>",
"   <p>",
"    Treatment of seizures with an anticonvulsant medication such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    may be necessary as a temporary measure. In some patients, seizures do not respond to antiepileptic drugs but may respond to steroid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of Hashimoto's encephalopathy (HE) is generally but not universally good. While a delay to diagnosis and therefore treatment might be expected to be associated with less complete recovery, case series and reports suggest that patients can improve with treatment even after a few years of symptoms. However, residual cognitive impairment occurs in about 25 percent of patients with long-standing untreated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/7,37,40\">",
"     7,37,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous recovery can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/22,37\">",
"     22,37",
"    </a>",
"    ]. However, most reports of long-term follow-up are in treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Many of these patients remain disease-free after discontinuation of steroids over several years of follow-up. In one series of 20 patients, eight discontinued use of steroids after treatment and had no relapse, three relapsed and were treated with additional course of steroids, and nine required continuous treatment with steroids or other immunomodulatory therapy to maintain remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/40\">",
"     40",
"    </a>",
"    ]. A lower rate of long-term immunosuppressive therapy use (3 of 18) was reported in another case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hashimoto's encephalopathy (HE) is a syndrome of acute or subacute encephalopathy that is associated with elevated anti-thyroid antibody titers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HE appears to be a rare syndrome, but may be underrecognized. As with Hashimoto's thyroiditis, women are more commonly affected than men. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The bulk of evidence suggests that HE is an autoimmune disorder and is not due to thyroid disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presentation is heterogeneous with a fulminant, subacute, or more chronic course of declining mental status that is frequently accompanied by seizures and myoclonus. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of elevated antithyroid antibody titres and the exclusion of other causes of encephalopathy support the diagnosis of HE. While the diagnosis is disputed, there appears to be enough evidence to support checking antithyroid antibody levels as a second- or third-tier diagnostic test in patients presenting with unexplained encephalopathy and considering the diagnosis of HE if levels are elevated.",
"      <br/>",
"      <br/>",
"      Other test findings are nonspecific. Nonetheless, magnetic resonance imaging (MRI), electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, and other laboratory studies are essential in these patients to exclude other causes of encephalopathy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a patient with encephalopathy and elevated antithyroid antibody levels in whom other causes of encephalopathy are rigorously excluded, we recommend a trial of corticosteroid therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Other immunosuppressive treatments have also been used. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients have a good outcome, but a significant minority have persistent cognitive deficits, particularly those with long-standing untreated disease. Relapses may require prolonged immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/1\">",
"      Brain L, Jellinek EH, Ball K. Hashimoto's disease and encephalopathy. Lancet 1966; 2:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/2\">",
"      Kothbauer-Margreiter I, Sturzenegger M, Komor J, et al. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol 1996; 243:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/3\">",
"      Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol 2003; 60:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/4\">",
"      Peschen-Rosin R, Schabet M, Dichgans J. Manifestation of Hashimoto's encephalopathy years before onset of thyroid disease. Eur Neurol 1999; 41:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/5\">",
"      Shaw PJ, Walls TJ, Newman PK, et al. Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers--report of 5 cases. Neurology 1991; 41:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/6\">",
"      Duffey P, Yee S, Reid IN, Bridges LR. Hashimoto's encephalopathy: postmortem findings after fatal status epilepticus. Neurology 2003; 61:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/7\">",
"      Chaudhuri A, Behan PO. The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimoto's encephalopathy (recurrent acute disseminated encephalomyelitis). Curr Med Chem 2003; 10:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/8\">",
"      Sunil GS, Mariash CN. Hashimoto's encephalitis. J Clin Endocrinol Metab 2001; 86:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/9\">",
"      Rodriguez AJ, Jicha GA, Steeves TD, et al. EEG changes in a patient with steroid-responsive encephalopathy associated with antibodies to thyroperoxidase (SREAT, Hashimoto's encephalopathy). J Clin Neurophysiol 2006; 23:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/10\">",
"      Fatourechi V. Hashimoto's encephalopathy: myth or reality? An endocrinologist's perspective. Best Pract Res Clin Endocrinol Metab 2005; 19:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/11\">",
"      Cant&oacute;n A, de F&agrave;bregas O, Tintor&eacute; M, et al. Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition? J Neurol Sci 2000; 176:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/12\">",
"      Oide T, Tokuda T, Yazaki M, et al. Anti-neuronal autoantibody in Hashimoto's encephalopathy: neuropathological, immunohistochemical, and biochemical analysis of two patients. J Neurol Sci 2004; 217:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/13\">",
"      Forchetti CM, Katsamakis G, Garron DC. Autoimmune thyroiditis and a rapidly progressive dementia: global hypoperfusion on SPECT scanning suggests a possible mechanism. Neurology 1997; 49:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/14\">",
"      Fujii A, Yoneda M, Ito T, et al. Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto's encephalopathy. J Neuroimmunol 2005; 162:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/15\">",
"      Mahad DJ, Staugaitis S, Ruggieri P, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci 2005; 228:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/16\">",
"      Ferracci F, Moretto G, Candeago RM, et al. Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto's encephalopathy. Neurology 2003; 60:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/17\">",
"      Caselli RJ, Boeve BF, Scheithauer BW, et al. Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy. Neurology 1999; 53:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/18\">",
"      Josephs KA, Rubino FA, Dickson DW. Nonvasculitic autoimmune inflammatory meningoencephalitis. Neuropathology 2004; 24:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/19\">",
"      Hoffman Snyder C, Mishark KJ, Caviness JN, et al. Nonvasculitic autoimmune inflammatory meningoencephalitis imitating Creutzfeldt-Jakob disease. Arch Neurol 2006; 63:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/20\">",
"      Seo SW, Lee BI, Lee JD, et al. Thyrotoxic autoimmune encephalopathy: a repeat positron emission tomography study. J Neurol Neurosurg Psychiatry 2003; 74:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/21\">",
"      Ferracci F, Carnevale A. The neurological disorder associated with thyroid autoimmunity. J Neurol 2006; 253:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/22\">",
"      Ferracci F, Bertiato G, Moretto G. Hashimoto's encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci 2004; 217:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/23\">",
"      Spiegel J, Hellwig D, Becker G, M&uuml;ller M. Progressive dementia caused by Hashimoto's encephalopathy -- report of two cases. Eur J Neurol 2004; 11:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/24\">",
"      Ferlazzo E, Raffaele M, Mazz&ugrave; I, Pisani F. Recurrent status epilepticus as the main feature of Hashimoto's encephalopathy. Epilepsy Behav 2006; 8:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/25\">",
"      McKeon A, McNamara B, Sweeney B. Hashimoto's encephalopathy presenting with psychosis and generalized absence status. J Neurol 2004; 251:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/26\">",
"      Marshall GA, Doyle JJ. Long-term treatment of Hashimoto's encephalopathy. J Neuropsychiatry Clin Neurosci 2006; 18:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/27\">",
"      Vander T, Hallevy C, Alsaed I, et al. 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy. J Neurol 2004; 251:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/28\">",
"      Passarella B, Negro C, Nozzoli C, et al. Cerebellar subacute syndrome due to corticosteroid-responsive encephalopathy associated with autoimmune thyroiditis (also called \"Hashimoto's encephalopathy\"). Clin Ter 2005; 156:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/29\">",
"      Manto M, Goldman S, Bodur H. [Cerebellar syndrome associated with Hashimoto's encephalopathy]. Rev Neurol (Paris) 1996; 152:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/30\">",
"      Taurin G, Golfier V, Pinel JF, et al. Choreic syndrome due to Hashimoto's encephalopathy. Mov Disord 2002; 17:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/31\">",
"      Selim M, Drachman DA. Ataxia associated with Hashimoto's disease: progressive non-familial adult onset cerebellar degeneration with autoimmune thyroiditis. J Neurol Neurosurg Psychiatry 2001; 71:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/32\">",
"      Nakagawa H, Yoneda M, Fujii A, et al. Hashimoto's encephalopathy presenting with progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry 2007; 78:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/33\">",
"      Cao NJ, Tselis AC, Li J, Gorman M. A case of Hashimoto's encephalopathy: association with sensory ganglionopathy. J Neurol Sci 2005; 238:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/34\">",
"      Sheng B, Lau KK, Li HL, Cheng LF. A case of Hashimoto's encephalopathy with demyelinating peripheral neuropathy. Eur Neurol 2005; 53:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/35\">",
"      Kastrup O, Maschke M, Schlamann K, Diener HC. Hashimoto encephalopathy and neuralgic amyotrophy--causal link or chance association? Eur Neurol 2005; 53:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/36\">",
"      Hern&aacute;ndez Echebarr&iacute;a LE, Saiz A, Graus F, et al. Detection of 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy. Neurology 2000; 54:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/37\">",
"      Gayatri NA, Whitehouse WP. Pilot survey of Hashimoto's encephalopathy in children. Dev Med Child Neurol 2005; 47:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/38\">",
"      Henchey R, Cibula J, Helveston W, et al. Electroencephalographic findings in Hashimoto's encephalopathy. Neurology 1995; 45:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/39\">",
"      McCabe DJ, Burke T, Connolly S, Hutchinson M. Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto's encephalopathy. Neurology 2000; 54:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/40\">",
"      Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/41\">",
"      Thrush DC, Boddie HG. Episodic encephalopathy associated with thyroid disorders. J Neurol Neurosurg Psychiatry 1974; 37:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/42\">",
"      Jacob S, Rajabally YA. Hashimoto's encephalopathy: steroid resistance and response to intravenous immunoglobulins. J Neurol Neurosurg Psychiatry 2005; 76:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/43\">",
"      Nieuwenhuis L, Santens P, Vanwalleghem P, Boon P. Subacute Hashimoto's encephalopathy, treated with plasmapheresis. Acta Neurol Belg 2004; 104:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/44\">",
"      Nagpal T, Pande S. Hashimoto's encephalopathy: response to plasma exchange. Neurol India 2004; 52:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33527/abstract/45\">",
"      Boers PM, Colebatch JG. Hashimoto's encephalopathy responding to plasmapheresis. J Neurol Neurosurg Psychiatry 2001; 70:132.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4821 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-EFB8DDA1F5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33527=[""].join("\n");
var outline_f32_47_33527=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELATED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonvasculitic autoimmune inflammatory meningoencephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acute disseminated encephalomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antithyroid antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Thyroid hormone levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cerebrospinal fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4821|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/43/3773\" title=\"table 1\">",
"      Causes of delirium and confusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/52/25416?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8566?source=related_link\">",
"      Myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36585?source=related_link\">",
"      Neurologic manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/11/27833?source=related_link\">",
"      Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_47_33528="Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis";
var content_f32_47_33528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/47/33528/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33528/contributors\">",
"     Peter C Taylor, MA, PhD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33528/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/47/33528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33528/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/47/33528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33528/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/47/33528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rheumatoid arthritis (RA) follow a variable disease course with regard to outcome measures such as functional status or radiological assessment of joint damage. Early identification of patients with RA and, in particular, those likely to assume a more rapidly destructive form of disease is important because of the possible benefit from early, aggressive intervention with disease modifying agents. This realization has prompted the investigation and measurement of numerous biologic &ldquo;markers&rdquo; in blood and joint fluids that may serve as indicators of prognosis and the response to therapy. Although some of the markers under consideration are accessible in routine practice, many are in the stage of experimental evaluation and require access to specialized technology and customized reagents.",
"   </p>",
"   <p>",
"    This topic will review those markers that are used in clinical practice as aids in the diagnosis of rheumatoid arthritis (RA) or for prognostic purposes in patients with already established disease. Other tests that are still investigational or are of historic interest are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2234?source=see_link\">",
"     \"Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important associations have been noted between certain genetic polymorphisms and the susceptibility to and severity of RA. These are presented separately, as genetic testing has yet to play a role in diagnosis or treatment of RA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=see_link\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICALLY USEFUL MARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the many biologic markers that have been assessed for usefulness in estimating disease activity and prognosis of rheumatoid arthritis, only a few have found a role in clinical practice. The main clinically useful biologic markers in patients with RA are rheumatoid factors and antibodies to citrullinated peptides for diagnosis and prediction of functional and radiographic outcomes, and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) for aid in assessing disease activity and predicting functional and radiographic outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RHEUMATOID FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid factors (RF) are autoantibodies directed against the Fc portion of immunoglobulin G (IgG). They are found in 75 to 80 percent of RA patients at some time during the course of their disease. High titer IgM RF is relatively specific for the diagnosis of RA in the context of a chronic polyarthritis and was, for decades, the sole serologic criterion widely used in the diagnosis of RA. However, it has little predictive value in the general population, because the overall disease prevalence is relatively low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42648?source=see_link\">",
"     \"Origin and utility of measurement of rheumatoid factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for IgM RF remains useful in clinical practice, despite the widespread availability of tests for anti-citrullinated peptide antibodies (ACPA) and the recognition of ACPA among the criteria for RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/1\">",
"     1",
"    </a>",
"    ]. A small proportion of patients eventually diagnosed with RA may be positive for RF, but not for ACPA, in the early stages of their presentation; thus, measurement of both RF and ACPA, rather than ACPA alone, improves the specificity and sensitivity of serologic testing for establishing a diagnosis of RA. Moreover, high titer RF appears to be a better predictor of a severe disease course, showing a stronger correlation with extraarticular manifestations, such as interstitial lung disease and vasculitis, than appears to be the case for ACPA. The presence of RF also increases the likelihood of a clinically significant response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    after failure of tumor necrosis factor inhibitor therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Anti-CCP antibodies'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\", section on 'Autoantibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42648?source=see_link\">",
"     \"Origin and utility of measurement of rheumatoid factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RF also occurs in other diseases. As an example, some connective tissue diseases, such as systemic lupus erythematosus (SLE) and primary Sj&ouml;gren's syndrome, may be associated with the presence of RF. In addition, RF levels may be elevated in patients with certain infections, such as malaria, rubella, hepatitis C, and those following vaccinations.",
"   </p>",
"   <p>",
"    Rheumatoid factor may have some prognostic value with regard to disease manifestations and activity, as well as the severity of joint erosions. Seropositive RA (ie, RA associated with a positive rheumatoid factor test) is often associated with more aggressive joint disease and is more commonly complicated by extraarticular manifestations than seronegative RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheumatoid nodules and vasculitis occur almost exclusively in seropositive patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/5-8,10\">",
"       5-8,10",
"      </a>",
"      ]; these findings are associated with increased mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiographic progression may be more rapid among patients with a positive RF at initial evaluation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/12-14\">",
"       12-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis of a case control study of 135 women with early RA found that patients with persistently positive RF had more erosions, nodules, extraarticular disease, functional disability and disease activity than seronegative or intermittently seronegative individuals over a mean period of six years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has also been proposed that the rate of formation of new erosions among seropositive patients correlates with the RF titer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/16\">",
"     16",
"    </a>",
"    ]. This finding, however, was not confirmed in an eight-year study of a community-based cohort of patients with recent-onset arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of RF, particularly at high levels, may antedate the clinical development of RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/18\">",
"     18",
"    </a>",
"    ]. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\", section on 'Autoantibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42648?source=see_link&amp;anchor=H7#H7\">",
"     \"Origin and utility of measurement of rheumatoid factors\", section on 'Healthy individuals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTI-CITRULLINATED PEPTIDE ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for anti-citrullinated",
"    <span class=\"nowrap\">",
"     peptide/protein",
"    </span>",
"    antibodies (ACPA) has become common in the evaluation of patients for RA. The sensitivity of ACPA assays for RA varies from about 50 to 75 percent, depending upon the assay and study population, while specificity of ACPA for RA is relatively high, usually over 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/19-26\">",
"     19-26",
"    </a>",
"    ]. Enzyme-linked immunosorbent assays (ELISA) for antibodies against cyclic citrullinated peptides (CCP) are the most commonly used assays for ACPA. Another ACPA assay that is commercially available detects antibodies against mutated citrullinated vimentin (MCV).",
"   </p>",
"   <p>",
"    As with RF, ACPA may be present prior to the appearance of symptoms of RA. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=see_link&amp;anchor=H15#H15\">",
"     \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\", section on 'Autoantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of ACPA is useful in the differential diagnosis of early polyarthritis, because of the relatively high specificity for RA of these antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=see_link\">",
"     \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A decrease in ACPA titers can be seen in patients treated effectively, particularly if treated early with nonbiologic or biologic DMARDs, but is less frequent and of a lesser magnitude than the decrease in IgM RF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-CCP and anti-MCV assays are discussed below. The historical bases for these assays, including studies of antiperinuclear factor and antikeratin antibodies, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2234?source=see_link&amp;anchor=H5#H5\">",
"     \"Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis\", section on 'Autoantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anti-CCP antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a standardized enzyme-linked immunosorbent (ELISA) assay for ACPA, arginine residues are replaced by citrulline in a mixture of cyclic citrullinated peptides (CCP), increasing the sensitivity of the assay for ACPA. These anti-CCP assays have become the principal commercially available assay kits for the detection of ACPA.",
"   </p>",
"   <p>",
"    The newer generation assays, including the second generation anti-cyclic citrullinated peptide antibody assays (anti-CCP2), have improved sensitivity and specificity compared with the original anti-CCP assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/25,27,29-31\">",
"     25,27,29-31",
"    </a>",
"    ]. The best data regarding test performance characteristics of ACPA come from a 2010 systematic review and meta-analyses of 151 studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/27\">",
"     27",
"    </a>",
"    ]. The pooled results in the 2010 meta-analysis confirmed the results of a 2007 meta-analysis, which did not stratify by study design or disease duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/20\">",
"     20",
"    </a>",
"    ]. Sensitivity of ACPA in both analyses was 67 percent, and the specificities in the 2010 and the 2007 analysis were 96 and 95 percent, respectively.",
"   </p>",
"   <p>",
"    This analysis included the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was substantial heterogeneity in test performance, which resulted from differences in study design, stage of disease, and type of ACPA used in a given study. Cross-sectional and case-control studies of patients with established RA overestimated sensitivity.",
"     </li>",
"     <li>",
"      In the cohort studies of patients with RA for less than two years, the sensitivity of anti-CCP2 and RF were nearly the same (58 versus 56 percent), but specificity was significantly higher for anti-CCP2 (96 versus 86 percent).",
"     </li>",
"     <li>",
"      There was insufficient evidence to determine whether the combination of anti-CCP2 and RF provides greater benefit than the use of anti-CCP2 alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationships of ACPA to cigarette smoking and to the shared epitope are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\", section on 'Cigarette smoking'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis of rheumatoid arthritis\", section on 'Citrullinated proteins and peptides'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Positive anti-CCP in other diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ACPA testing is more specific than RF for RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/20,27\">",
"     20,27",
"    </a>",
"    ], positive results can occur in other diseases, including several autoimmune rheumatic diseases, tuberculosis, and sometimes chronic lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/26,32-36\">",
"     26,32-36",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-CCP antibodies have been reported in SLE and primary Sj&ouml;gren&rsquo;s syndrome (SS), usually in association with deforming or erosive arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/37-42\">",
"       37-42",
"      </a>",
"      ]. As examples, 17 percent of a cohort of 335 patients with SLE were anti-CCP positive in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/38\">",
"       38",
"      </a>",
"      ], and, in another, 10 percent of 155 consecutive patients with primary SS were anti-CCP positive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/41\">",
"       41",
"      </a>",
"      ]. However, in such cases, some experts suggest that such patients should be reclassified as SLE-RA and primary",
"      <span class=\"nowrap\">",
"       SS/RA",
"      </span>",
"      overlap syndromes, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/42\">",
"       42",
"      </a>",
"      ]. Similar findings have also been reported among patients with psoriatic arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increased prevalence of anti-CCP antibodies has been noted in patients with active tuberculosis (TB). The rate in different studies has ranged from as high as 32 to 39 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/32,33\">",
"       32,33",
"      </a>",
"      ] to as low as 7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/34\">",
"       34",
"      </a>",
"      ]. Many patients with TB and anti-CCP also have antibodies to a cyclic peptide that contains an unmodified arginine residue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/33\">",
"       33",
"      </a>",
"      ]. This suggests that binding of the antibodies from patients with TB is determined by portions of the CCP other than the citrulline moiety.",
"     </li>",
"     <li>",
"      In contrast to RF, anti-CCP antibodies are rarely present in the serum of patients with HCV infections.",
"     </li>",
"     <li>",
"      In a study of 257 patients with &alpha;",
"      <sub>",
"       1",
"      </sub>",
"      -antitrypsin deficiency (AATD) and 113 patients with chronic obstructive pulmonary disease, anti-CCP antibodies were detected in 3 and 5 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/36\">",
"       36",
"      </a>",
"      ]. In the patients with AATD, there was no difference in the presence of anti-CCP antibodies between cigarette smokers and nonsmokers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Anti-CCP and RA prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACPA-positive patients with early RA are at increased risk of progressive joint damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/9,14,21,44,45\">",
"     9,14,21,44,45",
"    </a>",
"    ]. ACPA testing may predict erosive disease more effectively than RF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/20,46\">",
"     20,46",
"    </a>",
"    ]. This was illustrated in a series of 145 such patients in which there was more radiographically apparent damage after five years of observation in those with detectable ACPA compared with those who were RF-positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/44\">",
"     44",
"    </a>",
"    ]. The presence of ACPA was also predictive of more rapid radiographic progression in two studies of 183 and 279 Swedish patients with early RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/14,45\">",
"     14,45",
"    </a>",
"    ] and in the BeSt trial of 508 Dutch patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positive ACPA testing also appears to predict an increased risk for radiographic progression in patients with early oligo- or polyarthritis who are IgM-RF negative. This was demonstrated in a prospective study that included 178 such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/47\">",
"     47",
"    </a>",
"    ]. Radiographic progression (more than 5 units by Sharp score) was more frequent in the ACPA positive patients than in those with a negative test result (40 versus 5 percent). The anti-CCP test for ACPA correctly predicted whether or not there would be worsening radiographic damage in 83 percent. Similar findings have been noted in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anti-MCV antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-mutated citrullinated vimentin (MCV) antibodies recognize a naturally occurring isoform of citrullinated vimentin, which can be found in patients with RA and in which arginine residues are replaced by glycine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Vimentin is a widely expressed intermediate filament. It becomes citrullinated through deimination, which occurs in macrophages undergoing apoptosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2234?source=see_link&amp;anchor=H5#H5\">",
"     \"Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis\", section on 'Autoantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic and prognostic value of anti-MCV antibodies in RA was analyzed in a 2010 systematic review of 14 studies, most of which used a commercially available assay, finding similar performance to anti-CCP antibody testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/53\">",
"     53",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 10 diagnostic case-control studies, the sensitivity for RA ranged from 64 to 84 percent, and the specificity ranged from 79 to 96 percent.",
"     </li>",
"     <li>",
"      In the case-control studies, the specificity of anti-MCV for RA was slightly lower than the specificity of anti-CCP. The sensitivity of either antibody for RA was slightly greater in two studies each and comparable in four studies.",
"     </li>",
"     <li>",
"      There were moderate associations of anti-MCV antibodies with radiologic progression, comparable to that seen with anti-CCP antibodies.",
"     </li>",
"     <li>",
"      Study heterogeneity, choice of study population, and the methods used limited overall conclusions, especially regarding prognostic value.",
"     </li>",
"     <li>",
"      There were no studies that analyzed the added diagnostic value of anti-MCV to anti-CCP and RF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A report subsequent to the systematic review, which evaluated a longitudinal cohort of 238 patients with RA over 10 years, found that anti-MCV predicted joint damage and did so comparably with anti-CCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/54\">",
"     54",
"    </a>",
"    ]. The odds ratios (OR) for radiographic progression were increased in the presence of either anti-MCV or anti-CCP (OR 7.3, 95% CI 3.2-16.5, and OR 5.7, 95% CI 2.6-12.5, respectively). Additionally, the odds of progression increased not only based on the presence or absence of anti-MCV antibodies but also with increasing levels of anti-MCV antibodies. Similar observations were previously made in this cohort with anti-CCP antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with undiagnosed early inflammatory arthritis or established RA, the diagnostic and prognostic value of adding anti-MCV antibody testing to anti-CCP and RF testing, or substituting anti-MCV for other tests, remains uncertain. Further study is required to more clearly define its role in routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ERYTHROCYTE SEDIMENTATION RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate at which erythrocytes fall through plasma, the ESR, depends largely upon the plasma concentration of fibrinogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/56\">",
"     56",
"    </a>",
"    ]. ESR can be greatly influenced by the size, shape, and number of red cells, as well as by other plasma constituents such as immunoglobulins. Thus, results may be imprecise and sometimes misleading. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the shortcomings, an elevated ESR in patients with early RA is predictive of greater radiographic joint damage in subsequent years despite treatment with conventional disease modifying antirheumatic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/13,14,57\">",
"     13,14,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ESR values tend to correlate with disease activity in rheumatoid arthritis as well as disease severity and may be useful for monitoring therapeutic response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     C-REACTIVE PROTEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;C-reactive protein (CRP) has been advocated as an objective measure of disease activity in RA. Unlike the ESR, CRP can be measured using stored serum samples, is independent of the hemoglobin concentration, and can be performed in automated serum analyzers. Radiologic damage, as assessed by erosion counts in RA, is significantly more likely to progress when CRP and ESR are elevated, irrespective of the presence or absence of RF and irrespective of therapeutic intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/13,14,61\">",
"     13,14,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevations of both ESR and CRP are stronger indications of radiologic progression than CRP alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/62\">",
"     62",
"    </a>",
"    ]. In one study of 147 patients, for example, absence or progression of radiographic joint damage after two years was correctly predicted in 83 percent of the patients using a combination of disease activity at presentation (assessed by ESR, CRP, or disease activity score) and DR4 and RF positivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study assessed progression of radiologic damage in 110 patients with early RA who had symptoms for less than one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/64\">",
"     64",
"    </a>",
"    ]. A highly significant correlation between radiologic progression and cumulative CRP production was noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33528/abstract/64\">",
"     64",
"    </a>",
"    ]. However, a wide variation in the relationship between the degree of radiographic change and cumulative CRP was noted between patients, particularly those with low CRP levels. This interindividual variability could not be accounted for by HLA DR4, positive RF, sex, or age, and limits the value of serial measurements of acute phase proteins in predicting radiologic progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Widely available tests that may predict functional and radiographic outcomes in patients with rheumatoid arthritis (RA) are serum IgM rheumatoid factor (RF), serum anti-citrullinated peptide antibodies (ACPA), erythrocyte sedimentation rate (ESR), and C reactive protein (CRP).",
"     </li>",
"     <li>",
"      Unless it is demonstrated that there is an intervention that effectively and safely reduces the risk of developing RA, there is no role for screening asymptomatic individuals for either RF or ACPA.",
"     </li>",
"     <li>",
"      Patients with early arthritis who are RF or ACPA positive are at an increased risk of developing RA and erosive joint disease, while those with neither of these markers are less likely to develop joint damage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=see_link&amp;anchor=H15#H15\">",
"       \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\", section on 'Autoantibodies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diagnoses other than RA should be considered in patients who are both RF and ACPA negative. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34039?source=see_link\">",
"       \"Evaluation of the adult with polyarticular pain\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14057?source=see_link\">",
"       \"Evaluation of the child with joint pain or swelling\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with an established diagnosis of RA who have a positive test for RF, ACPA, or both are at a higher risk of developing erosive joint damage and functional impairment. As a result, such patients should receive antirheumatic therapy that suppresses disease activity early in the course of their disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"       \"General principles of management of rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other tests may also have prognostic importance but are either still investigational or have limited clinical availability. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2234?source=see_link\">",
"       \"Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/1\">",
"      Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/2\">",
"      Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/3\">",
"      Egeland T, Munthe E. The role of the laboratory in rheumatology. Rheumatoid factors. Clin Rheum Dis 1983; 9:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/4\">",
"      Jacoby RK, Jayson MI, Cosh JA. Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J 1973; 2:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/5\">",
"      Masi AT, Maldonado-Cocco JA, Kaplan SB, et al. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome. Semin Arthritis Rheum 1976; 4:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/6\">",
"      Aho K, Steiner G, Kurki P, et al. Anti-RA 33 as a marker antibody of rheumatoid arthritis in a Finnish population. Clin Exp Rheumatol 1993; 11:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/7\">",
"      Alarc&oacute;n GS, Koopman WJ, Acton RT, Barger BO. Seronegative rheumatoid arthritis. A distinct immunogenetic disease? Arthritis Rheum 1982; 25:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/8\">",
"      Westedt ML, Herbrink P, Molenaar JL, et al. Rheumatoid factors in rheumatoid arthritis and vasculitis. Rheumatol Int 1985; 5:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/9\">",
"      de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008; 58:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/10\">",
"      SHARP JT, CALKINS E, COHEN AS, et al. OBSERVATIONS ON THE CLINICAL, CHEMICAL, AND SEROLOGICAL MANIFESTATIONS OF RHEUMATOID ARTHRITIS, BASED ON THE COURSE OF 154 CASES. Medicine (Baltimore) 1964; 43:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/11\">",
"      Erhardt CC, Mumford PA, Venables PJ, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/12\">",
"      Listing J, Rau R, M&uuml;ller B, et al. HLA-DRB1 genes, rheumatoid factor, and elevated C-reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. Berlin Collaborating Rheumatological Study Group. J Rheumatol 2000; 27:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/13\">",
"      Combe B, Dougados M, Goupille P, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001; 44:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/14\">",
"      Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005; 64:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/15\">",
"      van Zeben D, Hazes JM, Zwinderman AH, et al. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992; 51:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/16\">",
"      SIEVERS K. THE RHEUMATOID FACTOR IN DEFINITE RHEUMATOID ARTHRITIS. AN ANALYSIS OF 1279 ADULT PATIENTS, WITH A FOLLOW-UP STUDY. Acta Rheumatol Scand Suppl 1965; :SUPPL 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/17\">",
"      Aho K, Tuomi T, Palosuo T, et al. Is seropositive rheumatoid arthritis becoming less severe? Clin Exp Rheumatol 1989; 7:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/18\">",
"      Nielsen SF, Bojesen SE, Schnohr P, Nordestgaard BG. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ 2012; 345:e5244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/19\">",
"      Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/20\">",
"      Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/21\">",
"      Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/22\">",
"      Zeng X, Ai M, Tian X, et al. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. J Rheumatol 2003; 30:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/23\">",
"      Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/24\">",
"      van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/25\">",
"      Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/26\">",
"      Fabien N, Olsson NO, Goetz J, et al. Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study. Clin Rev Allergy Immunol 2008; 34:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/27\">",
"      Whiting PF, Smidt N, Sterne JA, et al. Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010; 152:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/28\">",
"      Bobbio-Pallavicini F, Caporali R, Bugatti S, Montecucco C. What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies? J Rheumatol 2008; 35:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/29\">",
"      Nijenhuis S, Zendman AJ, Vossenaar ER, et al. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004; 350:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/30\">",
"      Zendman AJ, van Venrooij WJ, Pruijn GJ. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/31\">",
"      Pruijn GJ, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010; 12:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/32\">",
"      Elkayam O, Segal R, Lidgi M, Caspi D. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis 2006; 65:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/33\">",
"      Kakumanu P, Yamagata H, Sobel ES, et al. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum 2008; 58:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/34\">",
"      Mori S, Naito H, Ohtani S, et al. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for rheumatoid arthritis in patients with active lung tuberculosis. Clin Rheumatol 2009; 28:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/35\">",
"      Matsui T, Shimada K, Ozawa N, et al. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol 2006; 33:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/36\">",
"      Wood AM, de Pablo P, Buckley CD, et al. Smoke exposure as a determinant of autoantibody titre in &alpha;-antitrypsin deficiency and COPD. Eur Respir J 2011; 37:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/37\">",
"      Qing YF, Zhang QB, Zhou JG, et al. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus. Lupus 2009; 18:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/38\">",
"      Kakumanu P, Sobel ES, Narain S, et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol 2009; 36:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/39\">",
"      Gottenberg JE, Mignot S, Nicaise-Rolland P, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sj&ouml;gren's syndrome. Ann Rheum Dis 2005; 64:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/40\">",
"      Mohammed K, Pope J, Le Riche N, et al. Association of severe inflammatory polyarthritis in primary Sj&ouml;gren's syndrome: clinical, serologic, and HLA analysis. J Rheumatol 2009; 36:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/41\">",
"      Atzeni F, Sarzi-Puttini P, Lama N, et al. Anti-cyclic citrullinated peptide antibodies in primary Sj&ouml;gren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther 2008; 10:R51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/42\">",
"      Chan MT, Owen P, Dunphy J, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 2008; 35:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/43\">",
"      Bogliolo L, Alpini C, Caporali R, et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005; 32:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/44\">",
"      Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/45\">",
"      R&ouml;nnelid J, Wick MC, Lampa J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005; 64:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/46\">",
"      Finckh A, Liang MH. Anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis: bayes clears the haze. Ann Intern Med 2007; 146:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/47\">",
"      Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, et al. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003; 30:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/48\">",
"      van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005; 7:R949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/49\">",
"      Quinn MA, Gough AK, Green MJ, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006; 45:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/50\">",
"      Bukhari M, Thomson W, Naseem H, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007; 56:2929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/51\">",
"      Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/52\">",
"      Vossenaar ER, Despr&eacute;s N, Lapointe E, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6:R142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/53\">",
"      Luime JJ, Colin EM, Hazes JM, Lubberts E. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 2010; 69:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/54\">",
"      Syversen SW, Goll GL, van der Heijde D, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 2010; 69:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/55\">",
"      Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008; 67:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/56\">",
"      Bedell SE, Bush BT. Erythrocyte sedimentation rate. From folklore to facts. Am J Med 1985; 78:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/57\">",
"      Dixey J, Solymossy C, Young A, Early RA Study. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J Rheumatol Suppl 2004; 69:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/58\">",
"      Lane SK, Gravel JW Jr. Clinical utility of common serum rheumatologic tests. Am Fam Physician 2002; 65:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/59\">",
"      Donald F, Ward MM. Evaluative laboratory testing practices of United States rheumatologists. Arthritis Rheum 1998; 41:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/60\">",
"      Nam J, Villeneuve E, Emery P. The role of biomarkers in the management of patients with rheumatoid arthritis. Curr Rheumatol Rep 2009; 11:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/61\">",
"      Amos RS, Constable TJ, Crockson RA, et al. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. Br Med J 1977; 1:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/62\">",
"      Davis MJ, Dawes PT, Fowler PD, et al. Comparison and evaluation of a disease activity index for use in patients with rheumatoid arthritis. Br J Rheumatol 1990; 29:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/63\">",
"      van der Heijde DM, van Riel PL, van Leeuwen MA, et al. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33528/abstract/64\">",
"      van Leeuwen MA, van Rijswijk MH, van der Heijde DM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993; 32 Suppl 3:9.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7503 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33528=[""].join("\n");
var outline_f32_47_33528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICALLY USEFUL MARKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RHEUMATOID FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTI-CITRULLINATED PEPTIDE ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anti-CCP antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Positive anti-CCP in other diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Anti-CCP and RA prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anti-MCV antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ERYTHROCYTE SEDIMENTATION RATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      C-REACTIVE PROTEIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=related_link\">",
"      Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34039?source=related_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14057?source=related_link\">",
"      Evaluation of the child with joint pain or swelling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2234?source=related_link\">",
"      Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/41/42648?source=related_link\">",
"      Origin and utility of measurement of rheumatoid factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42968?source=related_link\">",
"      Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_47_33529="Nonmucinous minimally invasive adenocarcinoma";
var content_f32_47_33529=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nonmucinous minimally invasive adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 600px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) This subpleural tumor consists primarily of lepidic growth with a small (&lt;0.5 cm) central area of invasion.",
"    <br>",
"     (B) To the left is the lepidic pattern and on the right is an area of acinar invasion.",
"     <br>",
"      (C) These acinar glands are invading in the fibrous stroma.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33529=[""].join("\n");
var outline_f32_47_33529=null;
var title_f32_47_33530="Sustained low efficiency or extended daily dialysis";
var content_f32_47_33530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sustained low efficiency or extended daily dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/47/33530/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33530/contributors\">",
"     Mark R Marshall, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33530/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/47/33530/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33530/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33530/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/47/33530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/47/33530/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/47/33530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous renal replacement therapies (CRRT) have advantages over intermittent hemodialysis (IHD) in the treatment of critically ill patients with acute renal failure (ARF). These benefits include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improved cardiovascular stability",
"     </li>",
"     <li>",
"      Improved tolerance to ultrafiltration, thereby enabling the removal of large obligatory fluid loads",
"     </li>",
"     <li>",
"      Ability to maintain excellent azotemia and solute control even in severely catabolic patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal replacement therapies have been developed which, although not necessarily continuous, have therapeutic aims in common with CRRTs; these include lower solute clearances that are maintained for longer periods of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/1\">",
"     1",
"    </a>",
"    ]. In this topic review, such regimens will be collectively referred to by the umbrella term \"prolonged (daily) intermittent renal replacement therapy\" (PIRRT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], although the term \"hybrid therapy\" is also acceptable (",
"    <a class=\"graphic graphic_figure graphicRef56474 \" href=\"mobipreview.htm?39/20/40269\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Other terms are used in the literature to refer to subsets of PIRRT, and include \"sustained low efficiency (daily) dialysis\" (SLEDD), \"sustained low efficiency (daily) diafiltration\" (SLEDD-f), \"extended daily dialysis\" (EDD), \"slow continuous dialysis\" (SCD), \"go slow dialysis\", and \"accelerated venovenous hemofiltration\" (AVVH).",
"   </p>",
"   <p>",
"    PIRRT using a variety of machines are safe and convenient, providing excellent control of electrolytes and fluid balance. Urea kinetics follows single compartment models and the delivered dose of dialysis is high. Larger solute clearance is enhanced by concurrent use of high flux membranes and on-line diafiltration.",
"   </p>",
"   <p>",
"    Hemodialyzer clotting is a common complication; available data indicate that monitoring the degree to which dialysate is saturated with urea may enable elective hemodialyzer or tubing changes and optimization of anticoagulation, prior to clotting of the extracorporeal circuit.",
"   </p>",
"   <p>",
"    PIRRT is also increasingly utilized. As an example, at the start of the Acute Renal Failure Trial Network (ATN) study, 7 percent of patients received PIRRT as primary treatment, while 25 percent of practitioners routinely prescribed this modality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/6\">",
"     6",
"    </a>",
"    ]. Similar results are described from surveys of predominantly European practices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the experience with PIRRT will be presented in this topic review. An introduction to CRRTs is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous hemodialysis was originally described as an arteriovenous technique (CAVHD), a setting in which extracorporeal circuit perfusion is driven by patient arterial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/9\">",
"     9",
"    </a>",
"    ]. Continuous venovenous hemodialysis (CVVHD) is a logical evolution of this technique, performed with a blood pump and single venous access resulting in higher and more reliable blood flows (and thus solute clearances), and lower vascular complication rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CVVHD without filtration was initially performed in the 1980s; investigators found that it was safe and effective (within limits) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/11\">",
"     11",
"    </a>",
"    ]. Apparatuses utilized at that time were developed via the adaptation of existing hemofiltration machines and blood circuitry; any of several commercial dialysate preparations were also used, usually at dialysate flow rates (QD) between 15 and 30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Delivery of dialysate was by volumetric pumps (such as those used for intravenous infusions) that independently controlled afferent and efferent dialysate flows, thereby allowing for negative and positive fluid balance by differential pump rates. By modern standards, these systems were clumsy, expensive, and inadequate in terms of solute control in the severely catabolic patient.",
"   </p>",
"   <p>",
"    By comparison, the modern practice of CVVHD with or without filtration most commonly utilizes one of many specialized automatic pump systems. However, several negative features emerge when establishing and maintaining such programs. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial costs of specialized CRRT machinery",
"     </li>",
"     <li>",
"      Subsequent running costs of specialized CRRT lines and filters",
"     </li>",
"     <li>",
"      Increased costs from reconstituted or commercial fluid for dialysate or filtrate replacement",
"     </li>",
"     <li>",
"      Procedural complexities resulting in increased workload for already busy intensive care unit (ICU) nurses",
"     </li>",
"     <li>",
"      Frequent unexpected interruptions to CRRT because of out-of-unit diagnostic and therapeutic procedures, leading to reduction in dialysis dose from \"down time\"",
"     </li>",
"     <li>",
"      Expense and inconvenience from unexpected extracorporeal circuitry replacement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For reasons of cost, simplicity, and convenience, initiatives to adapt batch and single pass iHD machinery for CRRT have been ongoing since the late 1980s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. Although this strategy initially did not meet with optimal results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/16\">",
"     16",
"    </a>",
"    ], several groups have more recently implemented durable renal replacement programs for critically ill patients using techniques that combine the therapeutic advantages of CRRT with the logistic and cost advantages of iHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The programs use adapted iHD equipment from respective end-stage renal disease programs, including machinery, hemodialyzers, extracorporeal blood circuitry, and on-line fluid production for dialysate and filtrate replacement. Treatments are deliberately intermittent rather than attempting to be continuous, with longer session durations than conventional iHD. Solute and fluid removal are slower than conventional iHD, but faster than conventional CRRT. This allows for scheduled \"down time\" without compromise in dialysis dose.",
"   </p>",
"   <p>",
"    The operating parameters of representative PIRRT regimens are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef55056 \" href=\"mobipreview.htm?25/42/26285\">",
"     table 1",
"    </a>",
"    ); similar programs have also reported their experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/17-31\">",
"     17-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROGRAM IMPLEMENTATION AND MAINTENANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before any new program of renal replacement therapy is implemented in an ICU, a medical need should be identified which is supported and endorsed by both ICU and Nephrology staffs. Protocols should be developed establishing operational procedures and demarcation of roles between ICU and dialysis nursing personnel. Continuous therapies are unique in this regard, because of the shared responsibility between these two nursing groups in some programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/16\">",
"     16",
"    </a>",
"    ]. The following are the details of some programs and how they are implemented.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beth Israel Medical Center (BIMC), New York &mdash; At BIMC, Nephrology nursing or physician personnel were responsible for the provision and initiation of hybrid treatments. ICU nurses were trained to monitor the treatment, flush the circuit, and handle routine alarms. Nursing personnel were reported as preferring PIRRT over CRRT, because of a less intensive degree of associated labor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      University of Arkansas for Medical Sciences (UAMS), Little Rock &mdash; At UAMS, Nephrology nurses are responsible for the provision and initiation of hybrid treatments, while troubleshooting and discontinuation responsibilities are shared. The ICU nurse manages hourly monitoring and documentation, and is the first line in management of machine alarms according to simple algorithms.",
"      <br/>",
"      <br/>",
"      The Nephrology nurse does not need to be in-house, but is always available from home by pager or direct call for telephone or bedside advice and assistance to the ICU nurse. There is no theoretical limit to the number of hybrid treatments that can be simultaneously managed by one Nephrology nurse, but three has been the maximum number to date. Patient instability is managed by the ICU medical team in consultation with the Nephrology service, with a consensus change to prescription thereafter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The UAMS Nephrology division has a specialist nursing educator who inservices Nephrology nursing personnel in the ESRD program; that responsibility has been broadened to encompass PIRRT for both Nephrology and ICU nurses. Formal training was undertaken by all full-time ICU nurses at the time of the PIRRT program inception, consisting of a brief instructional video and a two hour \"hands-on\" training session. Inservice is now offered on an as needed basis, and has been incorporated into Nephrology and ICU nursing orientation programs and quarterly skills updates.",
"      <br/>",
"      <br/>",
"      Two months after the introduction of PIRRT, satisfaction of ICU nurses was formally assessed. When compared to CRRT using a Hospal BSM-22, all felt that hybrid treatments were technically easier. All preferred PIRRT to CRRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      University of California at Davis (UCD), Sacramento &mdash; At UCD, Nephrology nurses are responsible for the provision and initiation of hybrid treatments, and also manage routine monitoring and documentation. The ICU nurse monitors the patients clinical state on an hourly basis (alerting the Nephrology nurse as needed), and can provide urgent machine and patient care, such as activating the reset, bypass, UF off functions, and emergent discontinuation of treatment. The Nephrology nurse is always in-house with a response time of less than 5 minutes to the bedside, and he or she can be responsible for two concurrent treatments at a given time. ICU nursing satisfaction with PIRRT was assessed as at least equal to continuous venovenous hemofiltration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medical School Hospital, Hannover (MSHH), Germany &mdash; At MSHH, the Fresenius Genius dialysis machine and dialysate are prepared by the Nephrology nurses in the dialysis unit. ICU nurses are responsible for routine monitoring and documentation of the treatments, with backup from the dialysis team [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/27,35\">",
"       27,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Middlemore Hospital (MHNZ), Auckland, New Zealand",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      and the Austin Repatriation Medical Center (ARMC), Melbourne, Australia &mdash; At MHNZ and ARMC, ICU nurses are responsible for the provision of an initiation of hybrid treatments (including preparation of the Fresenius 4008S ARrT Plus machine), routine monitoring and documentation of the treatments, and do not require backup from the dialysis team other than for hardware problems of a technical nature with machinery or RO systems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/2,3,36-40\">",
"       2,3,36-40",
"      </a>",
"      ]. PIRRT prescription is primarily determined by the ICU medical team, with or without consultation by the Nephrology service.",
"     </li>",
"     <li>",
"      University of Parma (UPI), Parma, Italy &mdash; At UPI, Nephrology nurses are responsible for the initiation of hybrid treatments (including preparation of the Gambro AK200S Ultra machine), routine monitoring and documentation of the treatments, and troubleshooting. PIRRT prescription is primarily determined by the Nephrology service, with consultation by the ICU medical team [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/28,40-43\">",
"       28,40-43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The table describes in more detail demarcations in nursing responsibilities at BIMC, MSHH, UAMS, UCD,",
"    <span class=\"nowrap\">",
"     MHNZ/ARMC,",
"    </span>",
"    and UPI according to a previous published model of practice (",
"    <a class=\"graphic graphic_table graphicRef69967 \" href=\"mobipreview.htm?39/43/40637\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TECHNICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each center utilizes equipment that is routine and familiar to medical and nursing staff. The following are the technical considerations that must be addressed when administering PIRRT (",
"    <a class=\"graphic graphic_algorithm graphicRef87704 \" href=\"mobipreview.htm?7/62/8173\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodialysis machines",
"     </li>",
"     <li>",
"      Dialysate",
"     </li>",
"     <li>",
"      Dialysate flow",
"     </li>",
"     <li>",
"      Ultrafiltration rate",
"     </li>",
"     <li>",
"      On-line fluid for filtrate replacement during hemodiafiltration",
"     </li>",
"     <li>",
"      Hemodialyzers",
"     </li>",
"     <li>",
"      Anticoagulation",
"     </li>",
"     <li>",
"      Vascular access",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hemodialysis machines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Machines for PIRRT should ideally have the following characteristics :",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flexible options for QD, allowing for low flows should the clinical situation mandate low solute clearance and ultrafiltration rate (UFR)",
"     </li>",
"     <li>",
"      Flexible options for hybrid treatment duration, allowing prolonged or even continuous treatments",
"     </li>",
"     <li>",
"      Clear interface with the nurse managing the treatment preferably via a dedicated PIRRT screen",
"     </li>",
"     <li>",
"      Standard procedures for changing between iHD and PIRRT, allowing either modality to be conveniently chosen at treatment commencement without any resultant delay.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of the North American programs have in the past used the Fresenius 2008H machine for PIRRT, without addition or change to software or hardware. However, minor adjustments are necessary to operating parameters of the 2008H in service mode to achieve a QD of less than",
"    <span class=\"nowrap\">",
"     300mL/min.",
"    </span>",
"    Upgrade software is available for this machine (part number",
"    <span class=\"nowrap\">",
"     P/N",
"    </span>",
"    190178) that eliminates the need for recalibration of the temperature control when changing between hybrid and iHD treatments (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Dialysate flow'",
"    </a>",
"    below), and includes a dedicated screen for PIRRT.",
"   </p>",
"   <p>",
"    More current machines include the Fresenius 2008K machine in the United States, and the 4008S elsewhere. Both have a built-in option for PIRRT; they can be selected from the startup screen without any delay or further adjustment. The Gambro 200S Ultra has also been used for hybrid treatments, although the lower limit of QD on this machine is 300",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    The Fresenius machines are therefore the preferred single pass machines for PIRRT providing predominantly diffusive solute transport.",
"   </p>",
"   <p>",
"    Important subsets within PIRRT include the use of hemofiltration for purely convective solute transport and hemodiafiltration for combined diffusive and convective solute transport. This is relevant to those interested in the ability of renal replacement therapy to remove middle-molecule inflammatory mediators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/44\">",
"     44",
"    </a>",
"    ]. The Gambro AK-10 machine was used in the first program to report hemofiltration-based PIRRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/45\">",
"     45",
"    </a>",
"    ], although the most promising modern experience is with the NxStage System One machine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/29,46\">",
"     29,46",
"    </a>",
"    ]. Fresenius 4008E or 4008H machines were used in the first program to report hemodiafiltration-based PIRRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/20\">",
"     20",
"    </a>",
"    ], although the most positive and widespread modern experience is with the Fresenius 4008S ARrT-plus machine which is currently used in a large number of ICUs across Australia and New Zealand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/2,3,36,40\">",
"     2,3,36,40",
"    </a>",
"    ]. The Fresenius 4008 series machines are therefore the preferred hemodiafiltration machinery for PIRRT providing combined diffusive and convective solute transport.",
"   </p>",
"   <p>",
"    Two machines that have been used for PIRRT are batch systems (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Dialysate flow'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first is the Fresenius Genius machine, in which a single roller pump with two pump segments circulate dialysate and blood in either a 1:1 or a 1:2 ratio depending on the diameter of the dialysate and blood tubing used, with maximum flows of 300",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. The system has a well established utility for maintenance dialysis in outpatient end-stage renal disease programs, and requires no modifications for use in critically ill patients with acute renal failure (ARF).",
"     </li>",
"     <li>",
"      The second is the NxStage System One hemofiltration machine, a cartridge system using volumetric control of filtrate removal, which is disposed of directly into a drain, and replacement fluid, which is administered from pre-packaged bags [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both machines are suitable for PIRRT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dialysate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysate for the single pass machines is generated on-line with a bicarbonate proportioning system using reverse osmosis treated tap water. A canister of dialysate concentrate lasts a single treatment without replacement (a maximum of approximately 16 to 17 hours at 100",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and 5 to 6 hours at 300",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"   </p>",
"   <p>",
"    For",
"    on-line dialysate, there is general concern about the possibility of backfiltration of bacterial contaminant (specifically endotoxin) from the dialysate compartment into the patient. If this were to occur in critically ill patients, it is quite plausible that this may result in exacerbation of the patient's inflammatory milieu, and perpetuation of microcirculatory insult and cytokine mediated injury. At present, there are insufficient data to justify a strong recommendation as to whether dialysate for diffusive therapies should be of purity greater than that accepted for routine maintenance hemodialysis. On theoretical grounds, many opinion leaders do opt for dialysate cold-sterilization using ultrafilters in the dialysate pathway. However, to date, this remains opinion based and further studies are warranted.",
"   </p>",
"   <p>",
"    The Fresenius Genius machine utilizes a 75L or 90L insulated, but not heated glass container, in which all the dialysate destined for one treatment is stored. This dialysate is mixed from pre-packed salts and RO water prior to treatment. Fresh dialysate is pumped from the top of the tank around the extracorporeal circuit and then into the bottom of the tank, where temperature and density differential keeps this spent dialysate from mixing with the fresh dialysate on the top [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Constant UV light maintains tank sterility. One 75L tank will last about 18 hours at flow of 70",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and a 90L tank about 8 to 12 hours at 150 to 200",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    The NxStage System One machine uses pre-packaged commercial fluids. This is prepared either by the company or by an outsourced fluid compounding company [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dialysate composition is varied according to clinical need. In general, when the duration of PIRRT is eight hours or more, most common dialysate solution contains the following concentrations of ions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Potassium at 4",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Bicarbonate is from 24 to 28",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Calcium from 1.5 to 2.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the duration of PIRRT is less than eight hours, the most common dialysate solution contains the following concentrations of ions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Potassium at 3",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Bicarbonate from 28 to 32",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Calcium from 1.5 to 2.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both authors of this topic review have had some experience with Citrisate, a commercially available dialysate that uses citric instead of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    as buffer. The use of Citrisate during iHD in the ICU reportedly decreased extracorporeal circuit clotting by 60 to 70 percent compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    free-dialysis, due to regional anticoagulation of the tubings and hemodialyzer by back diffusion of citrate and chelation of plasma calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of Citrisate during hybrid treatments has not been definitively explored, although a preliminary report suggested that the use of Citrisate might allow more than 80 percent of hybrid treatments to be completed when combined with hourly flushes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/55\">",
"     55",
"    </a>",
"    ]. Anecdotal evidence from the authors does not suggest that it will be dramatically effective, although further study is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dialysate flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysate flow rate (QD) is varied according to clinical need and dialysis machine specifications. The main factor governing QD is tolerance to ultrafiltration. If the targeted UFR is tolerated, treatment duration can be shorter (eg, 6 to 10 hours), and QD should be higher in this setting (eg, 300",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    If tolerance is low, duration will be correspondingly longer (eg, 10 to 18 hours, even continuous), and QD correspondingly lower (eg, 100 to 200",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"   </p>",
"   <p>",
"    Within",
"    the United States, the most commonly used machines for hybrid treatments are the Fresenius 2008H and 24008K. For the 2008H, dialysate flow (QD) of 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    requires activation of the 2008H's \"slow dialysis\" option (with 2008H in service mode &mdash; \"options\" menu &mdash; \"treatment options\" submenu &mdash; \"allow for slow dialysis\" &mdash; \"yes\"). This is not necessary for the regimens with QD of 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or greater.",
"   </p>",
"   <p>",
"    QD of 100",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    but not 300",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    is commonly associated with persistent low dialysate temperature alarms after an hour or so with this machine. This problem can be obviated by either upgrade software (part number",
"    <span class=\"nowrap\">",
"     P/N",
"    </span>",
"    190178) or manual recalibration of the temperature control to 37 degrees Centigrade at QD of 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (Cal Temp DAC can be expected to rise from 150 to 170 by about 75 units). This procedure, which takes approximately 45 minutes, should be done in service mode prior to the initiation of treatment. As stated previously, upgrade software is available that eliminates the need for this recalibration. At QD of 100",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    the time required for the dialysate conductivity to enter the proper range at the initiation of therapy is untenably long; it is therefore easiest to set the QD to 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    after the conductivity has stabilized on a flow of 500 to 800",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    This takes about five minutes.",
"   </p>",
"   <p>",
"    There are no special procedures required for the reduction in QD using the Fresenius 42008K; the machine can routinely deliver QD of 100",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    Outside of the United States, the most commonly used machines for hybrid treatments are Fresenius 4008 and 54008 series of machines. The technical specifications and software platforms are slightly different between Fresenius single pass machines in the United States versus elsewhere.",
"   </p>",
"   <p>",
"    With regard to QD, most Fresenius single pass machines outside the United States can only deliver QD as low as 300",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    The exception is the 4008S ARrT plus machine (Asia-Pacific only), which can routinely deliver QD of 200",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and the 5008 series which can routinely deliver QD of 100",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    There are programs outside the United States that report the use of the Fresenius 4008 series with a lower QD than standard; this is achieved through minor modification of the dialysate path. As an example, a program from Belgium uses the 4008H machine with a QD of between 50 to 300",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Technicians in the unit use a length of tubing (with an external flowmeter) as a connector between the sampling ports on the afferent and efferent dialysate lines to effectively create a bypass; QD is regulated between this bypass and the dialysate compartment of the hemodialyzer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As stated previously, the Gambro 200S Ultra has also been used for hybrid treatments. As with machines mentioned above, the 200S Ultra can only deliver QD as low as 300",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    To achieve QD of 100",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    the machine is used in hemofiltration mode. The on-line replacement fluid is not infused, but instead runs in countercurrent manner through the hemodialyzer at 100",
"    <span class=\"nowrap\">",
"     ml/min;",
"    </span>",
"    the machine is performing hemodialysis in hemofiltration mode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no special procedures required for the reduction in QD using the Fresenius Genius; there is no lower limit for QD with this machine.",
"   </p>",
"   <p>",
"    In the literature as a whole, there does not appear to be a large difference in the technical success of hybrid treatments or patient outcomes between different QD. In practical terms, however, the machine specifications and PIRRT regimens reported in the United States literature will require adaptation before being applied outside of the US, and vice versa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ultrafiltration rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrafiltration goals are determined by clinical need. The main factor governing UFR is cardiovascular stability. If a prescribed ultrafiltration goal can be achieved over a shorter period, higher UFR is prescribed as tolerated. If not, UFR will be lower, and treatment duration correspondingly longer.",
"   </p>",
"   <p>",
"    UFR for the 2008H is controlled in standard fashion for QD of 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    using the \"TIME\" and \"GOAL\" parameters on the dialysis screen. For QD of 100",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    UFR is controlled by the \"RATE\" parameter on the dialysis screen, with nullification of the \"TIME\" and \"GOAL\" parameters by setting them to zero (\"TIME\" parameter cannot be set to beyond eight hours and causes incessant alarms once treatment duration exceeds set time). There is a mandatory lower limit to the UFR of 70",
"    <span class=\"nowrap\">",
"     mL/hour,",
"    </span>",
"    below which frequent alarms occur for low TMP.",
"   </p>",
"   <p>",
"    These limitations do not apply to 2008H machines that have the CRRT software installed or to the",
"    <span class=\"nowrap\">",
"     4008/5008",
"    </span>",
"    series, and UFR in these systems is easily set from the dedicated PIRRT screen. UFR for the Genius is controlled by a simple volumetric pump on the dialysate tank, and can be set between 20 and 1000",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     On-line fluid for filtrate replacement during hemodiafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major step forward in acute renal replacement therapy is the use of on-line production of fluid for filtrate replacement. Fluid is produced from dialysate which is separated after the proportioning system and purified by a two (Fresenius) or three step (Gambro) ultrafiltration process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/57\">",
"     57",
"    </a>",
"    ]. This technique has been established to produce fluid that does not differ from commercial hemofiltration solutions and depyrogenated saline in terms of microbial counts, endotoxin concentration, and cytokine-inducing activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. This technique avoids the need for pre-packaged hemofiltration solutions, reducing inconvenience and cost.",
"   </p>",
"   <p>",
"    On-line filtrate replacement fluid is not yet approved by the Federal Drug Administration in the United States, and some regulatory authorities in Europe. However, the technique is widely used elsewhere and in the authors' opinions clearly represent the future direction of replacement fluid management for acute renal replacement therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hemodialyzers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard extracorporeal circuit tubing and hemodialyzers are used (",
"    <a class=\"graphic graphic_table graphicRef55056 \" href=\"mobipreview.htm?25/42/26285\">",
"     table 1",
"    </a>",
"    ). Other membranes may have different clearance properties. As an example, diffusive clearance with polyamide filters is significantly lower compared to these membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/60\">",
"     60",
"    </a>",
"    ]. Cuprophane, polyacrylonitrile, and AN69 membranes have only been examined in CVVHD in the context of dialysate and blood flows of approximately 30 and 100",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    respectively; older studies found urea clearances with these membranes similar to that of polysulfone regardless of dialyzer geometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the relationship between blood flow rate (QB) and intradialytic hypotension is unproven, it is widely believed that cardiovascular stability can be improved by decreased clearance and associated solute and fluid shifts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/62\">",
"     62",
"    </a>",
"    ]. The common practice of prescribing lower QB in critically ill patients leads to a propensity for clotting in extracorporeal circuit tubings and hemodialyzers.",
"   </p>",
"   <p>",
"    However, low QB lacks biological plausibility as intervention for the prevention or treatment of hypotension during PIRRT. When QD is significantly lower than QB (as is often the case during hybrid treatments) dialysate is saturated with solutes. As an example, when QD = 100",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    QB of 200 or 300",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    makes no difference to solute clearance as shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef60742 \" href=\"mobipreview.htm?20/20/20814\">",
"     figure 2",
"    </a>",
"    ). For this reason, we recommend that QB is maximized to the tolerance of the catheter, and our experience is of improved circuit patency and unchanged cardiovascular stability.",
"   </p>",
"   <p>",
"    Extracorporeal circuit clotting is less of a problem with the Genius system. As an example, none was reported in one series of 20 patients who received a 1000 units",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    loading dose and infusion of 500",
"    <span class=\"nowrap\">",
"     units/hour",
"    </span>",
"    for the duration of treatment using this machine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/27,63\">",
"     27,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, clotting requiring replacement of tubing or hemodialyzer is more frequently reported with single pass machines, occurring in about 20 to 25 percent of treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/26,32,33\">",
"     26,32,33",
"    </a>",
"    ]. A reduction in hemodialyzer size from 1.8m",
"    <sup>",
"     2",
"    </sup>",
"    to 0.7m",
"    <sup>",
"     2",
"    </sup>",
"    in one series and from 2m",
"    <sup>",
"     2",
"    </sup>",
"    to 1m",
"    <sup>",
"     2",
"    </sup>",
"    in another series reportedly reduced the frequency of this problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/30,32\">",
"     30,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is the most commonly utilized anticoagulant, and reported regimens are remarkably consistent. In general, heparin is concurrently administered in the majority of hybrid treatments, although up to 40 percent of treatments may be completed without anticoagulation. Heparin regimens typically consist of a 1000 to 2000 unit bolus, followed by an infusion of 500 to 1000",
"    <span class=\"nowrap\">",
"     units/hour",
"    </span>",
"    to keep the activated partial thromboplastin time 10 to 20 seconds above or 1.5 times control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/2,26,27,31,33,36\">",
"     2,26,27,31,33,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    exposure is less for PIRRT than for CRRT. Mean heparin requirements vary according to the particular PIRRT regimen, but are reported to be between 4000 and 10,000 units per treatment-day, between 50 and 75 percent less than for CRRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regional citrate anticoagulation has been used for both batch and single pass machines to successfully maintain extracorporeal circuit patency during hybrid treatments. For the Genius, this involved a low calcium dialysate concentration (1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    combined with a 3 or 4 percent sodium citrate solution infused into the arterial line of the extracorporeal circuit (adjusted according to target the post-filter ionized calcium concentration of 0.5 to 0.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    without routine calcium substitution. No significant untoward effects were observed on blood levels of calcium, sodium, or acid base balance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. For single pass machines, several studies have reported routine use of regional citrate anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/23,30,67\">",
"     23,30,67",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    However, only two disclosed their actual technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/23,67\">",
"     23,67",
"    </a>",
"    ]. In both, this involved calcium-free dialysate combined with a 4 percent sodium citrate solution infused into the arterial line, with routine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    infusion into the venous line to maintain normal serum ionized calcium.",
"   </p>",
"   <p>",
"    Both protocols result in safe and effective anticoagulation, specifically as a result of the higher clearance of PIRRT that continuously corrects any alkalosis or hypernatremia, while at the same time removing the calcium chelated citrate complexes. This feature of PIRRT allows RCA even in patients with severe liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in PIRRT, however, the safety of regional citrate anticoagulation can only be ensured by exact policies and procedures that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disallow deviation or interruption of QB and QD without appropriate correction of citrate and calcium infusions.",
"     </li>",
"     <li>",
"      Disallow deviation or interruption of either citrate or calcium infusions without appropriate correction of the other.",
"     </li>",
"     <li>",
"      Mandate regular surveillance and adjustment of the citrate and calcium infusions to avoid hyper- and hypocalcemia. Such surveillance might include initially intradialytic laboratory monitoring especially for high risk patients (eg, those with pre-treatment hypocalcemia) and inexperienced programs, until the patient has stable citrate and calcium requirements at which time surveillance can be down-scaled to only pre- and post-treatment surveillance.",
"     </li>",
"     <li>",
"      To improve standardization and eliminate errors, one group has been developing a near-automated system for regional citrate anticoagulation for use during intermittent HD, PIRRT, and CRRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/68\">",
"       68",
"      </a>",
"      ]. The system implements a flexible set of protocols that use a fixed high-citrate infusion rate and varies the calcium replacement rate according to QB and the serum albumin and hemoglobin levels. The objective of such predictive calcium-infusion dosing is to obviate the need for frequent laboratory monitoring. Prescription is by electronic order generation. An optical hematocrit sensor monitors blood volume and oxygen saturation with live-data transfer to a secure server via commercial dialysis telemetry software for real time quality assessment. Preliminary data shows this system to be extremely effective in preventing clotting, with no systemic citrate accumulation even in patients with severe liver disease, while maintaining normal ionized calcium levels. To date, the regimen has not been published or presented in detail [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/68-71\">",
"       68-71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An in-vitro technique for regional citrate anticoagulation during PIRRT using hemodiafiltration has been presented in detail, but is yet to be validated in clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a single report of prostacyclin (PGI2) as anticoagulation during PIRRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/28\">",
"     28",
"    </a>",
"    ]; PGI2 was infused at 6",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per min before the hemodialyzer. Although there was no control arm, PGI2 was associated with clotting in 11 percent of treatments, and no undue cardiovascular instability was observed.",
"   </p>",
"   <p>",
"    For patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia, the direct thrombin inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     Argatroban",
"    </a>",
"    can be used. In the absence of liver failure, a bolus of 250",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    is given, followed by a 2",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per min infusion throughout the treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioaccess is usually established in a central vein at the usual sites. Preservation of subclavian veins for future access is often not of high priority since many ICU patients requiring renal replacement therapy do not survive to be chronic dialysis patients or do not require chronic dialysis if they survive to hospital discharge. Standard hospital brands of hemodialysis catheters may be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OPERATIONAL CHARACTERISTICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Urea kinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The theoretical principles of solute removal in hemodialysis with low flow rates have been elegantly elucidated in the setting of CAVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/9\">",
"     9",
"    </a>",
"    ]; these can be equally applied to CVVHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=see_link\">",
"     \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .) Although several reports have addressed the effects of comparably low QD on solute removal in the end-stage renal disease (ESRD) setting, there are limited data clearly describing solute removal in CVVHD for ARF in the setting of critical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With CVVHD, the degree to which dialysate is saturated with urea (expressed as the percentage ratio of dialysate urea nitrogen to blood urea nitrogen, or",
"    <span class=\"nowrap\">",
"     DUN/BUN)",
"    </span>",
"    is pivotal to the success of therapy delivery. It has been established that up to a QD of 30 to 50",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    the",
"    <span class=\"nowrap\">",
"     DUN/BUN",
"    </span>",
"    is 100 percent, implying complete saturation of dialysate with urea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At these low flow rates, diffusive urea clearance is numerically equal to, and therefore limited by, dialysate flow. However, increasing QD above these rates leads to proportionally decreasing gains in urea clearance as the",
"    <span class=\"nowrap\">",
"     DUN/BUN",
"    </span>",
"    progressively falls, although this is also dependent upon blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This phenomenon is illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef60742 \" href=\"mobipreview.htm?20/20/20814\">",
"     figure 2",
"    </a>",
"    ), where urea clearances were studied in an in-vitro system of CVVHD using a 1.5 m",
"    <sup>",
"     2",
"    </sup>",
"    cupra-ammonium rayon dialyzer, under conditions of different blood and dialysate flows. The flattening of the curves describe the conditions where increases in blood flow do not enhance clearance. The greater the dialysate flow, the less likely this is to occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Urea clearance predicts a failing filter",
"    </span>",
"    &nbsp;&mdash;&nbsp;With CVVHDF, the",
"    <span class=\"nowrap\">",
"     DUN/BUN",
"    </span>",
"    ratio can be used to permit an elective change of a failing filter before it clots. This strategy is based upon the observation that there is a decline in",
"    <span class=\"nowrap\">",
"     DUN/BUN",
"    </span>",
"    over the treatment course, probably due to a combination of concentration repolarization and filter clotting. Although not prospectively validated, it is the firm recommendation from opinion leaders that a",
"    <span class=\"nowrap\">",
"     DUN/BUN",
"    </span>",
"    less than 60 percent mandates filter replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With hybrid treatments studied in nine patients at UAMS, the",
"    <span class=\"nowrap\">",
"     DUN/BUN",
"    </span>",
"    across a 12 hour treatment (presented as mean &plusmn; SD) was 77.9 &plusmn; 5.2 percent (",
"    <a class=\"graphic graphic_figure graphicRef62174 \" href=\"mobipreview.htm?13/0/13325\">",
"     figure 3",
"    </a>",
"    ). As a group, the",
"    <span class=\"nowrap\">",
"     DUN/BUN",
"    </span>",
"    tended to remain stable over the course of the treatments (r = 0.25, p= 0.09). When analyzed on a case by case basis, the greatest decline in",
"    <span class=\"nowrap\">",
"     DUN/BUN",
"    </span>",
"    occurred when the dialyzers clotted, as indicated by arrows in the figure (",
"    <a class=\"graphic graphic_figure graphicRef58622 \" href=\"mobipreview.htm?33/27/34237\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fouling of membranes by plasma proteins is directly proportional to transmembrane hydraulic pressure gradient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/74\">",
"     74",
"    </a>",
"    ]. In these nine patients, those with the higher ultrafiltration rates (and thus transmembrane pressures) had the least change in",
"    <span class=\"nowrap\">",
"     DUN/BUN.",
"    </span>",
"    These preliminary data suggest that clotting rather than protein concentration polarization may be playing the major role in progressive dialyzer dysfunction during hybrid treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Small solute control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistent with recommendations elsewhere in UpToDate, we also recommend that PIRRT be provided at least three times per week with monitoring of the delivered dose of therapy to ensure a minimum delivered",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.2 per treatment. There is no evidence currently that more frequent treatment is associated with improved outcomes unless necessitated for specific acute indications (eg, hyperkalemia, volume excess, hypotension, etc) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In contrast, there is clear evidence that a lower dose of dialysis is associated with worse outcomes. A quasi-randomized controlled trial using intermittent hemodialysis reported almost twice the mortality risk with a",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 0.94 delivered on 3.2 occasions per week (TAC(BUN) of 104",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    as compared with a",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 0.92 on delivered 6.2 occasions per week (TAC(BUN) of 60",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To compare small solute control between continuous and intermittent therapies, one can use the corrected equivalent renal urea clearance (EKRc) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/78\">",
"     78",
"    </a>",
"    ], which re-expresses all of the above dose expressions as a continuous clearance that provides the same time averaged concentration of BUN for the same mass of urea removed, corrected for a urea redistribution volume of 40 L or to body weight (assuming V = 0.65*body weight), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Expressed in this way, metabolic control with PIRRT in most case series is comparable to that observed during CRRT, with one quasi-randomized controlled trial also reporting similar conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/30,81,82\">",
"     30,81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multicompartmental effects due to urea disequilibrium can confound measurements of dialysis dose in iHD for both ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/83\">",
"     83",
"    </a>",
"    ] and ARF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/84-89\">",
"     84-89",
"    </a>",
"    ]. Significant urea disequilibrium, as implied by post-dialysis urea rebound, has also been reported in ESRD patients on long slow maintenance iHD consisting of eight hours three times a week with blood and dialysate flows of 220 and 500",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/90-92\">",
"     90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, intercompartmental resistance to urea transfer is increased by low cardiac output, predialysis and intradialytic hypotension, fluid overload, and labile body temperature. All of these are common findings in critically ill patients with ARF.",
"   </p>",
"   <p>",
"    Urea disequilibrium may therefore be expected to occur during hybrid treatments, despite the low efficiency of dialysis (low",
"    <span class=\"nowrap\">",
"     K/V).",
"    </span>",
"    Detailed and rigorous study of urea kinetics during hybrid treatments was undertaken at UAMS to assess this issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/5,81\">",
"     5,81",
"    </a>",
"    ]. The results demonstrated parity between whole body and hemodialyzer urea clearance, minimal post-dialysis urea rebound, and conformity between observed intradialytic time-concentration BUN profiles and those predicted from a standard single-pool urea kinetic model (",
"    <a class=\"graphic graphic_table graphicRef80028 \" href=\"mobipreview.htm?36/44/37579\">",
"     table 3",
"    </a>",
"    ). These findings all indicate minimal urea disequilibrium.",
"   </p>",
"   <p>",
"    DUN has also been used to assess for solute disequilibrium. DUN time-concentration profiles during iHD in ESRD patients follow a double exponential curve, indicating an initially rapid phase of urea removal lasting 30 to 60 minutes, followed by a slower removal in the second phase of dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. This has also been observed during treatments of hemodiafiltration in the critically ill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/95\">",
"     95",
"    </a>",
"    ]. By comparison, the mean DUN time-concentration profile during hybrid treatments in the nine patients investigated at UAMS is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef62830 \" href=\"mobipreview.htm?17/16/17677\">",
"     figure 5",
"    </a>",
"    ). The points fit a monoexponential curve without the early rapid phase of urea removal, and this finding also indicates minimal urea disequilibrium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Large solute control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports of PIRRT have focused on large solute clearance. The rationale lies with clearance of middle-molecule inflammatory mediators, which may have a role in the pathophysiology of the systemic inflammatory response syndrome in critically ill patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/96\">",
"     96",
"    </a>",
"    ]. However, what data there are do not show a survival advantage in patients treated with convective as opposed to diffusive therapies that more efficiently eliminate these larger solutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. More definitive studies to test the effect of diffusive versus convective clearance on mortality and morbidity in the setting of acute renal replacement therapy are currently in the design phase. Notwithstanding this, the greatest removal of such molecules can be achieved with hemodiafiltration, although some removal also occurs with PIRRT based on high flux dialysis without filtration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/22,31,36,100,101\">",
"     22,31,36,100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The literature as a whole suggests that clearance of larger molecules is at best only between 50 and 66 percent of that of small solute solutes, and very low with hybrid treatments using dialysis with low-flux membranes. Support for beneficial immunomodulation by PIRRT can be found in one study that showed similar restoration of function for stimulated but exhausted circulating monocytes for both PIRRT and CVVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/102\">",
"     102",
"    </a>",
"    ], and another that showed at least equivalent if not more favorable plasma cytokine profiles with PIRRT versus CVVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the present time, there are insufficient data to support the routine clinical use of any acute renal replacement therapy to achieve large solute clearance targets (eg, targeting middle-molecule inflammatory mediators) in isolation. PIRRT, however, are technically able to deliver high convective clearances, and would be suitable for current research settings, or for future clinical settings if human studies in this area yield conclusive results. A preliminary study comparing those treated with a diffusive PIRRT to those treated with a combined convective and diffusive one has suggested a difference in clinical outcomes and goes some way to allowing key assumptions and sample sizes to be calculated for a more definitive clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fluid removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;All reports of PIRRT have shown ultrafiltration to be well tolerated, and not associated with undue cardiovascular instability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. Reported ultrafiltration volumes vary between zero and 6 L per treatment, with an average of approximately 3 L. In some series, a minor temporary increase in inotrope dose has been noted during hybrid treatment, especially in those patients with higher illness severity and greater cardiovascular instability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. In the literature as a whole, between zero and 7 percent of patients were reported to have discontinued hybrid treatment because of intractable hypotension. However, most of these patients were also subsequently unsupportable on conventional CRRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/33\">",
"     33",
"    </a>",
"    ]. A 2 year single center experience of PIRRT versus CRRT suggested no difference in cardiovascular stability between modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most rigorous assessment of cardiovascular stability during hybrid treatments comes from a randomized controlled trial of PIRRT versus CRRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/31\">",
"     31",
"    </a>",
"    ]. Thirty nine critically ill patients were randomly assigned to either arm, achieving total ultrafiltration of 3 L over 12 hours and 3.3 L over 24 hours during the hybrid treatment and CRRT, respectively. There was no significant difference in inotrope dose or number, although there was an insignificant trend to lower blood pressure and cardiac output, and higher peripheral vascular resistance. This trend was not reflected in outcomes, and any associated cardiovascular instability that might exist is likely to be of little clinical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Electrolyte control and nutritional considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;All reports of PIRRT have shown that electrolyte concentrations were able to be maintained within normal limits. At BIMC only, there was a tendency to alkalosis, thereby necessitating a reduction in dialysate of the bicarbonate concentration.",
"   </p>",
"   <p>",
"    At UAMS, 1.5 &plusmn; 0.6 gm of phosphate was removed per treatment, and it was their experience that treatments performed on a daily basis often necessitates a small amount of phosphate supplementation, approximately 0.1 to 0.2",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/33\">",
"     33",
"    </a>",
"    ]. At UCD, this problem is avoided by the addition of phosphate to the dialysate 3 to 4 days after initiation of PIRRT (45 mL of Fleet Phosphosoda added to 9.5 L of the bicarbonate gives a final concentration of 0.81",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The properties of PIRRT are also quite conducive to regional citrate anticoagulation (RCA). The relatively high and also predominantly diffusive treatments correct to a large degree the electrolyte abnormalities that so often complicate RCA. Hypernatremia and metabolic alkalosis can be corrected through lowering of dialysate sodium and bicarbonate concentrations, respectively. Citrate accumulation can be corrected through increasing QD. Such complications of RCA are more easily and completely corrected with PIRRT than with any other form of acute renal replacement therapy.",
"   </p>",
"   <p>",
"    Albumin removal is negligible during hybrid treatments. However, amino acid removal is significant, with the reported loss between 6.2 and 15.7 gm, depending upon the actual PIRRT regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Protein prescriptions should therefore be augmented by 0.2",
"    <span class=\"nowrap\">",
"     gm/kg",
"    </span>",
"    per day during hybrid treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Drug clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug clearance can be considerable with PIRRT and intermediate between that iHD and CRRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/108-111\">",
"     108-111",
"    </a>",
"    ]. Dosing decisions need to be made on an individual basis. Several studies have been published that provide information on the pharmacokinetics of specific drugs during PIRRT, and can be used for guidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/17,42,112-126\">",
"     17,42,112-126",
"    </a>",
"    ]. It is important when using these data to ensure that operating parameters of the PIRRT being applied to the patient is consistent with those as published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/127\">",
"     127",
"    </a>",
"    ]. Experience is also beginning to emerge about the utility of PIRRT for the treatment of drug intoxications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/18,52,128-133\">",
"     18,52,128-133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, no single modality of renal replacement therapy in the critically ill patient with acute renal failure has a clear benefit compared with other modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. However, PIRRT have certain operating characteristics that require special consideration with respect to patient outcomes. As an example, treatments expose patients for lengthy periods to on-line dialysate prepared with reverse-osmosis treated water, with potential to exacerbate inflammatory milieu through back-filtration of pro-inflammatory impurities. Treatments also result in lower nadirs of solutes over the course of treatment compared to continuous therapies, with potential for threatening electrolyte abnormalities such as hypokalemia and hypophosphatemia.",
"   </p>",
"   <p>",
"    Overall, observational data suggest that PIRRT are safe and effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/2,22,24,28,29,36,76,134\">",
"     2,22,24,28,29,36,76,134",
"    </a>",
"    ]. A time-series analysis of three intensive care units from three different countries showed that a change from CRRT to PIRRT was not associated with a change in mortality risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/40\">",
"     40",
"    </a>",
"    ], even when accounting for patient illness severity and underlying trends for improvement in mortality rates of AKI patients over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/135-137\">",
"     135-137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective studies have been inconclusive related to survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The largest study that has examined outcomes with PIRRT is the Stuivenberg Hospital Acute Renal Failure (SHARF) 4 study; investigators have provided interim analyses of the multicenter, prospective, randomized study of 996 patients, and reported a hospital mortality of 68 percent for those treated with PIRRT and 64 percent for those treated with CRRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/138-140\">",
"     138-140",
"    </a>",
"    ]. However, there are concerns about randomization imbalance and poor recruitment, and premature termination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a paucity of data on outcomes with PIRRT in patients with head injuries, cardiogenic shock and severe hepatic failure. Very preliminary data suggest that PIRRT may be safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/69,142-145\">",
"     69,142-145",
"    </a>",
"    ], but further data are necessary before recommendations can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cost analyses of PIRRT have been presented, both within the health care reimbursement structure of the United States as well as within a more widely applicable nationalized health care structure. In general, daily costs for PIRRT are between 6 and 8 times less expensive than for CRRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/47/33530/abstract/24,146-149\">",
"     24,146-149",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PIRRT or sustained low efficiency (daily) dialysis is a durable renal replacement modality for critically ill patients that combines the therapeutic advantages of continuous replacement therapy (CRRT) with the logistic and cost advantages of intermittent hemodialysis (iHD). Programs currently use adapted iHD equipment from respective end-stage renal disease programs, including machinery, hemodialyzers, extracorporeal blood circuitry, and on-line fluid production for dialysate and filtrate replacement. Treatments are deliberately intermittent rather than attempting to be continuous, with longer session durations than conventional iHD. Solute and fluid removal are slower than conventional iHD, but faster than conventional CRRT. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Overview'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Program implementation and maintenance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We agree with the opinion of others that acute renal replacement modality choice should be based upon both technical and clinical issues, and that patient outcome is more a function of the skill and expertise of the medical and nursing personnel performing the treatments than the modality itself. There are numerous and consistent reported accumulated experiences of PIRRT, and it is clear that treatments can be delivered to patients across the spectrum of critical illness severity. In particular, the flexibility of treatment operating parameters allows hybrids to be applied to cardiovascularly unstable patients who would otherwise be treated with CRRT. Although not yet supported by objective data, our opinion is that PIRRT will become the dominant acute renal replacement therapy over the next 5 to 10 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Program implementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before PIRRT is implemented in an intensive care unit (ICU), a medical need should be identified and protocols should be developed establishing operational procedures and demarcation of roles between ICU and dialysis nursing personnel. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Program implementation and maintenance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Technical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the technical considerations that must be addressed when administering PIRRT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodialysis machines &mdash; The Fresenius 4008 series are the preferred single pass machines for PIRRT. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hemodialysis machines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysate &mdash; Although dialysate composition varies according to clinical need, the most common dialysate solution contains potassium at 4",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      bicarbonate from 30 to 35",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      and calcium from 1.5 to 2.5",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dialysate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysate flow &mdash; Dialysate flow rate varies according to clinical need and dialysis machine specifications, with the main factor governing flow being tolerance to ultrafiltration. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dialysate flow'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrafiltration rate &mdash; Ultrafiltration goals are determined by clinical need. The main factor governing the rate is cardiovascular stability. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ultrafiltration rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On-line fluid for filtrate replacement during hemodiafiltration &mdash; The use of on-line production of fluid for filtrate replacement produces fluid that does not differ from commercial hemofiltration solutions and depyrogenated saline, thereby avoiding the need for pre-packaged hemofiltration solutions (see",
"      <a class=\"local\" href=\"#H9\">",
"       'On-line fluid for filtrate replacement during hemodiafiltration'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hemodialyzers &mdash; Standard extracorporeal circuit tubing and hemodialyzers are used. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hemodialyzers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticoagulation &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      is concurrently administered in the majority of hybrid treatments, although up to 40 percent of treatments may be completed without anticoagulation. Heparin regimens typically consist of a 1000 to 2000 unit bolus, followed by an infusion of 500 to 1000",
"      <span class=\"nowrap\">",
"       units/hour",
"      </span>",
"      to keep the activated partial thromboplastin time 10 to 20 seconds above or 1.5 times control. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular access &mdash; Standard hospital brands of hemodialysis catheters, which are placed at the usual sites, may be used. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vascular access'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Operational characteristics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urea kinetics &mdash; There is ongoing uncertainty about the utility of small solute clearance as a determinant of outcomes in this setting. At the present time, we recommend that treatment be provided at least three times per week with monitoring of the delivered dose of dialysis to ensure delivery of a",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      of at least 1.2 per treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). More frequent treatment may be required if clinical or laboratory parameters suggest that therapeutic objectives of the therapy are not being achieved in other regards. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Urea kinetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Small solute control'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urea clearance predicts a failing filter &mdash; With PIRRT, the degree to which dialysate is saturated with urea (expressed as the percentage ratio of dialysate urea nitrogen to blood urea nitrogen, or",
"      <span class=\"nowrap\">",
"       DUN/BUN)",
"      </span>",
"      can be used to permit an elective change of a failing filter before it clots. We utilize filter replacement when the",
"      <span class=\"nowrap\">",
"       DUN/BUN",
"      </span>",
"      ration is less than 60 percent.",
"     </li>",
"     <li>",
"      Large solute control &mdash; PIRRT are technically able to deliver high convective clearances, and would be suitable in research settings for the clearance of middle-molecule inflammatory mediators, or for this purpose in future clinical settings if human studies in this area yield conclusive results. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Large solute control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluid removal &mdash; All reports of PIRRT have shown ultrafiltration to be well tolerated, and not associated with undue cardiovascular instability. Reported ultrafiltration volumes vary between zero and 6 L per treatment, with an average of approximately 3 L. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Fluid removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrolyte control and nutritional considerations &mdash; All reports of PIRRT have shown that electrolyte concentrations were able to be maintained within normal limits. However, variable results have been reported in different centers. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Electrolyte control and nutritional considerations'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Given that amino acid removal is significant, protein prescriptions should be augmented by 0.2",
"      <span class=\"nowrap\">",
"       gm/kg",
"      </span>",
"      per day during hybrid treatment.",
"     </li>",
"     <li>",
"      Drug clearance &mdash; Drug clearance can be considerable with PIRRT and intermediate between that iHD and CRRT. Dosing decisions need to be made on an individual basis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Drug clearance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the reported experiences with PIRRT suggest patients outcomes are similar to those reported with other acute renal replacement therapies. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Outcomes'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/1\">",
"      Tolwani AJ, Wheeler TS, Wille KM. Sustained low-efficiency dialysis. Contrib Nephrol 2007; 156:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/2\">",
"      Naka T, Baldwin I, Bellomo R, et al. Prolonged daily intermittent renal replacement therapy in ICU patients by ICU nurses and ICU physicians. Int J Artif Organs 2004; 27:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/3\">",
"      Bellomo R, Baldwin I, Fealy N. Prolonged intermittent renal replacement therapy in the intensive care unit. Crit Care Resusc 2002; 4:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/4\">",
"      Marshall MR, Golper TA, Shaver MJ, Chatoth DK. Hybrid renal replacement modalities for the critically ill. Contrib Nephrol 2001; :252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/5\">",
"      Marshall MR, Golper TA. Low-efficiency acute renal replacement therapy: role in acute kidney injury. Semin Dial 2011; 24:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/6\">",
"      Overberger P, Pesacreta M, Palevsky PM, VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute kidney injury: a survey of practitioner prescribing practices. Clin J Am Soc Nephrol 2007; 2:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/7\">",
"      Ricci Z, Ronco C, D'Amico G, et al. Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant 2006; 21:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/8\">",
"      Basso F, Ricci Z, Cruz D, Ronco C. International survey on the management of acute kidney injury in critically ill patients: year 2007. Blood Purif 2010; 30:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/9\">",
"      Sigler MH, Teehan BP. Solute transport in continuous hemodialysis: a new treatment for acute renal failure. Kidney Int 1987; 32:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/10\">",
"      Bellomo, R. Choosing a therapeutic modality: hemofiltration vs. hemodialysis vs hemodiafiltration. Semin Dial 1996; 9:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/11\">",
"      Macias WL, Mueller BA, Scarim SK, et al. Continuous venovenous hemofiltration: an alternative to continuous arteriovenous hemofiltration and hemodiafiltration in acute renal failure. Am J Kidney Dis 1991; 18:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/12\">",
"      Kihara M, Ikeda Y, Shibata K, et al. Slow hemodialysis performed during the day in managing renal failure in critically ill patients. Nephron 1994; 67:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/13\">",
"      Hombrouckx R, Bogaert AM, Leroy F, et al. Go-slow dialysis instead of continuous arteriovenous hemofiltration. Contrib Nephrol 1991; 93:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/14\">",
"      Kudoh Y, Iimura O. Slow continuous hemodialysis--new therapy for acute renal failure in critically ill patients--Part 1. Theoretical consideration and new technique. Jpn Circ J 1988; 52:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/15\">",
"      Kudoh Y, Shiiki M, Sasa Y, et al. Slow continuous hemodialysis--new therapy for acute renal failure in critically ill patients--Part 2. Animal experiments and clinical implication. Jpn Circ J 1988; 52:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/16\">",
"      Mehta, RL, Martin, RK. Initiating and implementing a continuous renal replacement therapy program. Semin Dial 1996; 9:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/17\">",
"      Ahern, J, Lai, C, Rebuck, J, et al. Experience with vancomycin in patients receiving slow low-efficiency dialysis. Hosp Pharm 2004; 39:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/18\">",
"      Lund B, Seifert SA, Mayersohn M. Efficacy of sustained low-efficiency dialysis in the treatment of salicylate toxicity. Nephrol Dial Transplant 2005; 20:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/19\">",
"      Stragier, A, Backus, G, Concepcion, D, et al. EDTNA/ERCA dialysis technology Journal Club 2001/2002 Summary. EDTNA-ERCA J Suppl 2002; 28:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/20\">",
"      Van Malderen P, De Rijck L, Vermaut M, et al. Intermittent venovenous haemodiafiltration in critically ill patients with acute renal failure. EDTNA ERCA J 1998; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/21\">",
"      Vanholder R, Van Biesen W, Lameire N. What is the renal replacement method of first choice for intensive care patients? J Am Soc Nephrol 2001; 12 Suppl 17:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/22\">",
"      Holt BG, White JJ, Kuthiala A, et al. Sustained low-efficiency daily dialysis with hemofiltration for acute kidney injury in the presence of sepsis. Clin Nephrol 2008; 69:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/23\">",
"      Finkel KW, Foringer JR. Safety of regional citrate anticoagulation for continuous sustained low efficiency dialysis (C-SLED) in critically ill patients. Ren Fail 2005; 27:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/24\">",
"      Berbece AN, Richardson RM. Sustained low-efficiency dialysis in the ICU: cost, anticoagulation, and solute removal. Kidney Int 2006; 70:963.",
"     </a>",
"    </li>",
"    <li>",
"     Wu, VC, Wang, CH, Wang, WJ, et al. Sustained low-efficiency dialysis versus continuous veno-venous hemofiltration for postsurgical acute renal failure. Am J Surg; Apr 16 2009 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/26\">",
"      Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 2000; 36:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/27\">",
"      Lonnemann G, Floege J, Kliem V, et al. Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system. Nephrol Dial Transplant 2000; 15:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/28\">",
"      Fiaccadori E, Maggiore U, Parenti E, et al. Sustained low-efficiency dialysis (SLED) with prostacyclin in critically ill patients with acute renal failure. Nephrol Dial Transplant 2007; 22:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/29\">",
"      Gashti CN, Salcedo S, Robinson V, Rodby RA. Accelerated venovenous hemofiltration: early technical and clinical experience. Am J Kidney Dis 2008; 51:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/30\">",
"      Kumar VA, Yeun JY, Depner TA, Don BR. Extended daily dialysis vs. continuous hemodialysis for ICU patients with acute renal failure: a two-year single center report. Int J Artif Organs 2004; 27:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/31\">",
"      Kielstein JT, Kretschmer U, Ernst T, et al. Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004; 43:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/32\">",
"      Schlaeper C, Amerling R, Manns M, Levin NW. High clearance continuous renal replacement therapy with a modified dialysis machine. Kidney Int Suppl 1999; :S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/33\">",
"      Marshall MR, Golper TA, Shaver MJ, et al. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 2001; 60:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/34\">",
"      Hall, JA, Shaver, MJ, Marshall, MR, K. CD, Golper TA. Daily 12-hour sustained low-efficiency hemodialysis (SLED). A nursing perspective. Blood Purif 1999; 17:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/35\">",
"      Fliser D, Kielstein JT. A single-pass batch dialysis system: an ideal dialysis method for the patient in intensive care with acute renal failure. Curr Opin Crit Care 2004; 10:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/36\">",
"      Marshall MR, Ma T, Galler D, et al. Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy. Nephrol Dial Transplant 2004; 19:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/37\">",
"      Baldwin I, Naka T, Koch B, et al. A pilot randomised controlled comparison of continuous veno-venous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance. Intensive Care Med 2007; 33:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/38\">",
"      Baldwin I, Bellomo R, Naka T, et al. A pilot randomized controlled comparison of extended daily dialysis with filtration and continuous veno-venous hemofiltration: fluid removal and hemodynamics. Int J Artif Organs 2007; 30:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/39\">",
"      Bellomo R, Baldwin I. Sustained low-efficiency dialysis in the ICU. International Journal of Intensive Care 2002; Winter:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/40\">",
"      Marshall MR, Creamer JM, Foster M, et al. Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries. Nephrol Dial Transplant 2011; 26:2169.",
"     </a>",
"    </li>",
"    <li>",
"     Fiaccadori, E, 2005, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/42\">",
"      Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/43\">",
"      Fiaccadori E, Maggiore U, Rotelli C, et al. Sustained low-efficiency dialysis in acute renal failure. G Ital Nefrol 2006; 23:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/44\">",
"      Schetz M. Non-renal indications for continuous renal replacement therapy. Kidney Int Suppl 1999; :S88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/45\">",
"      Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993; 21:328.",
"     </a>",
"    </li>",
"    <li>",
"     Concepcion, LA, McLean, LB. ARF requiring dialysis: Use of shift CVVHD vs conventional dialysis. J Am Soc Nephrol 2009; Suppl, F-PO1557 (Abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/47\">",
"      Fassbinder W. Renaissance of the batch method? Nephrol Dial Transplant 1998; 13:3010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/48\">",
"      Kleophas W, Backus G. A simplified method for adequate hemodialysis. Blood Purif 2001; 19:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/49\">",
"      Clark WR, Turk JE Jr. The NxStage System One. Semin Dial 2004; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/50\">",
"      Clark WR, Ronco C. Continuous renal replacement techniques. Contrib Nephrol 2004; 144:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/51\">",
"      Dhondt A, Eloot S, Wachter DD, et al. Dialysate partitioning in the Genius batch hemodialysis system: effect of temperature and solute concentration. Kidney Int 2005; 67:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/52\">",
"      Dhondt AW, Vanholder RC, De Smet RV, et al. Studies on dialysate mixing in the Genius single-pass batch system for hemodialysis therapy. Kidney Int 2003; 63:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/53\">",
"      Dhondt A, Verstraete A, Vandewoude K, et al. Efficiency of the Genius batch hemodialysis system with low serum solute concentrations: the case of lithium intoxication therapy. Am J Kidney Dis 2005; 46:e95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/54\">",
"      Tu, A, Ahmad, S. Heparin-free hemodialysis with citrate-containing dialysate in intensive care patients. Dial Transplant 2000; 29:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/55\">",
"      Madison, JR, Ilumin, MP, Chin, AI. et al. Citrate-containing dialysate is well tolerated during slow extended daily dialysis in the ICU. J Am Soc Nephrol 2005; 16:314A.",
"     </a>",
"    </li>",
"    <li>",
"     Van Malderen, P. Personal Communication, 9 September 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/57\">",
"      Dinarello CA, Lonnemann G, Maxwell R, Shaldon S. Ultrafiltration to reject human interleukin-1-inducing substances derived from bacterial cultures. J Clin Microbiol 1987; 25:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/58\">",
"      Vaslaki L, Kar&aacute;tson A, V&ouml;r&ouml;s P, et al. Can sterile and pyrogen-free on-line substitution fluid be routinely delivered? A multicentric study on the microbiological safety of on-line haemodiafiltration. Nephrol Dial Transplant 2000; 15 Suppl 1:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/59\">",
"      Weber C, Groetsch W, Schlotter S, et al. Novel online infusate-assisted dialysis system performs microbiologically safely. Artif Organs 2000; 24:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/60\">",
"      Relton S, Greenberg A, Palevsky PM. Dialysate and blood flow dependence of diffusive solute clearance during CVVHD. ASAIO J 1992; 38:M691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/61\">",
"      Ifediora OC, Teehan BP, Sigler MH. Solute clearance in continuous venovenous hemodialysis. A comparison of cuprophane, polyacrylonitrile, and polysulfone membranes. ASAIO J 1992; 38:M697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/62\">",
"      Doshi M, Murray PT. Approach to intradialytic hypotension in intensive care unit patients with acute renal failure. Artif Organs 2003; 27:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/63\">",
"      Fliser D, Kielstein JT. Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol 2006; 2:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/64\">",
"      Morgera S, Scholle C, Melzer C, et al. A simple, safe and effective citrate anticoagulation protocol for the genius dialysis system in acute renal failure. Nephron Clin Pract 2004; 98:c35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/65\">",
"      Schneider M, Liefeldt L, Slowinski T, et al. Citrate anticoagulation protocol for slow extended hemodialysis with the Genius dialysis system in acute renal failure. Int J Artif Organs 2008; 31:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/66\">",
"      Morath C, Miftari N, Dikow R, et al. Sodium citrate anticoagulation during sustained low efficiency dialysis (SLED) in patients with acute renal failure and severely impaired liver function. Nephrol Dial Transplant 2008; 23:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/67\">",
"      Clark JA, Schulman G, Golper TA. Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis. Clin J Am Soc Nephrol 2008; 3:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/68\">",
"      Yang Y, Szamosfalvi B, Yee J, et al. Development of an online citrate/Ca2+ sensing system for dialysis. Analyst 2011; 136:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/69\">",
"      Szamosfalvi B, Frinak S, Yee J. Automated regional citrate anticoagulation: technological barriers and possible solutions. Blood Purif 2010; 29:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/70\">",
"      Szamosfalvi B, Frinak S, Yee J. Near-automated regional citrate anticoagulation (RCA) during dialysis: building a safe system and a low cost clinical program for new extracorporeal therapies. ASAIO J 2010; 57:132.",
"     </a>",
"    </li>",
"    <li>",
"     Szamosfavi B: Automated RCA Systems. Patent Application 0015487 A1 2008, United States.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/72\">",
"      Marshall MR, Ma TM, Eggleton K, Ferencz A. Regional citrate anticoagulation during simulated treatments of sustained low efficiency diafiltration. Nephrology (Carlton) 2003; 8:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/73\">",
"      Sigler MH. Transport characteristics of the slow therapies: implications for achieving adequacy of dialysis in acute renal failure. Adv Ren Replace Ther 1997; 4:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/74\">",
"      Leypoldt JK. Fouling of ultrafiltration and hemodialysis membranes by plasma proteins. Blood Purif 1994; 12:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/75\">",
"      VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/76\">",
"      Faulhaber-Walter R, Hafer C, Jahr N, et al. The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant 2009; 24:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/77\">",
"      Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002; 346:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/78\">",
"      Casino FG, Lopez T. The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant 1996; 11:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/79\">",
"      Casino FG, Marshall MR. Simple and accurate quantification of dialysis in acute renal failure patients during either urea non-steady state or treatment with irregular or continuous schedules. Nephrol Dial Transplant 2004; 19:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/80\">",
"      Clark WR, Mueller BA, Kraus MA, Macias WL. Dialysis prescription and kinetics in acute renal failure. Adv Ren Replace Ther 1997; 4:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/81\">",
"      Marshall MR, Golper TA, Shaver MJ, et al. Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. Am J Kidney Dis 2002; 39:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/82\">",
"      Depner, T, Craig, M, Hu, K, et al. Solute kinetics during extended daily hemodialysis in the intensive care unit (ICU). ASAIO J 1999; 45:185A.",
"     </a>",
"    </li>",
"    <li>",
"     Depner, TA. Prescribing hemodialysis. A guide to urea modeling. Kluwer Academic Publishers, Norwell, MA, 1991. p.74.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/84\">",
"      Evanson JA, Ikizler TA, Wingard R, et al. Measurement of the delivery of dialysis in acute renal failure. Kidney Int 1999; 55:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/85\">",
"      Evanson JA, Himmelfarb J, Wingard R, et al. Prescribed versus delivered dialysis in acute renal failure patients. Am J Kidney Dis 1998; 32:731.",
"     </a>",
"    </li>",
"    <li>",
"     Lo, AJ, Depner, TA, Chin, ES, Craig, MA. Urea disequilibrium contributes to underdialysis in the intensive care unit. J Am Soc Nephrol 1997; T173.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/87\">",
"      Kjellstrand C, Skr&ouml;der R, Cederl&ouml;f IO, et al. Patient related factors leading to slow urea transfer in the body during dialysis. ASAIO J 1994; 40:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/88\">",
"      Kanagasundaram NS, Greene T, Larive AB, et al. Prescribing an equilibrated intermittent hemodialysis dose in intensive care unit acute renal failure. Kidney Int 2003; 64:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/89\">",
"      Kanagasundaram NS, Greene T, Larive AB, et al. Dosing intermittent haemodialysis in the intensive care unit patient with acute renal failure--estimation of urea removal and evidence for the regional blood flow model. Nephrol Dial Transplant 2008; 23:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/90\">",
"      Jean G, Chazot C, Charra B, et al. Is post-dialysis urea rebound significant with long slow hemodialysis? Blood Purif 1998; 16:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/91\">",
"      Jean G, Charra B, Chazot C, Laurent G. Quest for postdialysis urea rebound-equilibrated Kt/V with only intradialytic urea samples. Kidney Int 1999; 56:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/92\">",
"      Jean G, Chazot C, Charra B, Vanel T. Urea kinetics on 8-hour hemodialysis: the third slope meaning. Nephron 2002; 90:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/93\">",
"      Keshaviah PR, Ebben JP, Emerson PF. On-line monitoring of the delivery of the hemodialysis prescription. Pediatr Nephrol 1995; 9 Suppl:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/94\">",
"      Garred LJ. Dialysate-based kinetic modeling. Adv Ren Replace Ther 1995; 2:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/95\">",
"      Canaud B, Bosc JY, Leblanc M, et al. On-line dialysis quantification in acutely ill patients: preliminary clinical experience with a multipurpose urea sensor monitoring device. ASAIO J 1998; 44:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/96\">",
"      Schetz, M. Non-renal indications for continuous renal replacement therapy. Kidney Int 1999; 56:S88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/97\">",
"      Tonelli M, Manns B, Feller-Kopman D. Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis 2002; 40:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/98\">",
"      Kellum JA, Angus DC, Johnson JP, et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 2002; 28:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/99\">",
"      Pannu N, Klarenbach S, Wiebe N, et al. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA 2008; 299:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/100\">",
"      Liao Z, Zhang W, Hardy PA, et al. Kinetic comparison of different acute dialysis therapies. Artif Organs 2003; 27:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/101\">",
"      Clark WR, Leypoldt JK, Henderson LW, et al. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol 1999; 10:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/102\">",
"      Lonnemann G, Bechstein M, Linnenweber S, et al. Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure. Kidney Int Suppl 1999; :S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/103\">",
"      Kielstein, J, Hafer, C, Reising, A, et al. Extended daily dialysis (EDD) but not venovenous hemofiltration (CVVH) increases soluble TNF alpha receptor (sTNFR) plasma concentration in septic patients with acute renal failure. J Am Soc Nephrol 2005; 16:542A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/104\">",
"      Fieghen HE, Friedrich JO, Burns KE, et al. The hemodynamic tolerability and feasibility of sustained low efficiency dialysis in the management of critically ill patients with acute kidney injury. BMC Nephrol 2010; 11:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/105\">",
"      Kron J, Kron S, Wenkel R, et al. Extended daily on-line high-volume haemodiafiltration in septic multiple organ failure: a well-tolerated and feasible procedure. Nephrol Dial Transplant 2012; 27:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/106\">",
"      Kihara M, Ikeda Y, Fujita H, et al. Amino acid losses and nitrogen balance during slow diurnal hemodialysis in critically ill patients with renal failure. Intensive Care Med 1997; 23:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/107\">",
"      Marshall, M, Shaver, M, Alam, M, Chatoth, D. Amino acid losses during sustained low efficiency dialysis (SLED). J Am Soc Nephrol 2000; 11:312A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/108\">",
"      Mushatt DM, Mihm LB, Dreisbach AW, Simon EE. Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis 2009; 49:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/109\">",
"      Dager WE. Filtering out important considerations for developing drug-dosing regimens in extended daily dialysis. Crit Care Med 2006; 34:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/110\">",
"      Bogard KN, Peterson NT, Plumb TJ, et al. Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Crit Care Med 2011; 39:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/111\">",
"      Roberts JA, Mehta RL, Lipman J. Sustained low efficiency dialysis allows rational renal replacement therapy, but does it allow rational drug dosing? Crit Care Med 2011; 39:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/112\">",
"      Kielstein, J, Czock, D, Schopke, T, et al. Pharmacokinetics and Elimination of Moxifloxacin in Intensive Care Unit Patients Undergoing Extended Daily Dialysis. J Am Soc Nephrol 2004; 15:.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/113\">",
"      Kihara M, Ikeda Y, Fujita H, et al. Effects of slowly performed daytime hemodialysis (slow HD) on the pharmacokinetics of vancomycin in hemodynamically unstable patients with renal failure. Blood Purif 1996; 14:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/114\">",
"      Kielstein JT, Czock D, Sch&ouml;pke T, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/115\">",
"      Burkhardt O, Hafer C, Langhoff A, et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 2009; 24:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/116\">",
"      Burkhardt O, Joukhadar C, Traunm&uuml;ller F, et al. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2008; 61:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/117\">",
"      Burkhardt O, Kaever V, Burhenne H, Kielstein JT. Extended daily dialysis does not affect the pharmacokinetics of anidulafungin. Int J Antimicrob Agents 2009; 34:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/118\">",
"      Burkhardt O, Thon S, Burhenne J, et al. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. Int J Antimicrob Agents 2010; 36:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/119\">",
"      Cremaschi E, Maggiore U, Maccari C, et al. Linezolid levels in a patient with biliary tract sepsis, severe hepatic failure and acute kidney injury on sustained low-efficiency dialysis (SLED). Minerva Anestesiol 2010; 76:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/120\">",
"      Czock D, H&uuml;sig-Linde C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 2006; 1:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/121\">",
"      Deshpande P, Chen J, Gofran A, et al. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED). Nephrol Dial Transplant 2010; 25:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/122\">",
"      Golestaneh L, Gofran A, Mokrzycki MH, Chen JL. Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing. Clin Nephrol 2009; 72:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/123\">",
"      Kihara M, Ikeda Y, Shibata K, et al. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. Clin Nephrol 1994; 42:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/124\">",
"      Kihara M, Ikeda Y, Shiratori K, et al. A serial application study on twice daily dose of imipenem/cilastatin in patients undergoing slow hemodialysis. Nephron 1994; 68:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/125\">",
"      Swoboda S, Ober MC, Lichtenstern C, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010; 66:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/126\">",
"      Kielstein JT, Lorenzen J, Kaever V, et al. Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury undergoing extended daily dialysis--a single case. Nephrol Dial Transplant 2009; 24:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/127\">",
"      Mueller BA, Pasko DA, Sowinski KM. Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 2003; 27:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/128\">",
"      Kielstein JT, Schwarz A, Arnavaz A, et al. High-flux hemodialysis--an effective alternative to hemoperfusion in the treatment of carbamazepine intoxication. Clin Nephrol 2002; 57:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/129\">",
"      Fiaccadori, E, Maggiore, U, Parenti, E, et al. Sustained low-efficiency dialysis (SLED) for acute lithium intoxication. NDT Plus 2008; 5:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/130\">",
"      Khan E, Huggan P, Celi L, et al. Sustained low-efficiency dialysis with filtration (SLEDD-f) in the management of acute sodium valproate intoxication. Hemodial Int 2008; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/131\">",
"      Kielstein JT, Linnenweber S, Schoepke T, Fliser D. One for all--a multi-use dialysis system for effective treatment of severe thallium intoxication. Kidney Blood Press Res 2004; 27:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/132\">",
"      Kielstein JT, Woywodt A, Schumann G, et al. Efficiency of high-flux hemodialysis in the treatment of valproic acid intoxication. J Toxicol Clin Toxicol 2003; 41:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/133\">",
"      Thanacoody RH. Extracorporeal elimination in acute valproic acid poisoning. Clin Toxicol (Phila) 2009; 47:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/134\">",
"      Marcelino P, Marum S, Fernandes AP, Ribeiro JP. [Hybrid or continuous renal replacement techniques for unstable haemodynamic patients in the intensive care unit]. Acta Med Port 2006; 19:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/135\">",
"      Waikar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006; 17:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/136\">",
"      Ympa YP, Sakr Y, Reinhart K, Vincent JL. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med 2005; 118:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/137\">",
"      Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005; 9:R700.",
"     </a>",
"    </li>",
"    <li>",
"     Lins, RL, Elseviers, MM, Van der Niepen, P, et al. Outcome of different treatment modalities in ARF: Randomized population (abstract). J Am Soc Nephrol 2004, 14:195A.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/139\">",
"      Lins RL, Elseviers MM, Daelemans R, et al. Re-evaluation and modification of the Stuivenberg Hospital Acute Renal Failure (SHARF) scoring system for the prognosis of acute renal failure: an independent multicentre, prospective study. Nephrol Dial Transplant 2004; 19:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/140\">",
"      Malbrain, M, Elseviers, MM, Van der Niepen, P, et al. Interim results of the SHARF4 study: outcome of acute renal failure with different treatment modalities (abstract). Critical Care 2004; 8:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/141\">",
"      Lins RL, Elseviers MM, Van der Niepen P, et al. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial. Nephrol Dial Transplant 2009; 24:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/142\">",
"      Bandyopadhyay S, Jakobson D, Chhabra KD, Baker A. Improvement of cerebral blood flow patterns in hepatorenal syndrome using sustained low-efficiency dialysis. Br J Anaesth 2010; 105:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/143\">",
"      Iarustovski MB, Nazarova EI. [Hybrid technologies of renal replacement therapy in the treatment of multiple organ failure in cardiosurgical patients]. Anesteziol Reanimatol 2006; :67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/144\">",
"      Iorio L, Violi F, Simonelli R, et al. [Sustained low-efficiency dialysis (SLED) in patients with prevalent systolic heart failure refractory to medical treatment and with chronic renal failure]. G Ital Nefrol 2006; 23 Suppl 34:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/145\">",
"      Violi F, Nacca RG, Iengo G, Iorio L. [Long-term sustained low efficiency dialysis in eight patients with class IV NYHA heart failure resistant to high-dose diuretic treatment]. G Ital Nefrol 2009; 26 Suppl 46:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/146\">",
"      Alam, M, Marshall, M, Shaver, M, Chatoth, D. Cost comparison between sustained low efficiency hemodialysis (SLED) and continuous venovenous hemofiltration (CVVH) for ICU patients with ARF (Abstract). Am J Kidney Dis 2000; 35:A9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/147\">",
"      Ma, T, Walker, R, Eggleton, K, Marshall, M. Cost comparison between sustained low efficency daily dialysis/diafiltration (SLEDD) and continuous renal replacment therapy for ICU patients with ARF (Abstract). Nephrology 2002; 7:A54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/148\">",
"      Golper TA. Hybrid renal replacement therapies for critically ill patients. Contrib Nephrol 2004; 144:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/47/33530/abstract/149\">",
"      Ahmed Z, Gilbert S, Krevolin L. Cost analysis of continuous renal replacement and extended hemodialysis. Dial Transplant 2009; 38:500.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1903 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33530=[""].join("\n");
var outline_f32_47_33530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROGRAM IMPLEMENTATION AND MAINTENANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TECHNICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hemodialysis machines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dialysate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dialysate flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ultrafiltration rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      On-line fluid for filtrate replacement during hemodiafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hemodialyzers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vascular access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OPERATIONAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Urea kinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Urea clearance predicts a failing filter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Small solute control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Large solute control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fluid removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Electrolyte control and nutritional considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Drug clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Program implementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Operational characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1903\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1903|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?7/62/8173\" title=\"algorithm 1\">",
"      Decisions regarding daily HD options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1903|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/20/40269\" title=\"figure 1\">",
"      Low-efficiency acute renal replacement therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/20/20814\" title=\"figure 2\">",
"      QB QD and urea clearance during SLED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/0/13325\" title=\"figure 3\">",
"      Frequency of dialysis and BUN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/27/34237\" title=\"figure 4\">",
"      High KtV enhances survival ICU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/16/17677\" title=\"figure 5\">",
"      Monoexponential DUN versus time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1903|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/42/26285\" title=\"table 1\">",
"      SLED hospital regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/43/40637\" title=\"table 2\">",
"      SLED nursing responsibilities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/44/37579\" title=\"table 3\">",
"      Choice of dialysis in ARF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=related_link\">",
"      Continuous arteriovenous hemodialysis: Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_47_33531="Causes of toxic megacolon";
var content_f32_47_33531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of toxic megacolon",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clostridium difficile pseudomembranous colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Salmonella - typhoid and non-typhoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Shigella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Campylobacter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Yersinia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Parasitic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Entameba histolytica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cryptosporidium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        CMV colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-limited colitis (culture negative)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudomembranous colitis secondary to methotrexate therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kaposi's sarcoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33531=[""].join("\n");
var outline_f32_47_33531=null;
var title_f32_47_33532="Etiology obscure GI bleed";
var content_f32_47_33532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of obscure gastrointestinal bleeding",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Upper GI and lower GI bleeding overlooked",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Upper GI lesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cameron's erosions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fundic varices",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Peptic ulcer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Angioectasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dieulafoy's lesion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gastric antral vascular ectasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Lower GI lesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Angioectasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neoplasms",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Mid GI bleeding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Younger than 40 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Meckel's diverticulum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dieulafoy's lesion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Crohn's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Celiac disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Older than 40 years of age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Angioectasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            NSAID enteropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Celiac disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Uncommon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hemobilia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hemosuccus pancreaticus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Aortoenteric fistula",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Raju GS, Gerson L, Das A, Lewis B. American Gastroenterological Association (AGA) Institute Technical Review on Obscure Gastrointestinal Bleeding. Gastroenterology 2007; 133:1697.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33532=[""].join("\n");
var outline_f32_47_33532=null;
var title_f32_47_33533="Clopidogrel timing before PCI";
var content_f32_47_33533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Clopidogrel timing and benefit before stenting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 347px; background-image: url(data:image/gif;base64,R0lGODlh+AFbAeYAAP///4CAgAAAAICZ/zMzM3d3d6qqqhEREczMzO7u7lVVVYiIiP+AgCIiIkRERP/w8EBm/8DN/7u7u/8QEP8gIP+goN3d3f9AQP9QUJmZmQAz/2ZmZv+wsP/AwP8AAP+QkPDz//9wcP/g4P/Q0FBz/6Cz/8DAwEBAQP9gYBBA//8wMH8Zf7DA/+Dm/zBZ/2CA/3CN/9DZ/yBN/5Cm/4BZvyA8739pz4CJ76CDz78MP4BJrx8s378cUK8gYL9cj385n7+MvwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD4AVsBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4cQI85K4ECAAAcWJGrcmEuBAAMIBBDgSLIkrAMCEgBAqdKky5ekEgg4IIilIBMBcuo0AbOnz0k2bQLAqTPAiQA/kypV5NGABJGJci6dShUARYsYoyKtyrWrIalew3YFK7bsUrJm0/ZEq7ZtSbZu/+NKhCu3bkO6dvMixKu370C+fgP7Ayy4cD7ChhPTQ6y48TvGjiOrgyy5cjnKljODw6y58zbOnkNbAy26dDTSplMzQ6269THWrmMLgy27di/atnPjwq279yzevoO7Ai68eCrixpOTQq68+SfmzqNrgi69eiXq1rNDwq69+yLu3sN/3Sq+fCjw5sWjT+99PXvHC0q5f++3AIECACwQGLmcPH3fGVh0EUoOyOfff7oV0IABG1i0QUujzIdgXfYlYIAAC0AY4YET1laAgALyt2GHvX0IIlT9kdhbAiy2mElFCCgioYpqZZDhJhdaFKNWNNr24QEKSLCJRzsiMmOPZVmwQP8DFjVwIyQECNgSkYQQpdNRSOYmwQYoiVgJlYNYmROWWdYmgQJdYgKmkRyWKZoFCgrogAGW5GiRAjy6qZqJThaZop6pLaAAnce1CahmC3h5ypGHTvWhhqYw2qhSHxZgqaXx/TmpZyaCqCgokm7qU6WXFpDpiKJ29qgqoab6UqKrtOqqSRYYYKutixo6a2KdWkQApKDqumthie63nwAbGDhsaBt8+pywyyrWrLLRwmfssclqWi2vJ/5K7baJ1Xorod+C2x605jYna7qFrctuQxtkm+u7hingrCju0qvQAgdceiq+6OqrVpQhlitwXhKMK6S2B+vl1LwN64UASiIB+2z/xHo10EABXOLJMMZtyUSofQaD3FYDg2ZAgMeomhzXAgIe4Od5AbvMlQSmZlSyzbrly7NYPv/sVdBCc0V00fsYMOjOSHv11EUze3J00/lYaGrLVMs2ddbwkDyI11hzvVQBB1zbwL2dbC12O736yvTaMNk3rr1vw+2SAf/ibcnEWOl8iNp2p2NAqZhaskB8FxbIZuCUnojiJQGiDTjj5sAskr+REJySIAagdKqYRtVMeURKC+BkJg0KwPJQRYU+elIJWG4xJB4JgJ+Mor/ekAVcArmwJbULGLUgk+sejonXyguw8S+1/fjyzLvUoot1R29Y8dYnhH32B22fVgwzDCD+/wAlgDCr9yaBEAEL47fvvvgkpJACCe2ToAH97+cvPgsRtCCa0uSCXl/UF4EClkB/CBwfDCDgAg1owAUQgEECxzeDGBwCBAecYPsgAIEUaCAFHNRgCQpoPoRhZXicQN8nDCi+EUbAFwQsYATCNz4ScJCDDszhDSGAPw3mj38ldEUL1qdBG0JAhzxsIQnNYrV/XWwa6mPfADgoAwfKIIRThEAVNXBFCPjwi2Bs3wJ36MEcamCHEHhB+1y4RHIQMINGRCL+ZlBAC8Ikdpj72DFiEIEBLLCBD4wg+QrICBbq7wY00MEKFsnIRjpyBT+gAQ3AaIMc8MAHQOhfQd4IPw6WEf+ESfShC4MYkIoUTI+/GKIftchFQQIREw/oAAcYEIILqMADHlDBBULAgF768pcV6EAHKvGACqDglipAwQeG2RA+zvCLcXQgB/E3SnzIhAC3+p0AYViCFxzxjGqMgB0hIYIO/PKXtbxlLnfJAA504AGr6MAHjplLZb4zKZwcQDTPGEr++c8d9ynUKThQgUpg0H7006Qk5ImCC+DyAig4py/dCc9bMNShFLhAO0fAlXx68oNY9Cc5LOWAjRUOlZ/gAAUo0MuCNuKg9yufJEYwT2RGtAMiWMYIZnkBCngAosusqFeGKMWPglJ8Cs2GTByHthTmLhMV6OVKXYqIGLwgBS7/kOkjHsBTD1DAntaI5TwxqlEOcDQtRB2AN6X5AjpeY1zZrJ4oKjBVoQqiBC5IwQvGyYhiosCnZbUrN3bKgJ7+NKIM+MBZzaLKFzTQBS/QqjQkoDPKynUUFcCABzBQ0BLIQAaSXUQxNYsBxapDrL3EwAQmgAEGdGCxZpkhQl8YjYACAGzbbEUxe7CDGpTAETQlbQUE+w6a1tKnGeXla8uCQdo6QwIEOMDZotvUTeQLBPHDgQd4OVxEZHa1nCXuPUZgzuN6dZfdpZGdLHKADFx2FCyYn/lmyQDSSnSlpj0Ieeu72fR2KAEbyNDsnsgK7KaABYcopkSpypDR9le876Ee/0pJEV8SkDIpDi5tTunDr1OG7RQwOHBYRjuBr3IAwtnRmEiA9F5OtMAFLvinWcyJTNc+5AA0mcSFVscLmcAMwDwOVioikAIY1IWrf2UtgwESEjnFCMeU2DEwRHYfuk3YEyBIwW/7IoIPrJQBKMZHSEbylJFAWceqC8bKTKQ8mqGCBCQwTAcuMIEQbLgfY7bKTFZCE8uZjk4IMGVKMsCkNF/oWA5QSaecOItaHW7ATj1FfC8cmBGgwAMogG0+8hwgPJ1ZEDArUANkJog8NygDUv7Q4WwHgIoEUBaWMwAB2ixkU4gvMiIIwQQuwMxNg0gBKoGyAQRNgDyD+kQFkDLMCv/QlNuyuhZnWxBu3WwKQkrmAQxYKQd8rSgoo0QCeR71jozNuTRXZNX4cXUtqMyg6k7nqcqh6wU0LQ9y16TPvoJKoKVEaAEtYL3ZMtEBGB2LBjSLbLQmcHqwXecwqyZA7PVbbtMjAtV+wDc4W4DEJ86eDqhABb12DVxtpU1qd+gDrL1zapbarRZ75wG6BnNrLIUymidcavDuzgh6umTRiEwQBVDch0mkUgr03DNlM4DK3J0JFSaGrhTYdmn8LAD3XrlDFWCtwx2DswKU3OR6eoBqpY4gp0eGA1ove87pI/YJkJ09Zq8M2kOwdb0UYOOQc3KeUvUAW9JbMFS+HSY24N7/AAl9PMP6gAcu3hjpStdYN49EgASP+GGNQJd1fxnFPOwIzamkyQfwG+jINCyYT+DofgmwhC8RkgaEqXWkX5ZKed2Yh11iTgB4iusXBy4GpLwwfKuYJVIHtb1vC+bbzXxZNMYxFl/dVRWfAAP68vPbMh0TcXfNnKOesZStzOWuyjoGVO4WP5P6+csyPePlknG817phHcjo33OTfd0wwAPTF079dbNzCoSc/mu3LChHd2bxaA4QZO/nMtGHelPhJLVDcDhXNLP3f1NBZbN2fZewf8aBchdAfkvRL7YzbQkoNAyHAh74E6kjawgYgVkjAiggfcqnEbGTAQlQACiUNgFI/y8iQGfr1xMjZ3tD1zTb93YmwXKeAn4mI34nuBE0pwA2h4Qmo3539BFAd3hgFzjxN28vkXRLB4U8c3/5VxJUZ3VBaDf9R4ES0XVfN4KvM4AxOBA/uIYsGD3RR4QMYYScd4XMg3YY8Ib/0IRPiH5203Z2qBDVF3ReyDV86If9wIX7kYhcQ4gOMYaQKDaL2BBqGCk5uDaSyBBAKIjGc4kIEXzeAorG04kGwXwdU4mMw4dL2A+HiIGWoIFuIoUEgTJK932mmD1ZOH/7YH43GGncEwlgOBDtp4nDOFM9hYZVQYub4oZAs4nZs4Bh4YypMoH7kDDjworJyIGvCA+aE3FlmP+MkFCC39gOa6YgDuB8ekiOlOCCMFgPBzAyDjAtHOeO78iD9OCI9yGLk2CN2zKE8tArGXCA44iPlKCE8TA4XpcJT/NqhACQ5mKL7/CJlWABo0aFvIeQntCL7UCKkNYIK9NsG8mRnlCM66CK7Nh5UuIAI0GSrFMUsWeSnXCG6RCLldBkIEIooyeNNKkI0HgOuKgyKxgJMFl5PwkK1Fg5MROMj3CUhSCREYON5XCM3JiUjOB74+cQUgkyyEeA5PCIu4iVlRB9YRgOYnmQZNkJAskN05MAaXmPaxkKWQeW2OA8/kgJXUmCfpcNeHmVcxkJiteD1fCWIWldPhmYM4V5f5H/mIoZCabHgIfhmI8ZCUUnmfawl2IDdZg5D5q5NlBXiPXwmXBTl/tAmnAjAh93ju6Amnaja6IJD65pNxXgAZ25DrNJm7c5GZRZmRqRm76JDcAZnKPRm8T5EMN5nNOQnK7yaZMAlV8iAE5ZnMqpCBZgSqHHZ48QJX4CnZSwJt7AnG6SAKNGJ0qjndEJkd8pneEgnmUSIG0GZVfxZwAQJQRDJ1SSOihBJ4uWHxWBYynxIWhSAAlQOwsCAODZDe6ZJapWCFDWFOR5AHApnRbwoNIJM3jSFMvWah/hEfHBEp3CbB9hAaaDoOy5GcZJjjATnzRhE1Eia+zJEkTSoE3RbJWC/xJPFqAYUhMnUqAn+g0LiiQRap6eRhMQOmoTigC6Z6IIsKGu5qQfoW4guqMmSoZM2p4pSo7XKY7yaUrYVJ8zYToxQiX/+aLONhPxgQD2OaWZ4qPsdaUoWp2awJ2YsKSymaWVSadRFiLTeRl4Kqfd86eAWhBBOqjIUKiGagyImqjEsKiMOhuC+qj/4KiS+guUWqm3EamYepqauqmT6akO0SuS06mgeg6VwgiXWqqo0CnFZnyqKhCeNwgBsnsxeSVH0Tq4mqu6uqu82qu++qvAGqzCOqzEWqzGeqzImqzKuqzM2qzOuqs8IQ0ykWO1Oia3+qzYWqwncK3Z2q2/uq3eGv+uvgqu4lquuUqu5pquV0KqqbA0neaqy7CX8squEOMMmtkpwAavyjCvz8Cv/UqvtqCZ/toMA0uwAFsLAnuwY8kLBbsaCvsbD6uWw9Cw+xqxcmkNJhCtzpCxz8CxG6uxzOCxH/uqJFuyJnuyKJuyKruyLGsN85kVyyCqyfAULJMBFAOBvkCzgoCH6tkLwZMpNmsROOuz/qZnO3kNTWFvyHCqykAwHpNn3tkLTruzFnGYu6AAGREl4AYVUeuzWSsAErBUVtsMQbE5ysCqfcoLIeExG7qhxLC2VCsglEcML9q2z2YML2qEcyute7YSZssMs5oMcOts8eG2wzC4hBAlVir/DBXheg1quMTQuIWguNdQtmM7ZX17DINrt3v7C4j7NVQqDAjAJKTGucUwujMxMw1qDU1RZszgrmmGDIObZ+r2trF7nmCatrXQZK0KALSrkaLrKzuCu3pamKYEs2crIPl6DOEYI0EbusLQvBjZJIvruSeCJ887tLugk3cyvaZTvS0bvuI7vuRbvuZ7vuibvuq7vuzbvu77vvAbv/K7lqmju3j7o68aPHcrCc02rQ4Zuzn5PJCgtJUAuZOLv6rabKG2nj1bCRfSuQMswI9AwJRgwImLwKVKklrboDh6aPvBvavmNlCmpn0Dpg9YCIumk15inxZBJ1GStMdboQIyOKrT/y9ueqCb52kz/MJCWxHe4mfx8SHrqDrcazE8vKMkfBFfiwAhQRM8rHQUQ61kSZJNwcHSaSci0sQmSihQhqSuq7VPIcVQijf7m7sV6sQzjKTwaWwh2hQkSqsAwCRbyx9gXKKntqFMAic7iqMWPAh1TBNeDBXcqcWacyHZqZgaLJ1WjABSlh/666NcLDNQIbbc6b+DYKO2Y8B0yhJ0yr0iwcZUunlV2ysggSKDDBWqpr8f0aDc2ceCUMmpO8lVe8povCPEV5QcqcAX4Wz40cGx66F+66NW18US+sXSacnHlm4focnSuaR6Omp+03pAR6UeQYYLnLQlmrt5pmorSgisfKahyHJsAQTLgFzMgvwRhIy/CYAS7meS+psp0zvEjBy7fBNdKVHP2pnEWUHOKMxehVvGUYISDRAjerpvd2Kiq0ylbjoTE1o2VFg7MMrEqLyjVIcA34wAE5oSJXXAGL1n+pwROfKfueu7MaO98/vKGCwMA3fSsFC8xCABEsrSMj3TNF3TNn3TOJ3TOr3TPN3TPv3TQB3UQj3URF3URn3USJ3USr3UJhEIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subgroup analysis from the CREDO trial of percutaneous coronary intervention (PCI) with stenting in patients with a non-ST elevation acute coronary syndrome showing the relationship of&nbsp;the time of study drug (clopidogrel 300 mg or placebo, given 3 to 24 hours prior to PCI) and the log odds of the primary end point, which was a composite of death, myocardial infarction (MI), and urgent target vessel revascularization (UTVR). The benefit from clopidogrel was first seen if given 10 to 12 hours before the procedure, did not become significant until 15 hours, and was maximum at 24 hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Steinhubl SR, Berger PB, Brennan DM, Topol EJ. J Am Coll Cardiol 2006; 47:939.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33533=[""].join("\n");
var outline_f32_47_33533=null;
var title_f32_47_33534="Schematic model of the course of PALF";
var content_f32_47_33534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Schematic model of the natural course and outcome of acute liver failure in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SIRS: systemic inflammatory response syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33534=[""].join("\n");
var outline_f32_47_33534=null;
var title_f32_47_33535="Patient tamponade";
var content_f32_47_33535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient tamponade",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAQ4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC2wbceT19aPm9T+dSuvzn60hHtXy9z1bER3ep/OnoSO5/OlK+lKox06UgHKT6n86lXd6n86aoqRFouA4FvU/nTwW9TSAU8CgQoJ9T+dOBPYn86AKcBzTEALep/On5b1P50AU4CgAG71P504Z9T+dKopwFMLCAn1P50uWx1P504ClApisIC3qfzpRn1P504Cl20AJz6n86XJ9TTgKXFMY0Z9T+dO59TS4pcUCGjPqfzp2T6n86XFLimA3J9T+dQSMVZiS3bpVrbzULD9434VrR+Ima0MaeSOS4LR7g2DubOOMVig6hbQEWUauGOSGbGM9662S2RlfAwWGCRUENpHGu1yOOnNbz5+ZcplZdTmbDTGnnefVZHdnIxGvTHbNbSaUsb74Mx8YAz0rQUW8ZJDJk9y2anUBlBBBB6EVSprd6sL6WK8cTJFtLEtj72azNQgZ7d0Vifx61tPhUJY4AFU8wAFR5rZ/2Sac480XEFoYNtBOGXcu1V4zuyajmW4luWEZdQvdDzW/5BlXdGWTB/iXFNithE5LuNx6nFckaUlK9htlR0+c/WmlasSD5j9ajYVzHSiArihV5qUjrSqtSAKtSKKFFSAUwACngUAU4CgQAU8ClApwFMQgFPAoFOApoAApwFLTgKYCAU4ClAp2KAEApcU4ClAoAaBTsUoFLTATFGKzL7XtNsn23N2iH061Hb+J9GnlEcV/CXPQE4pibNkClxTUdXUFGDD1Bp45oATFQN99z9Ks4qrPFcGXMJi2n+/mtKUlGV2KSutBR8yg4xn1pj28TvveNWb1IpPIvO88I+ik0v2W5PW6A+iV0+2iZcjEFvEoAWNAB0wtSgccDGKj+xTHreSfgoo+wt3upj+VL28R8jHkUhWm/YE7zTn/gdJ/Z0J6mQ/WQ0vboagxSKWMruPI6etM/s217xk/VjT4tOtQxxCvT1NH1hdg5DJcfMfrUbCp5ByfrUZFeeboiK05RTiKVRSAUCnqKFFPUUCACngULTqAACnAUUoFNAKBTgKAKeBVIQAU4CgCngUAAFOAoA4pQKYABS0orB8YeI7fw/p5diHvJQVgi7sfU+w9aaV9EDZd1vV7TRrI3N7JtUcKo+8x9hXm+v+NptRQx27fZoO4B+Yj61x93qV1dSTXV1I1xKp3+Y5z7fQD0rOfUXWMhEw7HOSOgx/nmuyGG7mLmWbq7e4lcuojhHO5icn2A/rVayLtcIULhAcjPUU+3tzJA7zPhU5we9DSNE22ZgJRxjOP1rZxsrIFJdTt9K8Q3thHmOdiAOjH5RXY6V44s541W5ASU8DByDXjou0aR4t5ZAOvOBTrV0j3FGDseck4wKwdFMu66H0TaX1vcf6qRGbAOAat4rxPQdbS3iWMdR0IOMfjXq3hrVY9S09GLYnHDK3BPviueUHEaZr4oIpwoqShuKCKU0UCGkUU6kxzQMaRToh834Uhp0f3qEDOfcfMfrTCO1St95vrTD3rEojI4pUxSkUDrQA8U4Ui08CgQoFOApBThQAtOHvTQKeBTAUU8CminimAq08Ug4py0xDhSgUgp1MCC+uorKzmubhwkMSl2YngAV88+J/ErazqlzfTZG75IYz0VP88133xz11rDSLTTYW+a7YvIP9heg/E/yrw64uTIF3PuzyR0/Cu/CUbrnZhVn0NO51Ezr5auEi3bioHWrNqyru81htYderEAZwKw49iHe3LEfKv8AntTopkHzOxLZ4XNd7h2MLm1JKtw6SI3lBRhtzdahWPzo/MDNgHCuwyW+gqkbmNFWVj+8YZVccCi3upZ5FKyMqKMc8D8KnlGmaCyMqMQjSxwnazKMZzWjbmWbaIoMIeRluao28rWSSRIC4lAITORk1saReRxMLe5RlbGFOOvtmspGiHNMsK7ZojC4GM55/KtPStauYbmF0mYSggrg846c1h62RcEsocEHhiecVRifyWXc2OQDg1k4KSKTPpTw3qA1LTUlLBnB2kitXmvPvhPerNa3KYKcrgHofpXoVcElZ2NlqhMUUtFIBuKMU6kxzSGNxTox8xopYx8xpoZ8yv4w1q2Zlg1Gbgnhju/nRaeMtau5wlxqc6rn/lnhf6Vylw3+lyf7xpsbFZgRxzXpKhDsZcx6WurNtBNzfTN3825OPyGKhi8R6jpd2LqKWWW3H37d3LKR7Z6GuatpW8sE5NXPNWSIq3es3TjtYq57bo2o2+radDeWb7oZRkeoPcH3FaAryz4NX5S51DS3Ylf9dGPTHB/pXqoFefVhySsWncAKeBSAVIik9ATUJN6IGxoFOAqVbdiMttUe55pzJHHEzFt23t0ruo5diKu0bepzzxNKG7IhTwKWJf4i4APOMZpQPcn60sTg3htJSTfYdGuquqWgopwFCinFCIpZSD5cSl3YDhVAySfwrltc3uKoJICjJPAArJ1DxFo+n38tld38Md1ESsiHPysOoJ6Zrr/BMP26wg1KeBoHm+eGKQ/ME7MfQn0rw34p+Dr9fHHiCdboCG5bz7eID+9yc/jmuhULRvN2Jh+8lyxPLPGOuyeIvEF1fXBOwttjjJ+4g6D+v41iRldxJXLHp9asahZywyOsi4IOD7GoI4HKkqCTjAxXrwUYxSjscck76khJZ9oUBR19alaNXKLGFjXPPOSa6jw/odtBaLqGsiSSNv8AV2qHaXPufSr+oppWpWckEdja2N2BmFoARn2b1rlni4xlyo7YYCbhzPQ4o2awupklDg9B0BFIyIVyHC4bGB6UoTLYKncvUVMLaEsMtnPIXvXRzdzkcWtCzoLtHP5kabmTlQecVrsJXtxmRWlcFyT1BB5rPixDFlQEyMBVGCRVlkZ4N6kl2Ix6Ad6xk7sqKew24mlWRZApYMMMvYH2qEz7HG8gseeF/rV61tJPLjZmLOTzu6D0ou9PYgMxGQfzrLnXNY6FSfJzHdfDm8kW6iO47AwyoPHP9a9mx3xXkHgq0igltt/7syD5cdsDn8a7XTdWUagscyzQtISI98u5W9j6Gur+yp1VzpnFLGRg+VnVgUYqFJwxwRzU+K8uth6lB2qKx1U6saivFjcUYpcUYrA0G05PvUYpYxk00B8a3X+uZvc009A1M84Sl1PXcak/g617LVtDnTTOo0mJZrIEcmmTAw5yayNP1c2cRQYOelRXGqvK24/lWfJJsvmSOz+FbMPHEYGcNE+fpivc0QsQAOTXk/wa0W58+fWryMorp5UGf4snk/pivV5L2008BrqdEb0zz+VYwwrxWIUI7LcmpXVGHMzC1vVL+zuGigtGQKeXdc5+lZv/AAld9EAJ0IHTITFbGp+NLVAfIjDnoC46/hXHaxrWq60/l2dnK49ViwK+wwuBp0YpRppefU+erYmdRv3rnTWniOKfbvkw/oeK1prwS2QMTbiWGcc8V5lFomu7t8lo6jrk8mrdoup2kwaOaWKUf3a6fYRvozD2jtqeveH7R71c3WYY+gKryfwrqYfC9rIoZLt3/wB0CvILLV/EWzAu5GHp5a/4V0Ol61rTdGlEmMgr3NeTismpzk5xSVzvoZjKKUZanpcHhyxhcFg8h7Bm6/gKTxHp5bw3f21qoAkt5F2ADBO007QLuWTQ7d7uYzXmMTNwCW9/QVekchNxIYHjjpj0ArxZ0o0m4WPUjNzSkZ+hzR3vhmwurfG1oEkQr245rhfizaBo7HUo1OVJglIHGO361q+B9RisbnUtAm+Q2Ny0cSMcnyn+ZP54/Cr3iW1Go6RcWsgxvXgt2YH/ABrCsueDRtQnyTUj5x1fw/bXUpcttYnmo7DR7OwUlUDOeMtzW1qSsrFSCCpwRWb87SZrhhUk48tz1nThzc1jI8R35jIRTgj5V4zisrTEeVvtEsocI3GxcYb3rbv4vOgkUIMOv3uuGFS+HbDyrARMqjB3Mf7xNLnUY+Z0Vb30OR1eIWzK6j55cnmqNvIjyhZtxHqOor0LVNJt7yDY64IBwR2rO0jQLWyLO7+a56EiuqGJioa7nmVMNKc7rYxoVTf918AcZGT+FaMOXOJEwi8Be5rTlWFSQAM+1NijQtnNYzr3RrDDRi9xikKWZ+FxVcM13OwVgIowWYn2FXZDEVwCGduFUdzVnT9L8mAlyruX3n0B9KmhWhGfPUV7G9Wk5Q5IaXG6THq7w/aYopGYtsj9FH94102iaVDLIJNSvLme4VgcRqcAj0q54avy4a3TDIOCAOK3WCIM7lH0rvp5/KmuVw/E86rk0ajvGTNHTr+OWRhJ56c8ecADW1E6umVOQK4K7upHzJEplKIwCMcH8DVfRdfntpot28q4BCnnA7g13VKlLMqN4PVdDzfZVMFUtPZnpApaapyoPY0tfPWPSQlPT71NNOjHzfhTQHh9z8I7MSsbfUZVBJOHjB/rVdvhGrNg6oAntFz/ADr1hh8x+tJT+t1e4vZx7HmMHwi0xMedqN0/sqha3NL+HXh2xYObV7hx0Mzkj8q7A0juEQsfugU41q9WSgnqxSjGC5mQXFxDp1oMKqhRhEHAFc7YabLrupNcTbTGvzFWOM+n4U+7lfUL7aSuxOTzkD61p2l8LHi2G4nrx1r7PA4dYKlyr4nuz57FVXiJ3ey2N7TdHjtypFvbnA4xGB/9etoWyugDx4H+y5rI03U55ipkh2oeCTWtFcg/dxx/OuhzbMVEa2kW+chpVY+jmq0nh5GfhyR33AGtJJQWDde3B6VNbTeexI5ReB/jRzMLEUOnWtsg3RqzduKcwjgVpQiqFBzgVPKwIyy4+prNvy0yCGJgAxwxPYd/8KfM2NKwaNPJA5nbJEx3OmevOa6o3SwRiYOJEbgDv9FHauQBzL5bfu37DsfpV6CV4lKuCUPBx1H0rzsZhvae/Dc7cPW5fdlscv4/dtG8X6frcamOG5T7Jc7eg5+Rs+zY5966m31OPUY3ZcRyH5nUnJB6H9eapeILSHWNIuLOf5w6EKzHGD/TmuO0HUSbGC6Eo+0Rk297Gg5SReGP0PWvGcZbM9C63Rl/EC1Wy1QzLwlwCTns4+9/Q/jXII+9gRyK6/xgrX1hcRDm4Q+YmOSSP8RXm9peFRgk5z0NcU6DTuj1cPXUoWe6NK8j/fBY3KKeWA708XAQBVPtVCafc+41EZQM4NZypdzf2rZrfaNzbe/1phA3Y7mszzwACeDT3uD1WspQZUWZeu3FzYzh1YeWecYrE/4SC7mbyoYcO3oa0/EEzyKitzk9PWqtjZmOWPgB3PU9q66SioXmrswqRm5+67GxoUNz9o/0gZuDxgdFH17V6Bp1nAkY+0kztj7g4Uf41z8csUNh+72hhySf4j71NpMmpanKBJItnYp9+UD5iPRc965Jxc7y6HTBqOjep21rHcXI8q1jSJB2iXp+VTy6fPpiO02WZhxuIwaw18SHSJvIgQm2HAJ5J9yaz5fEF1r2pfZ9JUzMn+sb+BPbNYcja2L5uiNiQyo6O5GOtVLa3e+1uK0iEg3yOdycBQOpPt1qTZPI/kEhrkssaDsCa7fw7okWj22NxluXGJJT39h6Cu3L631fmn1tZHmZhD2nLD5mygwAOwGBS0gpRWZiLSx/eNNzTo/vGhDOfkIBbJ4BrLk17S4mdXvYgynBHJNZeo+I41ilR0jiDZXcZOR71y1hqtlC967XMCSBlkiYsOTjpShS5txOXY9HtLqC9hEtrIskZ7iuf8W6wIIxbQHMzHAAqh4a1W7Olz3d1DHBFKx8lVOcju30zWXpTrqXiaITZZFJkJ+nT9a+lynL1SbrT+R5OOxLl+6j8zqtOsmS3it1R2bGWcD7zd81u2tjFAoLDaw7HmprWJIYsDd9W61IjKxHqDXr3uefsPCowG7cp9amTyuvL/jR5JKkt3poUo4WNQznt2/GkgJ3kcr5UK4d+mOw9amgWXptZEAxyajiZbdWJ+aVvvN6/wD1qJJnmPJOOmPWmBorkJgHI+tYms3LIdsZx2wKv3VythZyztkbEyB6nsPzrnLgyJFDG7kybcsfUnrTashmrpdyZ4fLuGDHt7fjWrPKltbF5XCIOBuNcely9rcIeqjqM9fan+JdTN3bxIibFLAkZqd9ATsbktxlyD0HQ1hXmmWtvdzXccflyXHMpU4D/UVLplwbi0Qk5Zflb6irUkRuYZYpCpXHy+tZygpaNGim1szh9fnuLNQ0Efmqo/hPI/CvM9a1KzF600TlBI3zRsMFTXpuuWr2+4ZOMcGvK/ESbmdtoJz3FcVXC0+mh2UcROLL8c4lQEHj2qPJBIGfxrm9LvXtpRFOxMbHg+ldCWyMg5715FalyHsUa3OtB5YntxUwIC5JwBVdJFUZNU7y7lwfs8TSge+K43G7sjsUrBqSpLLE0wYwg8gHB9jU1rbvOzFBNI3BTjJx+FaGkaVLrS2UVoFM1wcMrZ/d4OOa938P6FZaJZRw2sMfmKuHm2/M57nNayiqUbT36GEsRr7uvc888K+B7+/hjn1IfY4W5+cZkI9l7fjTbzwjr0OrSwWUEk1oz/u5GcAAepNetg5qrq8FxdaXdQWcxguJIyqSD+En+X1rGVVySh0Mozam5dWcBb2+neHpG+2yxanrajCQLzFAfVvf6/8A16qaFfCB3srSBftc7k4jXG8nrwOlN074d6wLljcXMEEROS+7zGJ9cDv9TXoPh/w/Z6LF+5Hm3LffuHHzH6eg9hWU430On2yhqndlfw94eFhP9tu3El0w4UfdTPX6mujFN70tJK2xyyk5O7FFLSCimSFPj+9+FMp8f3vwpjPkK4kZ5XLu7fMerE1r+EtF/trVFjfItYhvmf0X0+prDZWkuCkYLMzYAHc5r1nSNN/sPREgUL57fPO2eren4CvdwmH9pPXZHHiK/s4abieIL2OCAQxAJBGNqqPQdql+Fls1w95qE6ZVmCRE+3WuM1aaXVNSS0tcl5HCL9TXq+kpHpFhb2doB5cS4J9T3P519BL3Icq6nhq7lzM6THTdkd6aY2DfJ0otLyGSANMCrejVL9rjIJGdv06+1ZobJUaSOIDflj91f6/SlQGPlTlz95vWoIkkJLPgu3UjoB6VZRDTsJDl5OG5qaEAyqMdOtMHCEnHWnWQOWkOdwGKaQ7mb4qmDSWlv5gSIv5spP8AdXt+f8qyLnUIb26LQOGKjkCuc8V6pJd69cJnEMeETB6gd6q6HcAXu5SP7tVa4HVXqMUBxj0qtOrSGJe459aervIpMjfL2GelFo3mXw5yqilYRbsW8ucfKRvGD6Zq9BM+VduNpwR7Vn3t9FbndMcDrwOa1NKZLpN7qSjc/WpWrKexm+ILYSxsBzkcV494lsjHM6n1r3TV4oo5hHFnYF6Mc15x4w0/LuwHvXPVRvTZ49fQAKcdc1o6ddN5arKeRwDU2oWpzkLxmmWtqTnIrmlRjVi1I6YV5UpKSLMoYgc4FXdAsGv72KFyVgB+Yjj8BUdtaHA3ciuo0NBHLHjg84rzY4Lln7zuj0pY/mh7qszsPAmmW9rq8xt49qRxkjJyckgf413qmuS8EAPNfuOi7I8/mT/SusWuLHNe2aWyIoNuF3uyQdKdTBTgcVyGw6igE45o7UALS02lzQAtGaTNFADs8U6P734UynRdfwpoD5s8AaR9o1KXUZh+4tmOzP8AE/8A9atvxPqhVWjVuT1wauXrQ6Lp62dr91Op7s3c1xd08l1cAZ5dsZNfb4WgqcLHz2Jq+0nodJ4A0sz3j6i6ZKnZEMfxdz+Ar0yC2ERXcBJL/d7Cqvh20tdN0+2giQNhBlycZPfFbBv7GJ9kssEJ+uP6Vo25sz+EbHaZbzJ8O3XaDxV6ztfOZZHTYBwqdh7/AFqvFc2zECDUrVs9mKn9c1aEt2v+pFtOvqkoBos0K6ZcEQU8Cl2AA81SN9dQkmaxnA9VG7+VLFqlvK2Gbyz6SKV/nRZhdE842p7DPQ1Qv7x7LQ7mZC28qQm7sTwP51PPdQ7MCQOPY5rC8Rzm7s1t4zjB3cd8dKuK7ifkcbJbsbVHkG6QKQW9axrGcwX45ON1dHqLG3tICw5JINcfLIp1NynC5zVLVsk9CmvPLVsDKsAeagOrQ2Nk0zkbjwBXJ32vp9lWEjaw4MhbjH0rQsNCmv3Wa5lAjIBjUHIxUSTsWivPqFzqEhkkJWPoFHevTfDx/wBCg7cDP4CuMbQZ1XEcZOOm3muvhf7Ho4dvlYIFXPYnrSVrA7t2Gajdb7tmHQGsfUAl9btuAEg7VVluWZ8k8DrURl3Sqyeua5ps3irHPXeiCWIBRg1Qt9BlEmG4B9q9HTTjLEHEZAbkE8VItjHFj7SAyjtnFcVbG0KCfNJenU66OCrVn7sfmebS2X2dgM8g1oWQEStN2RMAe5NdF44NjLJa/ZY4o2A6JjO33rmriVfKVIzkdSK56FeFa0m7G2IoSoNw3PR/BdsINI8zvcOZPwxj+ldCKzNCCJpVpGjqxWJc4YHnFaKmvErT56kpeZ101yxSJKdTAacKzLHg0uaYKdQAtLTRS0xCilptFIB2adH94/SmZ4p0Z5NNFHzxrlyZ7mTngE1nadB9p1CGIZ+ZwCanvQPNYL0yav8Ah62xeq5B4BIr76T5Y6Hy8Fdne6DHLJG772aVvkWTGdoHoO1XJ/CX2kFnvJ3c9eBVa1uvscSpuCKorV0nxMk06wCJpGPAZRWVNytoVUSb1MaXwVJkBZW/GtLTvBEBUedeXG7v5ZwBW3Lq9nBIwklVpBwVHaq8niaCPOxlA9K29pPuZ8kRYfCkUDDZqOoKPQTEVZTT7WA4bUb2Qjqrz7hWTP4ptmYeZIFHbnFUdR1qxkX91IjO3QrwRS5pvcdorY3dXvdJ0vSZ76SHznjGETH337Z9s15pF4mubi486dIkY9UjGFFbiXoklWJ1YxYxh+a5/wAT6IbGI3tkC1uT86jnZ7j2rSLi3aRLT3RY8QX4udIeaNQuwgkLXBzX62g81zlnPC9zWxBfiWxu4sbt0TDaD7VxcMxlufMODt4XPpVOPJohx97Vm1p9tcajJvuF8qE84PXFeleGdSi0+2it3+eNem6uBs55plXc+ParyJJ3YmhxurMTbvoez2upaZ5DS/a4YwFywZgMVz+qazDqEKpaFjAhxlhgsfWuEgttzAyMdua3rJD5flAchugrnqRUUa03dkgJkJ4OOgro9C0cSbJrn7vZfX60aNpRIEkoKqORnvW0ZSigIu3FfM5pmXs37Kk9erPoMvwPP+9qLToTXxCxtt69K8+17WmtXMDKzPnnHQCu085i2W5B9aoanpWnaqn+kxlHAwHRtpFfNcybuz37tKyMi2S0urMfY7q2klK8+bhHz/wL/GudXRtTgJEljOVzwyLuH5itaTwzdWmWtT9oh7dm/KmiO9gjLLFcRAfxKCtcbcoN9TCVDm1KlxHNbMPLSeIgDkKVOatad4n1WylVTvuo/wC46kt+BpG1TUEA/wBLuQPdzW34ca+vrsGW6nMS8thsZ9qulOfNZHPUp8q1OwtJvtFvHKUZNwBKsMEexqemDinZBr1le2pyDxTqjFLmqAfSg1HmlzQIkH1opgNGaBjqfH97r2qLNPiPzfhTQz5/j06eWdmljZIwTjIxmtjS4hbTNK/CRrk5rfu7RZGYj16VXisI57hIpPlhyC+O/oK+5m7rU+ZitdCjDFJfsbq9n+yWAPDkZLeyjvVu58QWljD5GlReWvd8Zd/qa072JNQ3QxGOK3gGGyQAB7CsDU9V0bQYxsjFxcnhcjJJ9hVwcbXZE076GfLc6ld/NBbMid5pm2KPxNSWuj32omeNNTQSIm8CLB/CqK22ueKJQ8++K2H3Ixxge9aenWknhm7mkuZF2PFsBLdOa0c7LTQSj3OS1LQ7pJP311cbx3LnFZ9zd6jpKLJ57yqTjaVyfzrtruWW/uBb2ds8jkcyOMIv+NW7XwaJNr30nmSenQLWftJdTSyMTT/EUU9ms0k3lhR84dsbfrSS+NriOdIYbWRrNuGndSdw9l/xrYvfB+lpfRbkXcSCwZwqtjpwa7zTfD1lLZJloXA7oQwH5VaaspWJ62PONVH2rTjLo2nuk037szm2ICA9TnHpWz4Y+Etne6Zb3F9fXAfdlvLUKGX0Hp9a9Kt4rW1gKq6bUXkU/Tbq1XTInN3BFGc5d3C/hzScuZXQLTQqaf4K8N6dGqw6bFI68Zl+cn86LvSLAPJEbC0QsOH8tQq1NceJ/DtijebqsLEddmZCfyFZUvjfRJ3RokvJo8/f8oKD+ZrK76lNIr6T4ZsjdtcSojwo20RhgVU+/qK6XUbPT4YVu4oojIpCs+0A4rE1PX4dNtbiWzspXinCsG3KFz145zmuZv8AxDey2Ek90YYbclcQo2WYk9TXDmPNOhPXZHbgGo14ebOruNRi2YVhntzWTLfEsSJCPYmuNn1wOny5A96qnWiVJzivhfZyZ9jzI62e7ZjgOQfY1Te8ljHDOf8AgVctJrGAfmOaiTV3Vsgk1Soy7EOcTtbbxHJENssZCY+8eKp3njJYsqDvz2zmuWkMl+S0jkAe9Z8WjwXN2scNxNJKx+6Og/8ArVvTw6k7MUq3IrnYxa9NftHHFYSTbz8oERbNd/oNq9rYIJo1inf5nUHOPQVS8PXyLbQWPlmMxxhFx0IArcBrWeG9jKzVmefPFe3XkS5pQajBpc0jIfml3VHmk3UxEuaXdUO6lDUwJQ1Lmod1OBpDJM06I/N17VFmnxfePTpTQziWIV2BHcms9rnE87NhY4R19TWprEAilZ1yoz2rhfF19IkUdlZ5a4nOT2wPU19tVXMlY+apvlbuZ2oapc3uqGz0tPMun6seRGPU1o2Vlp2kzb5lbUtU6tk5VT7ntWVa77S0NjpZ2O5zdXxHJPotWosJEsUAIjXv3b3PrVc/ItA5bs2p9U1GdFjEyW6MceXbjaPz61E/h+GULJdl5Aeu5ieajsIxEu+VgG/hB7VcW9tk6mS6df4c4UVKd9xbbF2B72zCHSj5qJx5ci7gR9etaqa3bRoRqCPZ3BH3WX5WPoDWVHez3EPmTSCGEcCOEYLH0pnkQyET37K2B+7gDbto9T71qldXkTe2xlalYRanp8+p3Cul3JMwTJz8q8D6CpPB0JckxzyQODjMZx+lT6hLGsccYULFzhB0FVdMuGshI8YG4nIqJVOi2KjHqzqtXOpW9jKTtuU2nDJ8r/iOn5Vwnh2aHUL+ez1VXdG5jZuHjPfFdVYeJZJD5V6EMZ4yo6VzmrWotvEKXEJ/cynginCqwlAdrWhy6UweRxLZnpIO319KntJUmtoIom3Bn2nHp1qlJeyyzTyknbuKgHkVmSSNFlbdni39SgztNJtMdrHaavJJJBEgH7pODz0rlrh86TMyh8AD5+3UUDU1TR5rea7jilHDB+pPsK5ibWnvdGFhsk+1O67SCQuB3rnrQ54Sj3RvRlyTUuzNAzMEI4zTDMxxWELeSEEuZZH7BelEUV45+RZB+NeK8u5ep7H9oX6G4JOOvNNS5Tk+Yo/GsO6ZrYl3lBmxgIpzj3qlZeaJR8rFWPJx0rWOXxtqzOWPl0R1sFy0j7fMbYa9J8OaTFD4fF0NvmM+Sw/u9K8rsJEidQ25myB04r1zw7O9lYrbttlQ8lG5xXTWoezpr2S1v95yqvKpN+0Zoaeha5ieIE7Tniumz71nWF5Fcp+7G0rwVxVwNXiYyq6k7ONrHZRiorR3JQ1LuqLcPWjd71yGxLupN3vURNG6mBLuo3VFupN1FwJw1ODVAGpwNAyfdUkR5/Cq4NSRN8x+lNAYOqESxsexrza/iEOt3U0gDFQAuew9K9AeUNE4zluwrhteYC7dT904JPvX2jeh87bUy55HuCdihI+wFSxERgH0pgIA+XB+lRPKO5wP1qEx2J3nMrgMxyeMCr1ra+ShmmBAHSMHBP19BWfDN5eDCmD/AH2HJ+gprmSeT965x3A71cZKO5LVy4+oTXR6iOEcYXjPsPaozdtuEcZxUMpVQEXpTYcLKHwDg96iU22OMUjUfDtCH5KrlvrTbo/uWxxn9Kp6hrVvDHmUxxkDHBrAl8WwsWRLeVk/vE4zSuykjYEm3o1T3WqRWunvJdgtGnKgHB3dgK5KTxFGRiK3dm9zgVlXs1zqEgadjjsg4Aqo6bD5b7mxD4mTymE0TbuqgGqUmp3d1JuiTYO2BVe3s9hyArEVe3zhQqR4B4zjiqXmDsRQ6fJdTDzZGZm5PeuosIILWCMeWjSJwGI6Vz5v008KTlnPLH1+lUZ9Wvr9tkX7lOgVOv505ySVgim9TqdT1eC1X59ik9BgZNczd6pPdkiHKIfTqa19L8Iyzos187BmPAJyfzrorbQbe2A2xDjvWPK5FcyRwFvZ3Ej4WNvqRWjDaTA4weK71bRduFjwDVqDTYhyVAP0oUAczn9It5QFLKcfSulguTFkkFW65qxFAsSjYoP0qylsJFG5AcjpWll1RF30K9vc6ghDWZjZ2OcPwTWza/8ACSSoGb7FGMdGJJ/QVJp+mrsHGMfd9q6O0iYxKGHI4+tZzo05/FFMqNWcdmZdompsu6VrVh327hS2F41xM8E8YiuFYgKDkMPUGtpYiHxj5cVDPYxvOr7SGXncKxlgMPOLTjb0LWJqxaaZA2QSG4NNJo1Gco4UqCPWodw7Gvn8VhZYeVt0z1KNZVVckLY70oNRFqA3WuU2J1NPU5qAGnKaQFhWqWJvm/CqwapYD8x+lUhnASzlHYo5yDXN6y0khLTtncegGK0by6Xe20gHNYl9cNO2MdK+wZ8+jNdQM7SwPsaqXM11DCzwlSV7MuauHJPNOMeYypHWoZRm6fq11cB1Kw717EEZqSXWp7dsTWTD3VuKzjA0F4MZUk1qo4I2zKGHuKtITKz+Ik2/8e8u73qrcazeXSFbaEx56k81uWlpDdTqjRJtPbbWpJoltbqCsfPoKpIVzgF0+4nk3zFmY92qFontp/3o47+1dxciK1RnZQMdBXNCKS/vXZh97jpT5VfQfN3GRwRRR7hznnNS2FnLdsZACqDjdjgf/XqvbsImltpD9wnH+FdZJbfYdOijXhsBiPc1pGmTKZQsowpVFQc9cjt2qxdaWZomNvKYX/Q1EbhYpWWKN5JEO0qo7/Wi8tNX1C3XYhijPUKf5mnJqJKuzNl06B7Uw7/Nvlbjb82fqa6PwnoHlyrNPFyBxkdKp6NYnSRukj3kMMnsRXoGmSwzwBoSMdx6VEtdUUn0I5LcCPB4qHYQ3Fas8RaPgVAkOSAOD3qEDIY4Q3birkcBI29z7VZjgChQBUjglhFF94/eb+6KYXIrW1DSYUZAPLf0FbNnZRpg4p9tbCOJQvar8CbR71Lu2NEttCi42pV4AccVAh2jmkFzyQOg707gW8L3psgBHAqETc5HIp+9W+6QDmhOwGZexqxKngVnsnlYU/nWnqiOxDJxjr71j3MxUAt92uHH0fa02ludWGqcstR+6jdUIYEAg5FLur5m1nqesThqerVWVqerUCLStUsLfMfpVRWqaBvmP0qkFjyi8ePfJhQCTWTK2ZCegqxdS4kfnnJ6VXjj82T5+FPpX2TWh8+NCg9BVmKLcQMYp/kBAAtTwKQwyKysVcoappoKCRV5HU1T8koqMwyK69IhJbshGTism6tCIOB901rHYmQzSFU3cWF71f13VI7WRY1TfIRwBUOkKiSoW45xWsdMQuxEYJP8XetYxuQ2cferNeFTKAM8hR2rT0fTEjZWKjjmt5tER1UxYEn86y9W1e00iNopXIlHBQDJppcoN32PO721mTUpN38UhJIHbNd/qQjuLq2TOcqHIH04rj9S12bU38tI1gi6Agcmuq0u1aWCJg/mSqBk9yuBWnMlYUk2jQFoiscADcc5rWhCW9uMjPoPWoETcVJHB4qxcIXwOwFc0t7Gkdik1qblZGlwE7KOmao25n0653x5C9x2NbMhEWAeKZJtkjIx1oTtqK1zc0u7hvrfKYDr95O4q2LYb9wHzH0ri4FmtZg8DFXU8YrsdM1AXNtmX5J/4h6/Sn6CTJiNo2AAyn8l9zSxPHAoAG9z196j8wdAuM9ajPyHIHNK/RDt1OgspkmjU4w3pVvAU81hWEwyADg+lbCy7kHGaloaZMzjbg1AzD8KhublYxgnGaRJF8pST97pSYyRptgOelZeoXI3Dc5X0IPSi5u0XdhskcVjtKZG3OfpVJisdJpupGeHy5zl143etVtY+VUIGCD+dZEMwjO4tirP9o29wnkSPhv4WPrSlDmQ4Ss9Qt1KqTng84qQnmmn5eB2pM18niantKrkj3KUeWCRKGpwaoAeacprA0LKtUsLfMfpVRWqSJvm/CqQHkc2TK+R3NM5BXBNXZ4ikrE+pqo+S4Ge9fZvU+dLgO5FYde4qVeDkdeuKrw54zzVgMOMGs2rMrc1dOO4ZJqS9hGxxjqM1V091VwG5zWzLGZFXAGMUxHMQgKAOhrqNHnWUKkpG7GMetY99pzofNjBI7gVBHK8ZUq5DD06itoysQdbdzR2qlYeSep9K4Xxvp0V9A13F/x8Rj5sD7wq9PeyMSZXJzzkmqpvUKlHOVPBHXNaNcyFezPPLdNr8iu58LXoQCJ+/ANctcwqt1IF+7uOK0dNJjK469qiPvKxUnbU9HhGWwcVaMYx1/OsTSLvzCoY/MK6FNpj461klZ6lX0K1xCDHgqKolSEIFa7KWz3qhOmw0NaiuVVAALNUTs7ybkJGOmDUjfvGKr26+lShQnA5ptiSNLTNWV3WG/AVz0l7H61oajFJGoePle+PSuaeMMM8D2NXNO1WexHlyBprY9VPJX6VK1GPWZxKrglcHNdLZ3qNExlO0AZzXOamsc0QubN9yHqB2+tLp8olURseCMEVa1Fc2p7+zfOZMiqM95FEpEUxcdh6VRvLRomIA9xVJlKyjPX9Kl6MouNOHIGDikXlu2KgU5bnn+lSFhH94/SkAk7ZBB6VnMvzY7VNJNvcjNRE4wc1SlditY6HTpfOswerR8E1Nu4rK0a5Ec4U/cf5SK1Zl8uQr27V4GaYX2c/aR2f5nqYKtzx5HugB5p4PpUOaXdivKO4m3UsUnzn6VXZ/SiFj5h+lUgOV/s2aS4YOhHNF3o8KRg4/eHuO1dPd4t5SMcnvVG8QsiEd819pFXPnG7HGBGjlIbscGpFRem4da0NVtdj7lHXrWRNIF5J/ChxvqJMtiRInB8wZHtW5a61aLbfvJP3g42hetcY0ozzTPtB6CnGHcHI6e716RiRDhV9TWRLeFmOW5Pesve7/SpIoJZG4Umr9yJNpMnluGOAKrq5DHc1XY9LmcAlTmra6C3DucD0rSFSLJlBo524g33II6Hnmr1vDgDFaD6cySnaQ4Hep0tDsGB83esXo9C73QyykMMgYdq6/TLkTQ9RmuPkhkj5A5q9pN75MoB4HfNKSUtgi+U62NgHwTgGoryFZEYK2Gz+lSxRgjzN3ygZyaQ/Om4cE8/Sptcq5Uisdi5BHHWkNsytkHNXbZ85DcmrAVQQCODSsMz0tGboOKkXTZkUuAGXqQOtaMRAYjsKv233CVxg+tS0COca0BJKKUJHIHGfrVSBljuMpxg8juK7NrVXGQBg1iavo7f66D73sOtUnYTRNJiaEYwXC9+9YlyHD7ScH2FaOnTF4SrDEicEU26tjIm9RyOtO11cLmTIXDAA5I9aSXzJYtrSYx6Cp9oUFe9NAGcMBx0FQyykMKNpGD6+tNOe/wCVXHgLKSw4/lVHkMd3X1pXsBNA5EgxXSoTPbK38Sj9K5Q4Ug5x61q2Ot2lshSSUM3TjpWWMdOVJxqOyZphlNTvFGhupC1Uo9QtnPyypz71J56N0dT+NfJntkzGnQt85+lV93NPhfEh+lUhst60jO7eWfmzWXbz7JPIvyFP8Le1XL28UTOQRnJrB1SJ7j98vzMOCB6V9knynztrmtqOmG4tibSRHb+HmuIu9D1CBj9ojYDPVeRWpaX9xZPtJYDtXQWmuxTAJcqDn1rRVNCHA4D7Iqths596ljtlLAYr0M2dheKTFsD+9VptC2cqgI9RQ/e6hdrocpaWEZYFsEema17aGGM/Koq//ZwQkbcUhshnGMfSl7JB7RldpOu0Dj2pI2d+H4SriWoUnmnGAgjHIrSK5WQ3crC2HAC7h7U37NhuRgHoa0FgyMZOParC26hAF4T+da8qkiU7GObLd0XNZ97pE23fDGxYc8V2tpbLG24JuXtntV5kR4iAoA+lYSVmaR1ON027aJUsrlm3gcFhjNa0G/lSOB0NStpcV2whkBDxnCv3x2rStNLSFAryl2HfFKWuw1oYiHbP0xV1mA2nIqLVbVoJRLHkpnnjpTcbwuMgVBVyyHKyuMZq/asDbms2NiG55GavW42rwcKfWiSBF1JGUcdKf9oRUyT9RVVnCd6zL68yuAcHoRWe+5ZHrd1BvH2ZNkp+8w7imWlx9ojCE4lHb+9WZK4die9N+aMCRWwR0qr2Fa5duoyCfl6d6ZBHubBGT27CpIZhdRnIxKByPWonZUBbJz0qmr6iTG3snkqY2YfReawrqURRknknoPWr11L5mfQetZFwhllGM8cCuDG4n2MNNzqw9LneuxFmWdXZixCjOKqN9K6CztgsLKw6gisGUbWIPY4r52U3N3kz1YxUVZEeeM0gkdT8rsPoaQ9KZ3zmlYotJfXKD5Z3/E1ZtdXvRIR5oPHcVlE1Jan94fpVJaiuarzSeY/7wnk9TV6x1MwKRIit6Gua+0nzG+pqaO6H8Rr6ZTaPGcUdBdtb3i8AhiOvpWTN5tucEZX1pqXCHocGrPnbk2thveqUyOUjttSMbfeK10On+IXjxvw6+orlZo1c/LjNQBDCciTH0rRVCXE9Ptb6zvhliFarEtiGG6JgV9q8whv5QwCqc+veug0nX7i3xvY49GOa0VQhwudMLU4ICk0wxBcZHWm2/iG3l+83lue5HFWlvbRySWaQj1PH5VrzGfKPtoQOFXPuauQ2ihsOM59e1MF7EANu1aQ3ik9Rz61KmyuVGkkao23Ax60zykSQpzhhkGqgl8wfO+MU4zb1AQnI5BNN66gtCyYEDZGdw70xVCkkZPuTT45PNGcgf0pZcCPg5NYqTTL5UMaJZkZGGQwrIkhEZKEAYNa0TkHr+FUdZjIfeo4Per0uTYotjse/SrUTfKQSPUVVXlAT1pJm2pyQPqaUvIcSS4n2r2rFu5yWwB+NJcXRJIU5qg7F+vasmzRIkZtz/SpAGZeuKrfd69alRwU9KnmHYljka3YOCdy1JcTI8O9G5bqvpVGRiwPr7VFG+XMY59fas6ldUoty2LhS53ZAY95y5Leg7Cpre3BIJFSxrz0q5BH+FfNYjESrT5pHq06SpqyGFNq8VzeoWkouZGRCVJzxXUTcCoFRHByASO9ZQNGcbIkinDKR+FRMcV2bWyHPBqtLYof7p+q1oriuckxqS2YeYevSt2TTIz/yzX8OKgj0lRKcCRePrVpgYcgzI/1NIEI5qzs3SMoHc1IFRB8xz9K+iseOVkR2xirKRzKRk7R7mpFfH3FxSEMxGSaXUY2ViQO7Dqaj3AHlalERU0jRnH0qyBvmheAKDOT3pDH39aYYqE2FkOS5kjYENwO1X7bVmB5JU1nGLI5FR7CDVKbQnE6iPVWPKnNXoNUBIz96uMjLxtlTir1vdq2A/D+taKqTyHaR6kBtLc1ow6gjEbOSeprh45WTryKsx3RGFUbRWsaiehDjY7b7SsUgYE7W6ir0N7HKNoPtXFW97IuUdsofXtVqO8xhlfBHBokle6CLZ1ykZHHFLfp5lmxH8NY1lqe5gkhxW1HKs0RUHIYYqRmGBtx/SqF7OCMHNWrmQRwtk4IOKxp5Q3qamTsxxWhCxHmHA60mQeB0puMknNKcBSQe1ZsuwsoB9qiLbcClGCvJ5qCWYITj73r6VlUnGmuaWxpCLk7IWeTZ8i43nqR2os12gn1PWqKvuk/GtC2GFr57E4iVZ3ex6dKmoKyLYJGDn2xU6ys3GeKqoDnkjHvVmMHHAxXKbEspO2ooTh8etLK2MZqNf9Yp96a3EyztzTWWpaRhW5JXK0sS/Pn2qXFEQw5+lNCOCZyzvhj1PFSwEd6pMwEr/U1YR+ARX0KldHlNF5TxxUoAZeetU0fHNTLIOoppiZOFx14ppTqaUOSMHFLwVPNVuTYi2gHB5FIVBPFTBQynHUU1CM9M0AR7MD2pGSrIztzSFCR04otcLlPZkmq8kZB3DNaBXmo5EoaBMjtrp4upyPetCK5SUdgaynQ5puWTkU9gNzdheaSO4KyAH7p4rOtr0jCuKuq0cnIIBqlIVi39odX4b6Gr9lrFzbNkMCPQmsf5XXaG5Hemo21jleR3o5mOyNm+v2u5S2Nq+lVVmA6c1VG+QZc7V9PWnqNvTH4VDk2ykkibdxk96V2CryeahY461i+JtcTSrMHhrlxiNM/qfalsO1y7qWqR2jJAp33L8hfQep9qryTttA5JPU15vZatMmqG7uHMjOcOT6V2tpqSyqCDwea8vHOUmux20EorzNa3yevWteLhBWDZ3TSThQgxmt8HgYry56HSh+VyMgk+1WoX7NnHpVBieg61NCSGUEYyMVnYonmcFqQDYFZj3FRM4EwHU9verEpCqC33hzt9D700BfpGqNG4HrTi2a3IEYcGki++c+lIWpqMN55HSqQM85KuZHwjdT2qRA4P3Gx9KKK9eg24o4KitIsIr/3W/KpkVz/CfyooroMSUK46q2fpUkYJPKsfwooqkSyVVbqEI/CkaNlbG04PI4ooqhC7JFP3CR9KkCsR91vyoopoBvlnP3G49qY8bZPynH0oooBkJidj9xsfSmtC3I2H8qKKQEP2dgfuN+VPjSUH7h2/Siihgixk4yquSO2Ks27NIPmiYehxRRVdALYibqQePalSI85BooqGUjN13UE0nT3uJELMOEXHLH0ryXULq71C8e4ugzSN/s8AegoorObN4JWIkhkYgBG/KtrRzLMWt4iyyIONw4NFFc9Ve6zWL1Or8Pm4SYi8iZGXpxwa6uB1ZgFSRs9wpooryKqTdzpixzwzvJkARr6nr+lPgtZlmBluPMUHhVjIP50UVjYstumzmNCOxbGTUQjdzgKffiiinFA2XdrDop/Kkw/ofyooraxBG+7+6fyqNd4k+6enpRRTQH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    While the provider assembles necessary materials, the patient can perform tamponade. The patient wears a protective gown. He bends at the waist to minimize swallowing of blood and the risk of aspiration, and grasps his nasal alae in firm approximation. The patient should be encouraged not to check for active bleeding, but rather to hold constant pressure for at least five minutes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harrison Alter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_47_33535=[""].join("\n");
var outline_f32_47_33535=null;
